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A B S T R A C T
Background
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Although grid or focal laser photocoagulation
has been shown to reduce the risk of visual loss in DMO, or clinically significant macular oedema (CSMO), vision is rarely improved.
Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities is used to try to improve vision in people
with DMO.
Objectives
To investigate the effects in preserving and improving vision and acceptability, including the safety, compliance with therapy and quality
of life, of antiangiogenic therapy with anti-VEGF modalities for the treatment of DMO.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 3), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to April 2014), EMBASE (January 1980 to April 2014), Latin American and Caribbean Health Sciences Literature Database
(LILACS) (January 1982 to April 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 28 April 2014.
Selection criteria
We included randomised controlled trials (RCTs) comparing any antiangiogenic drugs with an anti-VEGF mechanism of action versus
another treatment, sham treatment or no treatment in people with DMO.
1Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration. The risk ratios (RR) for visual loss and visual
gain of three or more lines of logMAR visual acuity were estimated at one year of follow-up (plus or minus six months) after treatment
initiation.
Main results
Eighteen studies provided data on four comparisons of interest in this review. Participants in the trials had central DMO and moderate
vision loss.
Compared with grid laser photocoagulation, people treated with antiangiogenic therapy were more likely to gain 3 or more lines of
vision at one year (RR 3.6, 95% confidence interval (CI) 2.7 to 4.8, 10 studies, 1333 cases, high quality evidence) and less likely to lose
3 or more lines of vision (RR 0.11, 95% CI 0.05 to 0.24, 7 studies, 1086 cases, high quality evidence). In meta-analyses, no significant
subgroup difference was demonstrated between bevacizumab, ranibizumab and aflibercept for the two primary outcomes, but there was
little power to detect a difference. The quality of the evidence was judged to be high, because the effect was large, precisely measured
and did not vary across studies, although some studies were at high or unclear risk of bias for one or more domains. Regarding absolute
benefit, we estimated that 8 out of 100 participants with DMO may gain 3 or more lines of visual acuity using photocoagulation
whereas 28 would do so with antiangiogenic therapy, meaning that 100 participants need to be treated with antiangiogenic therapy to
allow 20 more people (95% CI 13 to 29) to markedly improve their vision after one year. People treated with anti-VEGF on average
had 1.6 lines better vision (95% CI 1.4 to 1.8) after one year compared to laser photocoagulation (9 studies, 1292 cases, high quality
evidence). To achieve this result, seven to nine injections were delivered in the first year and three or four in the second, in larger studies
adopting either as needed regimens with monthly monitoring or fixed regimens.
In other analyses antiangiogenic therapy was more effective than sham (3 studies on 497 analysed participants, high quality evidence)
and ranibizumab associated with laser was more effective than laser alone (4 studies on 919 participants, high quality evidence).
Ocular severe adverse events, such as endophthalmitis, were rare in the included studies. Meta-analyses conducted for all antiangiogenic
drugs compared with either sham or photocoagulation did not show a significant difference regarding serious systemic adverse events
(15 studies, 441 events in 2985 participants, RR 0.98, 95% CI 0.83 to 1.17), arterial thromboembolic events (14 studies, 129 events
in 3034 participants, RR 0.89, 95% CI 0.63 to 1.25) and overall mortality (63 events in 3562 participants, RR 0.88, 95% CI 0.52 to
1.47). We judged the quality of the evidence on adverse effects as moderate due to partial reporting of safety data and the exclusion of
participants with previous cardiovascular events in some studies.
Authors’ conclusions
There is high quality evidence that antiangiogenic drugs provide a benefit compared to current therapeutic options for DMO, that
is grid laser photocoagulation, in clinical trial populations at one or two years. Future research should investigate differences between
drugs, effectiveness under real-world monitoring and treatment conditions, and safety in high-risk populations, particularly regarding
cardiovascular risk.
P L A I N L A N G U A G E S U M M A R Y
Anti-vascular endothelial growth factor for diabetic macular oedema
Background
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. The retina at the macula thickens and this can
cause gradual loss of central vision. Grid or focal laser photocoagulation is effective in treating DMO and has been used for several
years, but vision is rarely improved.
Review question
We have reviewed the evidence on antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities to try
to improve vision in people with DMO. Anti-VEGF drugs are delivered by an injection in the vitreous cavity of the eye and need to
be repeated for maintenance. We primarily measured the proportion of people improving or losing vision by three or more lines.
Search date
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This evidence is current to 28 April 2014.
Study characteristics
We included 18 studies in this review. These studies compared antiangiogenic therapy with macular laser photocoagulation (10 studies,
1333 participants) or compared antiangiogenic therapy with sham treatment (three studies, 497 participants). Four studies (919
participants) assessed the effect of antiangionetic therapy combined with photocoagulation compared to photocoagulation alone.
Study funding sources
Ten out of 18 studies were funded by the manufacturer.
Key results
About one in five more people gained a good amount of vision, that is 3 lines, using antiangiogenic therapy compared with laser, using
seven to nine intraocular injections in the first year, and three or four injections in the second year. Benefits were also detected when
the drug was compared to no treatment and when it was added to photocoagulation and compared to photocoagulation alone.
Antiangiogenic treatment was well tolerated in these studies, with few reported injection-related adverse events and no increase in the
number of reported overall and cardiovascular adverse events.
Quality of the evidence
Although aspects of some studies were judged to be at potential risk of bias, overall the evidence in this review was of high quality
regarding efficacy compared to laser photocoagulation, the standard treatment, because the effects were large and consistent between
studies. The evidence was also of moderate quality regarding safety, since safety had to be confirmed in patients with higher morbidity,
particularly regarding cardiovascular risk.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anti-VEGF versus laser for diabetic macular oedema
Patient or population: people with diabetic macular oedema
Settings: Ophthalmology clinics
Intervention: anti-VEGF
Comparison: laser
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Anti-VEGF versus laser
Gain 3+ lines of visual
acuity at 1 year
77 per 1000 276 per 1000
(207 to 368)
RR 3.6
(2.7 to 4.8)
1333
(10 studies)
⊕⊕⊕⊕
high1
Overall heterogeneity: I2
= 0%
Test for subgroup drug
differences: P value 0.80
Loss 3+ lines of visual
acuity at 1 year
115 per 1000 13 per 1000
(6 to 28)
RR 0.11
(0.05 to 0.24)
1086
(7 studies)
⊕⊕⊕⊕
high1
Overall heterogeneity: I2
= 0%
Test for subgroup drug
differences: P value 0.56
Visual acuity at 1 year no change
(0 logMAR, median
value)
The mean visual acuity at
1 year in the intervention
groups was
-0.16 logMAR better
(-0.14 to -0.18 better)
1292
(9)
⊕⊕⊕⊕
high1
Overall heterogeneity: I2
= 59%
Test for subgroup drug
differences: P value <0.
001
Central macular thick-
ness at 1 year
67 µm lower (median
value)
The mean central macular
thickness at 1 year in the
intervention groups was
78.8 µm lower
(94.6 to 63.1 µm lower)
1215
(8)
⊕⊕⊕⊕
high1
Overall heterogeneity: I2
= 68%
Test for subgroup drug
differences: P value <0.
001
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Adverse events: see Summary of findings 2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Although some studies had some domains that were judged to be at risk of bias we did not downgrade because the effect size was
large, precise and consistent between studies. Although I2 was relatively high for mean visual acuity and central macular thickness all
results were in the same direction and in most studies statistically significantly in favour of anti-VEGF treatment.
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B A C K G R O U N D
Description of the condition
Diabetic retinopathy (DR) is the most frequent and severe ocular
complication of diabetes mellitus (DM) and the leading cause of
blindness in the working age population in developed countries
(Frank 2004; Klein 1984; Tranos 2004).
Diabetic macular oedema (DMO) is the swelling of the retina re-
sulting from the exudation and accumulation of extracellular fluid
and proteins in the macula (Ciulla 2003) due to the breakdown of
the blood-retina barrier and an increase in vascular permeability
(Antcliff 1999). The Wisconsin Epidemiologic Study of Diabetic
Retinopathy (WESDR) (Williams 2004) reported that within five
years of diagnosis 0% of type I patients showed evidence of DMO
compared with 29% after 20 years (Klein 1984). Similarly, within
five years of diagnosis only 3% of type II patients presented with
DMO compared with 28% after 20 years. In this Wisconsin pop-
ulation the four-year incidence of clinically significant macular
oedema (CSMO) was 4.3%, 5.1%, and 1.3% in type I, insulin-
treated type II, and non-insulin treated type II patients respec-
tively. The 10-year incidence was 20.1%, 25.4%, and 13.9% re-
spectively in these groups (Klein 1984). The presence of DMO
has been associated with longer duration of diabetes, higher sys-
tolic blood pressure, insulin use, diuretic use, male gender, higher
glycosylated haemoglobin and presence of proteinuria (abnormal
presence of proteins in urine) (Klein 1984).
Intraretinal fluid accumulation results in significant reduction in
visual acuity that may be reversible in the short term, but pro-
longed oedema can cause irreversible damage resulting in perma-
nent visual loss. Blurred vision represents the most common clin-
ical symptom of DMO. Other symptoms can include metamor-
phopsia (distortion of visual image), floaters, changes in contrast
sensitivity, photophobia (visual intolerance to light), changes in
colour vision and scotomas (a localised defect of the visual field).
During the last decades, the clinical gold standard to detect mac-
ular oedema has been fundus examination with contact lens, but
non-contact lenses can also be used for this purpose with good sen-
sitivity. Optical coherence tomography (OCT) has progressively
been used as an objective and reproducible tool to measure retinal
thickness and has been suggested to be the new gold standard for
diagnosing DMO (Olson 2013; Ontario HTA 2009).
CSMO, as defined by the Early Treatment Diabetic Retinopathy
Study (ETDRS), presents with the following characteristics: reti-
nal oedema within 500 µm of the centre of the fovea; hard exu-
dates within 500 µm of the centre of the fovea, if associated with
adjacent retinal thickening (which may be outside the 500 µm
limit); and one disc area of retinal oedema (1500 µm) or larger, any
part of which is within one disc diameter of the centre of the fovea
(ETDRS 1985). Chronic DMO can be associated with cystic de-
generation of the macular retina, called cystoid macular oedema
(CMO). Fluorescein angiography (FA) can be useful to assess the
integrity of the blood retinal barrier as the amount of fluorescein
leakage is related to the dysfunction of the retinal vascular en-
dothelium. Apart from being a significant diagnostic modality, FA
improves the accuracy of laser treatment of DMO (Kylstra 1999).
With FA, DMO could be divided into two subtypes: focal and
diffuse. Focal DMO is caused primarily by focal leakage from in-
dividual microaneurysms or small clusters of microaneurysms and
dilated retinal capillaries (Cunha-Vaz 1998), often demarcated by
hard exudates. Diffuse DMO is characterised by generalised leak-
age from extensive areas of the posterior retinal capillary bed, a
generalised breakdown of the inner blood-retinal barrier (Aroca
2004). Retinal ischaemia is often a major complicating feature of
diabetic maculopathy and it can easily be visualised on FA. Differ-
ent degrees of capillary nonperfusion can be observed in the oede-
matous diabetic macula; and when the ischaemia is extensive the
visual prognosis is generally poor (Bresnick 1976; Bresnick 1984;
Ticho 1973). From the point of view of aetiology and pathogen-
esis, DMO can be classified according to the presence of a trac-
tional component or taut attached posterior hyaloid component.
In those cases OCT is useful in documenting the presence of a
thick, taut, premacular posterior hyaloid or vitreous strands that
contribute to DMO and may benefit from vitrectomy (Harbour
1996; Lewis 1992). Recently,OCTwas found to be in good agree-
ment with the clinical gold standard (slit-lamp examination with
a contact lens) for detecting the presence of macular oedema and
was found to be potentially more sensitive in cases of mild foveal
thickening (Brown 2004).
Description of the intervention
The ETDRS demonstrated that immediate focal photocoagula-
tion reduced moderate visual loss by 50% (from 24% to 12%,
three years after initiation of treatment), even if 12% of treated
eyes still lost≥ 15 ETDRS letters at the three-year follow-up inter-
val. Approximately 40% of treated eyes that had retinal thickening
involving the centre of the macula at baseline still had thickening
involving the centre at 12 months, as did 25% of treated eyes at 36
months. Furthermore, only 3% of laser-treated eyes experienced
a gain of ≥ 3 lines of vision (ETDRS 1985). This suggests the ex-
istence of a distinct subgroup of eyes with DMO resistant to con-
ventional laser photocoagulation, in particular eyes with diffuse
DMO (Bresnick 1983; ETDRS 1985; Ferris 1984; Ladas 1993;
Lee 1991).
Another therapeutic option for DMO treatment is represented by
steroids, administered as intravitreal injections or sustained release
implants in order to obtain high local concentrations, maximising
their anti-inflammatory, angiostatic and anti-permeability effects
while minimising systemic toxicity (Ciulla 2004; Haller 2010;
Kuppermann 2010).
Vitrectomy is considered in patients with progression of visual
loss despite laser photocoagulation treatment and in patients with
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DMO associated with a thickened, taut, posterior hyaloid or other
tractions (epiretinal membrane).
Anti-vascular endothelial growth factor (VEGF) treatments were
originally hypothesised as an alternative adjunctive treatment
for DMO (Cunningham 2005), following recent evidence that
VEGF-A plays a key role in the occurrence of increased vascu-
lar permeability in ocular diseases such as DMO (Aiello 2005).
At present, different types of VEGF antagonists are available and
they have increasingly replaced laser photocoagulation for DMO
(Jampol 2014). All these drugs inhibit VEGF angiogenic activity,
binding to VEGF protein and thus preventing its receptor activa-
tion or interaction. Pegaptanib (Macugen, Eyetech Pharmaceuti-
cals, Inc., New York, NY) is an example of an anti-VEGF drug.
It is a pegylated aptamer, a chemically synthesised short strand of
a ribonucleic acid (RNA) molecule that targets only the VEGF
165 isoform, and it is currently approved for the treatment of
neovascular age-related macular degeneration (AMD) (Gragoudas
2004; Solomon 2014). Phase II and III trial results in DMO have
been reported recently (Cunningham 2005; Macugen 2011). An-
other example of an anti-VEGF antagonist is ranibizumab (Lu-
centis, Genentech, Inc., South San Francisco, CA), a human-
ised monoclonal antibody fragment that binds all active forms
of VEGF-A (Presta 1997). It is currently approved for the treat-
ment of neovascular AMD, diabetic macular oedema, macular
oedema in retinal vein occlusion (RVO) and choroidal neovascu-
larisation due to pathologic myopia (Campochiaro 2010; Brown
2011; Brown 2010; Campochiaro 2011; Ferrara 2006; RESOLVE
2010; RESTORE 2011; Rosenfeld 2006). Bevacizumab (Avastin,
Genetech Inc., San Francisco, CA) is a full-length humanised an-
tibody that binds to all types of VEGF and is used successfully in
tumour therapy as a systemic drug (Ferrara 2004). Recent studies
have suggested the potential usefulness of off-label intravitreal in-
jections of bevacizumab in the reduction of macular oedema sec-
ondary to central retinal vein occlusion, DMO and the decrease
of vascular permeability and fibrovascular proliferation in retinal
neovascularisation secondary to proliferative DR and choroidal
neovascularisation secondary toAMD(Arevalo 2007; Avery 2006;
Iturralde 2006; Spaide 2006). Recently aflibercept (Eylea, Regen-
eron-Bayer HealthCare), a new, fully human recombinant fusion
protein designed to bind all isoforms of VEGF-A as well as placen-
tal growth factor (PGF), thereby inhibiting the binding and acti-
vation of VEGF receptors, has been evaluated in phase II and III
trials on people with AMD (Heier 2011) and RVO (Ogura 2014);
it has been approved for such indications. The phase II and III tri-
als to evaluate the efficacy and safety of aflibercept on DMO have
recently been published (DA VINCI 2011, Korobelnik 2014).
How the intervention might work
VEGF-A plays a key role in the occurrence of increased vascular
permeability in ocular diseases such as DMO (Aiello 2005). Anti-
VEGF agents inhibit VEGF angiogenic activity, binding to VEGF
protein thus preventing its receptor activation and interaction in
a selective or nonselective manner, or both.
Why it is important to do this review
DMO results in a significant burden of low vision and blindness,
thus the extent of the existing evidence base for the effectiveness
and safety of these agents needs to be assessed and updated. There
is a continuing clinical need to establish evidence-based recom-
mendations regarding anti-VEGF agents.
O B J E C T I V E S
The aim of this review was to investigate the effects in preserving
and improving vision and acceptability, including the safety, com-
pliance with therapy and quality of life, of antiangiogenic therapy
with anti-VEGF modalities for the treatment of DMO.
Since antiangiogenic therapy is widely approved for treatment of
DMO, in the 2014 updated version of this review we have no
longer reviewed cost-effectiveness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled clinical trials (RCTs) to in-
vestigate efficacy and safety.
Types of participants
We included people with DR and CSMO causing significant sight
loss. We defined CSMO as: thickening of the retina located≤ 500
µm from the centre of the macula; hard exudates with thickening
of the adjacent retina located ≤ 500 µm from the centre of the
macula; a zone of retinal thickening of one disc diameter or larger
in size located < one disc diameter from the centre of the macula.
We considered that recent studies on anti-VEGF drugs could use
definitions that incorporated or were centred on OCT.
Types of interventions
Any antiangiogenic drug with anti-VEGF modalities compared
with another treatment, sham treatment or no treatment. We also
included comparisons between different anti-VEGF drugs in this
review. However, we did not consider intravitreal steroids as a
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comparator because another Cochrane review has been published
on this subject (Grover 2008).
Regarding dose and regimens, we extracted data for schemes that
were more similar to EU and USA approved labels, as follows.
For ranibizumab, the EU label prescribes a 0.5 mg dosage, and
“treatment is given monthly and continued until maximum visual
acuity is achieved i.e the patient’s visual acuity is stable for three
consecutivemonthly assessments performedwhile on ranibizumab
treatment. If there is no improvement in visual acuity over the
course of the first three injections, continued treatment is not rec-
ommended. Thereafter patients should be monitored monthly for
visual acuity”, accessed on EMA on 28 August 2014. In the USA,
ranibizumab “0.3 mg (0.05 mL) is recommended to be admin-
istered by intravitreal injection once a month (approximately 28
days)”, accessed on FDA on 28 August 2014.
Aflibercept has been approved in the USA, as accessed on
REGENERON on 28 August 2014, and the “recommended dose
for EYLEA is 2 mg (0.05 mL) administered by intravitreal injec-
tion every 4 weeks (monthly) for the first 5 injections followed
by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks
(2 months). In the second year, a ”treat-and-extend“ regimen can
be adopted where treatment interval may be extended based on
visual and anatomic outcomes”.
Bevacizumab is used off-label and we extracted the available data.
Types of outcome measures
Primary outcomes
Best-corrected visual acuity (BCVA) measured after one year (plus
or minus six months). The proportion of patients with at least
15 ETDRS letters, that is 3 ETDRS lines or 0.3 logMAR, of
worsening and improvement were analysed.
Secondary outcomes
Other functional measures: contrast sensitivity; quality of life eval-
uated with specific questionnaires.
Anatomicmeasures: presence ofmacular oedemawith stereoscopic
fundus photography or biomicroscopy; assessment of retinal mac-
ular thickness with optical coherence tomography (OCT); pres-
ence of leakage on fluorescein angiography (FA).
Safety: frequency and severity of ocular and systemic adverse
events.
Measurements at varying lengths of follow-up were pooled at an-
nual intervals, plus or minus six months, the primary analysis be-
ing that at one year. The time point closer to one year, or the lat-
est time point in the window frame in the case of symmetry, was
chosen where multiple time points were available.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes and
Vision Group Trials Register) (2014, Issue 3), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to April 2014), EMBASE (January 1980 to April 2014), Latin
American and Caribbean Health Sciences Literature Database
(LILACS) (January 1982 to April 2014), themetaRegister of Con-
trolled Trials (mRCT) (www.controlled-trials.com), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organiza-
tion (WHO) International Clinical Trials Registry Platform (IC-
TRP) (www.who.int/ictrp/search/en). We did not use any date or
language restrictions in the electronic searches for trials. We last
searched the electronic databases on 28 April 2014.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), mRCT (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the ICTRP (Appendix 7).
Searching other resources
We handsearched the reference lists of the included tri-
als for other possible trials. We accessed the Novartis
Clinical Trials database (http://www.novctrd.com/ctrdWebApp/
clinicaltrialrepository/public/main.jsp) on 28 May 2014 and
checked all trials indexed under the headings: Ophthalmic Disor-
ders and ranibizumab.
Data collection and analysis
Selection of studies
Two review authors independently selected the studies for inclu-
sion. The titles and abstracts of all reports identified by the elec-
tronic searches and handsearching were examined by the review
authors. We classified the abstracts as (a) definitely include, (b) un-
sure and (c) definitely exclude. We obtained and re-assessed full-
text copies of those classified as (a) definitely include and (b) un-
sure. Having reviewed the full-text copies, we classified the studies
as (1) included, (2) awaiting assessment and (3) excluded. Studies
identified by both review authors as (3) excluded were excluded
and documented in the review. Studies identified as (1) included
were included and assessed for methodological quality. The review
authors were unmasked to the report authors, institutions and trial
results during this assessment. Disagreements between the two re-
view authors were resolved by a third review author.
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Data extraction and management
Two review authors independently extracted the data for the pri-
mary and secondary outcomes onto paper data extraction forms
developed by the Cochrane Eyes and Vision Group. A pilot test
of this form was carried out using a small number of studies. We
resolved discrepancies by discussion. One review author entered
all data into Review Manager (RevMan 2014.) The entered data
were checked by a second author.
Assessment of risk of bias in included studies
Two review authors independently assessed the included trials
for bias according to the methods described in Chapter 8 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011b). The following parameters were assessed: sequence gener-
ation; allocation concealment; masking (blinding) of participants,
personnel and outcome assessors; incomplete outcome data; selec-
tive outcome reporting. We evaluated these parameters for each
outcome measure or class of outcome measure as specified in the
latest version of the Cochrane Handbook for Systematic Reviews of
Interventions. As reported in the Handbook, other sources of bias
were: risk of bias related to the specific study design used; or trial
stopped early due to some data-dependent process (including a
formal stopping rule); or an extreme baseline imbalance; or the
study claimed to have been fraudulent. We classified each param-
eter as low risk of bias, high risk of bias or unclear.
If the information available in the published trial reports was in-
adequate to assess methodological quality, we contacted the trial
authors for clarification. We planned that if they did not respond
within six months we would classify the trial based on the avail-
able information. However, in the latest update of this review we
awaited unpublished information for no longer than one month.
Regarding the overall quality of evidence for each outcome in-
cluded in the summary of findings table, we followed guidance
in Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Schunemann 2011). To assess precision, we con-
sidered both the width of the 95% confidence interval (CI) and
the Optimal Information Size according to Guyatt 2011, that is a
sufficient number of participants is included in the meta-analysis
to have 80% power to detect 1/3 control risk reduction, or 1/4
increase, using conventional sample size calculations for RCTs.
Measures of treatment effect
Data analysis followed the guidelines set out in Chapter 9 of the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). The primary outcome was the proportion of patients with
at least 15 letters improvement or, separately, at least 15 letters
worsening in visual acuity at one year (separate analyses). For di-
chotomous outcomes we calculated a summary risk ratio (RR).
We also reported the risk difference (RD) and number needed to
treat (NNT). We calculated the mean difference (MD) for con-
tinuous outcomes. We planned to calculate a standardised mean
difference (SMD) if different scales had been used to measure any
continuous outcomes. Continous measures were pooled provided
that they were not very skewed, such as when the distance between
the mean value and its maximum or minimum physical limit was
larger than the standard deviation.
Dichotomous outcome measures were the primary outcome mea-
sures, as previously defined, the presence of macular oedema and
presence of leakage on FA.
Since other secondary outcome measures were variably reported,
we considered both dichotomous (as defined by the investigator)
and continuous measures (as the mean or mean change from base-
line) for contrast sensitivity, quality of life and retinal macular
thickness with OCT.
Unit of analysis issues
The unit of randomisation was the eye of individual participants.
If studies using a paired design are found for future updates of
this review, that is studies assigning one eye to treatment and
the fellow eye to control, the generic inverse variance method
will be used to combine the results of such studies with those of
studies randomising only one eye of each participant. However,
these studies have special problems. First, comparisons between
treatment and control regarding systemic adverse events cannot
be made. Second, they need to be properly analysed by taking
into account within-patient correlation statistically, which would
otherwise result in incorrect variance estimation at least. Third,
methods for random assignment of either eye to treatment must
be made explicit.
We decided to include studies with eyes, not individuals, as the
unit of analysis in the main meta-analysis and then conduct a
sensitivity analysis excluding studies with paired design from the
primary outcome. Such studies were also excluded from analyses
of systemic adverse events.
Dealing with missing data
Where data were missing due to dropping out of participants, we
conducted a primary analysis based on patients with complete data
(available case analysis). Although in the protocol we planned to
conduct a sensitivity analysis with missing imputation based on
the worst-case and best-case scenarios, given the further guidance
available in Chapter 16 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a), we considered that miss-
ing outcome data are not a problem if both loss to follow-up is
balanced in the study arms and causes of loss to follow-up are
documented and judged to be unrelated to outcome in both study
arms. When causes of missingness were not available for the ma-
jority of studies, we planned to use the Stata 10.2 software (Stata-
Corp, College Station, Tx) user written function metamiss to take
into account missing data and conduct sensitivity meta-analyses
if sufficient studies were found. The underlying theory and a link
to download metamiss are provided in White 2008. In the update
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of this review we felt such an approach was not needed and relied
on risk of bias assessment.
Assessment of heterogeneity
We looked for clinical heterogeneity by examination of the study
details then tested for statistical heterogeneity between trial results
using the Chi2 test and the I2 statistic (Deeks 2011) if a meta-
analysis of three or more studies was possible. We considered I2
values of more than 50% to be substantial heterogeneity, but we
were aware that I2 estimates are very uncertain when few studies
are included in a meta-analysis. We considered sources of hetero-
geneity related to study design, such as paired studies (that is ran-
domising one eye of the participant to one treatment and then
assigning the fellow eye to the alternative treatment) versus studies
including only one eye of each participant. Clinical sources of het-
erogeneity to be considered in future updates are type of diabetes
(type I versus type II), lower versus higher baseline visual acuity,
longer versus shorter duration of diabetes, and baseline central
retinal thickness more than 400 µm versus less, if subgroup data
are reported.
Assessment of reporting biases
In future updates of this review, we plan to prepare a funnel plot
to examine other sources of heterogeneity if 10 or more studies
can be combined in a meta-analysis.
We investigated selective outcome reporting by preparing an ’out-
come matrix’ and classifying missing outcomes according to the
following classification adapted from a list provided byWilliamson
2010.
A: states outcome analysed but only reported the P value > 0.05
i.e. not significant.
B: states outcome analysed but only reported that P < 0.05.
C: clear that outcome was analysed but insufficient data presented
to be included in the meta-analysis or full tabulation.
D: clear that outcome was analysed but no results reported.
E: clear that outcome was measured (e.g. includes structurally-
related outcomes) but not necessarily analysed.
F: states that outcome was not measured.
G: not mentioned but clinical judgement says likely to have been
measured.
H: not mentioned but clinical judgement says unlikely to have
been measured.
I: other (give details).
Data synthesis
We used the following criteria to synthesise the data. If there was
no substantial statistical heterogeneity, and if there was no clini-
cal heterogeneity between the trials, we combined the results in a
meta-analysis using a random-effects model. A fixed-effect model
was used if the number of trials was three or less. In the case of
substantial statistical (that is I2 value more than 50%) or clinical
heterogeneity we did not combine study results but presented a
narrative or tabulated summary of each study, with similar rules
applied to subgroups represented by drug type. However, if sub-
stantial statistical heterogeneity was detected (that is a high I2
value), we pooled the results of the studies if examination of the
forest plot indicated that the individual trial results were all con-
sistent in the direction of the effect (that is the RR or MD and
confidence intervals largely fall on one side of the null line).
Regarding drug type, we chose to present all drugs in the same
forest plot, using subgroups to be able to test for subgroup dif-
ferences. We were aware of the fact that there was little power to
test for subgroup difference given the small number of studies in-
cluded in this review. Moreover, when only one study per drug is
available, any differences can be due to known or unknown study
characteristics rather than to drug effect. Thus, readers are invited
to examine individual drug groups, as well as pooled estimates,
considering the significance of the test for subgroup differences
and overall heterogeneity. Additionally, we used random-effects
logistic regression models with studies as random-effects (melogit
command in Stata 13.1 software, StataCorp, College Station, TX)
to explore differences among antiangiogenic drugs and obtain a
relative odds ratio (OR), both regarding the gain of 3 or more
lines. These analyses should be considered exploratory.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were carried out to investigate heterogeneity,
especially regarding drug type. If more data are available in future
updates, other subgroups will be based on: baseline visual acuity;
baseline macular oedema severity defined by OCT thickness; and
adequacy of glycaemic control. See above for our decisions regard-
ing drug type subgroups.
Sensitivity analysis
If more studies are available for each drug in future updates of
this review, we will conduct sensitivity analyses to determine the
impact of exclusion of studies with lower methodological qual-
ity, exclusion of unpublished studies, and exclusion of industry-
funded studies.
R E S U L T S
Description of studies
See ’Characteristics of included studies’; ’Characteristics of
excluded studies’; ’Characteristics of ongoing studies’.
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Results of the search
Previous searches
2009
The search strategy was designed to be broad and inclusive, in-
cluding terms for diabetic retinopathy and macular oedema. The
electronic searches retrieved a total of 1733 citations. The Tri-
als Search Co-ordinator scanned these search results and removed
references which were not relevant to the scope of the review. A
total of 56 citations were forwarded to the authors for assessment
for inclusion in the review. Six full-text papers were obtained, of
which four studies were eligible for inclusion (Ahmadieh 2008;
Macugen 2005; Paccola 2008; Soheilian 2007), but two of the
potentially relevant studies were excluded because of the follow-
up of less than six months (DRCRnet 2007; Faghihi 2008) (see
’Characteristics of excluded studies’ table).
2012
An update search was undertaken in June 2012 which yielded
681 citations. TheTrials SearchCo-ordinator scanned these search
results and removed 593 references which were not relevant to the
scope of the review. We screened the remaining 183 records and
obtained full-text records of 27 references. We assessed nine full-
text reports and included the following studies: BOLT 2010; DA
VINCI 2011; DRCRnet 2010; Macugen 2011; READ2 2009;
RESOLVE 2010; RESTORE 2011; RISE-RIDE; Soheilian 2007.
A report of the DA VINCI 2011 study published in 2012 was
not retrieved by the search at that time, however the authors were
aware of this publication and included it in the review.
We identified 18 ongoing studies; two of these 18 studies, which
were ongoing in 2012, are now included in the current update (
LUCIDATE2014;NCT01131585 (RELATION)) andone study
is awaiting assessment (NCT01171976 (RETAIN)).
We excluded three studies (DRCRnet 2011; DRCRnet 2012;
Solaiman 2010). A new potentially interesting study (Solaiman
2010) was excluded because a single bevacizumab injection was
delivered by design. For the same reason, as well as because in-
travitreal triamcinolone was the comparator, we excluded Paccola
2008 which was included in the original version of this review (see
the ’Characteristics of excluded studies’ table).
Searches for current update
An update search run in April 2014 identified a further 411 refer-
ences (Figure 1). The Trials Search Co-ordinator removed 101 du-
plicates and screened the remaining 310 references, of which 157
were not relevant to the scope of the review. We searched the No-
vartis clinical trials database and after de-duplication found five ad-
ditional records.We reviewed 158 references and discarded 122 re-
ports as not relevant.We obtained 36 full-text reports for potential
inclusion in the review and included seven reports of five new stud-
ies (Azad 2012; Ekinci 2014;Nepomuceno 2013;NCT01131585
(RELATION); RESPOND 2013). We also found 19 new re-
ports for studies which are already included in the review. We ex-
cluded six studies (Ahmadieh 2013; CRFB002DFR08 (LUDIC);
CRFB002DNO02 (PTIMAL); CRFB002DGB14 (RELIGHT);
Zehetner 2013; Zhang 2013). We identified three new ongo-
ing trials (ChiCTR-TRC-12002417; NCT01635790 (BRDME);
NCT01845844 (ROTATE)). Finally, we included Korobelnik
2014 and LUCIDATE 2014, which were found using other
sources as they became available after our electronic searches were
conducted.
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Figure 1. #Results from searching for studies for inclusion in the review.
Included studies
We included a total of 18 studies in this updated review. BOLT
2010; DA VINCI 2011; DRCRnet 2010; Korobelnik 2014;
Macugen 2005; Macugen 2011; READ2 2009; NCT01131585
(RELATION); RESOLVE 2010; RESPOND 2013; RESTORE
2011; RISE-RIDE were industry-sponsored, multicentre RCTs
conducted in the USA or Europe. Ahmadieh 2008; Azad 2012;
Ekinci 2014; LUCIDATE 2014; Nepomuceno 2013; Soheilian
2007 were independent studies conducted in Iran, India, UK,
Turkey, Brasil and Iran, respectively; five of which included be-
vacizumab. See the ’Characteristics of included studies’ table for
further information.
We did not extract data on comparisons of antiangiogenic ther-
apy with triamcinolone and other intravitreal steroids, which were
study arms in Ahmadieh 2008, Azad 2012, DRCRnet 2010 and
Soheilian 2007, since this comparison is the subject of another
Cochrane Review (Grover 2008). Moreover, in the 2014 update
we did not update economic evidence since antiangiogenic ther-
apy is now widely approved for the treatment of DMO.
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Types of participants
Studies included participants with DMOdiagnosed clinically, and
often used OCT for confirmation of macular centre involvement.
Baseline visual acuity was generallybetween 20/200 and 20/40.
The number of participants and other characteristics are given for
each comparison in the following sections.
There was variability regarding the inclusion of participants with
previous macular laser photocoagulation since Ahmadieh 2008,
BOLT 2010 and Ekinci 2014 included participants who had re-
ceived laser and were unresponsive, while Soheilian 2007 excluded
participants with previous laser treatment. Most of the other stud-
ies required a three to six-month interval from previous central or
peripheral laser, as well as that no previous antiangiogenic treat-
ment had been received.
Types of interventions
Eight studies assessed ranibizumab (DRCRnet 2010; LUCIDATE
2014; READ2 2009; NCT01131585 (RELATION); RESOLVE
2010; RESPOND 2013; RESTORE 2011; RISE-RIDE), six
investigated bevacizumab (Ahmadieh 2008; Azad 2012; BOLT
2010; Ekinci 2014; Nepomuceno 2013; Soheilian 2007), two pe-
gaptanib (Macugen 2005; Macugen 2011) and three aflibercept
(DA VINCI 2011; and two studies conducted in USA and Eu-
rope using the same protocol, which we will refer to as a single
study, Korobelnik 2014). The drug dose was identical in all studies
(0.5 mg ranibizumab, 1.25 mg bevacizumab, 0.3 mg pegaptanib,
2 mg aflibercept) except for RESOLVE 2010 where dose adjust-
ment was allowed for ranibizumab, and RISE-RIDE where 0.3
mg ranibizumab was also delivered.
Anti-VEGF treatment regimens were monthly for ranibizumab in
RISE-RIDE. Monthly, bimonthly and as needed or pro re nata
(PRN) regimens were adopted in four arms of DA VINCI 2011,
and we selected PRN for data extraction because this is current
practice with other anti-VEGF drugs. Two studies on aflibercept,
reported inKorobelnik 2014 (VISTA andVIVID), compared laser
photocoagulation with both monthly injections (2q4) and a regi-
men of five initial monthly injections followed by bimonthly in-
jections (2q8) (treatment regimen ’treat-and-extend’ in year two,
but results are not available yet). We selected 2q8 for extraction
because the total number of injections in the first year was lower
and this is more similar to PRN regimens of most other studies,
and because it is the regimen approved in the USA. Ahmadieh
2008 was a short-term study which delivered only the first three
injections. All other studies adopted three initial injections fol-
lowed by various maintenance regimens.
PRN retreatment criteria were based on: visual acuity only
in Nepomuceno 2013; OCT only in BOLT 2010, Macugen
2011 and READ2 2009; OCT and visual acuity in Azad 2012,
DRCRnet 2010, Ekinci 2014, RESOLVE 2010 and in the
PRN arm of DA VINCI 2011; inclusion of clinical examina-
tion or at the examiners’ discretion in Macugen 2005, RESTORE
2011 and Soheilian 2007. They were unclear in NCT01131585
(RELATION) and RESPOND 2013.
The average numbers of injections in each study are summarised
in Table 1.
Types of outcomes
Completeness of reporting of our primary outcomes can be seen
in Table 2. Out of 18 studies with six to 12 months of follow-
up, 15 reported visual gain of 3 or more lines and 11 reported
visual loss. At 24 months, four out of five studies reported such
measures.
Among secondary outcomes, mean BCVA was reported by 16 out
of 18 studies at six to 12 months. Azad 2012 reported only values
roundedup to the nearest Snellen equivalent. Ekinci2014 reported
baseline and final decimal visual acuity, which were converted to
logMAR to extract the change in logMAR visual acuity, but SDs
had to be imputed from Nepomuceno 2013 since conversion was
inappropriate.
Mean change of OCT retinal thickness was reported by 15 studies
at six to 12 months. Two large studies with two-year follow-up did
not give one-year data (Macugen 2011; RISE-RIDE) and Azad
2012 didnot provide data.Mean changewas derived as a difference
in LUCIDATE 2014 and SDs of the mean final values were used
conservatively.
Excluded studies
See ’Characteristics of excluded studies’ table.
DRCRnet 2007 and Faghihi 2008 were excluded because the fol-
low-up was too short. Solaiman 2010 and Paccola 2008 were ex-
cluded since a single antiangiogenic drug injection was delivered,
which is an insufficient regimen. In addition, Paccola 2008 and
Lim 2012 compared bevacizumab with triamcinolone, a compar-
ison which we did not consider in this updated review. DRCRnet
2011 assessed the short-term effect of ranibizumab (two injections)
or triamcinolone (one injection) compared with sham in patients
with centre-involved DMO and proliferative diabetic retinopathy
(DR) undergoing both grid and panretinal laser photocoagulation,
finding an advantage of about 1 Snellen line with pharmacological
treatment. Finally, DRCRnet 2012 compared the effect of prompt
versus deferred laser in patients with DMO who were also treated
with ranibizumab, so the timing of laser was in fact investigated.
In the 2014 update we excluded six studies (Ahmadieh 2013;
CRFB002DFR08 (LUDIC); CRFB002DNO02 (PTIMAL);
CRFB002DGB14 (RELIGHT); Zehetner 2013; Zhang 2013).
See Characteristics of excluded studies for the reasons for exclu-
sion.
Risk of bias in included studies
See ’Risk of bias in included studies’; Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Sequence generation was low risk of bias in 12 studies and was un-
clear in six (Azad 2012; Ekinci 2014; Korobelnik 2014; READ2
2009; NCT01131585 (RELATION); RESPOND 2013). Meth-
ods for allocation concealment were also unclear in these studies,
as they were in Nepomuceno 2013.
Blinding
Masking of participants and outcome assessors was obtained in 10
and eight studies respectively, and was unclear in five and seven
respectively. LUCIDATE 2014, READ2 2009 and RESPOND
2013 were unmasked.
Incomplete outcome data
Ten studies were judged to be at low risk of attrition bias
(Azad 2012; BOLT 2010; DA VINCI 2011; DRCRnet
2010; Korobelnik 2014; LUCIDATE 2014; Macugen 2005;
Nepomuceno 2013; RESOLVE 2010; RESTORE 2011) and
unclear in five studies in which participants were missing but
causes of missingness were not fully reported (Ahmadieh 2008;
Macugen 2011; READ2 2009; RISE-RIDE; Soheilian 2007).
Three studies were judged to be at high risk of attrition bias: Ekinci
2014 excluded 15 participants after randomisation due to ocular
and systemic complications; NCT01131585 (RELATION)and
RESPOND 2013 lost many more participants in the laser arm
than in the ranibizumab arms.
Selective reporting
As reported above, most studies including larger studies reported
our primary outcomes at 12 months, plus or minus six months
(Table 2); we primarily considered such availability for GRADE
assessment of this bias, even if there were discrepancies between
the protocol and published study. Reporting was complete regard-
ing visual gain for the comparison of anti-VEGF versus laser treat-
ment, our main analysis; which was not available in only one small
study (Ahmadieh 2008). Because effects consistently favoured an-
tiangiogenic therapy we did not downgrade the quality of other
key outcomes, mean visual acuity and central macular thickness,
even if they were not completely reported in this and other com-
parisons.
Only five studies reached two years of follow-up (BOLT 2010;
DRCRnet 2010; Macugen 2011; READ2 2009; RISE-RIDE),
four of which reported our primary outcomes (BOLT 2010;
DRCRnet 2010; Macugen 2011; RISE-RIDE), which we believe
is at low risk of bias.
Other potential sources of bias
Soheilian 2007 suffered from an imbalance of visual acuity across
groups at baseline since the bevacizumab and bevacizumab-tri-
amcinolone arms were around 20/100 and eyes assigned to laser
were around 20/70, suggesting that milder CSMO was included
in the laser group. The trial investigators adjusted for baseline val-
ues in analyses on mean change of visual acuity, which also took
into account the within-participant correlation (150 eyes of 129
participants, 16% of participants with both eyes in the analyses).
However, we could not take within-participant correlation into
account when analysing dichotomous visual acuity.
Ahmadieh 2008 included 14 participants (14%) and
Nepomuceno 2013 included 15 participants (33%)with both eyes
in the analyses.
NCT01131585 (RELATION) was terminated early when
ranibizumab was approved for DMO in Germany, but this was
assumed not to be related to treatment effect.
No other source of bias was found in other studies.
Effects of interventions
See: Summary of findings for the main comparisonAnti-VEGF
versus laser for diabetic macular oedema; Summary of findings
2 Adverse events: Anti-VEGF compared with control for diabetic
macular oedema
Anti-VEGF versus laser
Eleven studies compared anti-VEGF versus laser photocoagula-
tion.
Three (249 participants) of these 11 studies used bevacizumab
(Azad 2012; BOLT 2010; Soheilian 2007), five studies (1529
participants) used ranibizumab (DRCRnet 2010; READ2 2009;
NCT01131585 (RELATION); RESPOND 2013; RESTORE
2011), and three studies (1120 participants) used aflibercept (DA
VINCI 2011, Korobelnik 2014; LUCIDATE 2014).
Soheilian 2007 delivered anunusually lownumber of bevacizumab
injections (3.1 ± 1.6 in two years), but the results were comparable
to other studies.
Korobelnik 2014 provided data on one-year outcomes for two
aflibercept regimens compared to laser: 2 mg monthly (2q4), and
five initial injections followed by bimonthly injections (2q8). We
used the latter for our main meta-analysis since the total number
of injections was lower and more similar to other included studies.
Furthermore, this is the registered regimen in the USA.
Data on the primary outcomeswere available for 10of these studies
for visual gain and seven of these studies for visual loss. The results
are summarised in Summary of findings for the main comparison.
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Primary outcomes at one year
Compared to people treated with laser photocoagulation, people
receiving antiangiogenic therapy were more likely to gain 3 or
more lines of visual acuity over one year (RR 3.60, 95% CI 2.70
to 4.80, 1333 participants, 10 studies; I2 = 0%) (Figure 3) and
less likely to lose 3 or more lines of visual acuity (RR 0.11, 95%
CI 0.05 to 0.24, 1086 participants, 7 studies; I2 = 0%) (Figure 4).
Figure 3. Forest plot of comparison: 1 Anti-VEGF versus laser, outcome: 1.1 Gain 3+ lines of visual acuity at
1 year.
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Figure 4. Forest plot of comparison: 1 Anti-VEGF versus laser, outcome: 1.2 Loss 3+ lines of visual acuity at
1 year.
There were no statistically significant differences between type of
anti-VEGF, but the power to detect such a difference may have
been limited in the meta-analysis.
In terms of absolute effects, 5 people (95% CI 3 to 8) had to be
treated with antiangiogenic therapy, compared to laser, to allow
one person to markedly improve their vision.
Secondary outcomes at one year
Secondary outcomes also favoured antiangiogenic therapy (
Analysis 1.3; Analysis 1.4; Analysis 1.5). A significant sub-
group difference (P < 0.001) was found between bevacizumab,
ranibizumab and aflibercept regarding mean visual change ver-
sus photocoagulation, which was around 1 ETDRS line for
ranibizumab in LUCIDATE 2014, READ2 2009, RESPOND
2013 and RESTORE 2011 versus 2 lines for bevacizumab in
BOLT 2010 and Soheilian 2007 and aflibercept in DA VINCI
2011 and Korobelnik 2014 (Analysis 1.3). The reduction of reti-
nal thickeningwithOCTalso favoured anti-VEGF treatment over
laser photocoagulation (Analysis 1.4) with significant drug differ-
ences (P < 0.001), the largest reduction achieved by aflibercept.
RESTORE 2011 reported quality of life findings at one year using
the National Eye Institute Visual Function Questionnaire (NEI-
VFQ score) and showed a benefit of about 4.4 units (95% CI 1.33
to 7.47) favouring ranibizumab (Analysis 1.5).
Outcome at two years
Regarding anti-VEGF versus laser, only one study of bevaciuzmab
(BOLT 2010) reported complete two-year data. This study con-
firmed the increased chance of improving visionwith bevacizumab
(RR 9.08, 95% CI 1.25 to 65.77, 65 participants) (Analysis 1.6).
People receiving anti-VEGF were less likely to lose vision but the
number of events was small and the effect uncertain (RR 0.08,
95% CI 0.00 to 1.51, 65 participants) (Analysis 1.7).
BOLT 2010 and Soheilian 2007 provided data at this time point
for mean change of visual acuity, which showed a benefit of about
1.5 lines of vision favouring bevacizumab over laser (MD -0.14
logMAR, 95% CI -0.24 to -0.05, 142 participants; I2=29%) (
Analysis 1.8). Central macular thickness at two years was slightly
lower in the anti-VEGFgroupbut theCI around theMD included
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0 and therefore the effect of anti-VEGF treatment on macular
thickness at two years was uncertain (MD -18.35 µm, 95% CI
-62.23 to 25.52, 142 participants, 2 studies; I2 = 0%) (Analysis
1.9).
Two-year data from RESTORE 2011 were published but partici-
pants in the laser arm could receive rescue ranibizumab after one
year, which made it impossible to include long-term data on the
effect of ranibizumab versus laser photocoagulation for the PRN
regimen.
Quality of the evidence
Differently from the previous version of this review, in this update
we assessed the quality of evidence separately for the main ques-
tion, that is overall effectiveness of any anti-VEGF treatment, and
for the question on differences between antiangiogenic drugs. A
similar efficacy of different drugs has been demonstrated for some
agents in AMD (CATT 2011; CATT 2012; Schmidt-Erfurth
2014). In the update of this review, we acknowledge that the abil-
ity to investigate heterogeneity due to drug differences in efficacy
and safety is a further question, preferentially dealt with in net-
work meta-analysis exploiting both direct and indirect compar-
isons. The response to such a question will be largely supported by
the Diabetic Retinopathy Clinical Research Network (DRCRnet)
ongoing multicentre study (NCT01627249) entitled ’A Compar-
ative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab
and Ranibizumab for Diabetic Macular Edema’. See a following
paragraph presenting the results of subgroup analyses.
The overall quality of the evidence for the effects of anti-
VEGF treatment was high (Summary of findings for the main
comparison). Although some individual studies were judged at
high or unclear risk of bias for some domains, RRs of visual gain
were all large (> 2) and RRs of visual loss were all small (< 0.5),
and they were consistent between studies. Moreover, although the
meta-analysis did not meet ’Optimal Information Size criteria’ ac-
cording to Guyatt 2011, the overall effect was large (RR > 2 or
< 0.5) and precisely estimated. Thus, no quality downgrade was
applied.
Anti-VEGF versus sham treatment
Five studies compared anti-VEGF with sham treatment at one
year. Two studies (460 participants) used pegaptanib (Macugen
2005; Macugen 2011), two studies (910 participants) used
ranibizumab (RESOLVE 2010; RISE-RIDE) and one study (101
participants) bevacizumab (Ahmadieh 2008).
Macugen 2005 did not report on loss of 3 or more lines visual
acuity but reported on loss of 2 or more lines. Ahmadieh 2008
reported mean visual acuity data at six months.
The studies presented above used less intensive or discontinuous
regimens, while RISE-RIDE provided data on the comparison
between monthly continuous ranibizumab and sham treatment at
24 months, but not at one year, also comparing 0.3 mg versus 0.5
mg doses.
It must also be considered that rescue grid laser was allowed in
RESOLVE 2010 (35% sham, 5% ranibizumab) and RISE-RIDE
(74% sham, 35% to 39% ranibizumab).
Primary outcomes at one year
People treated with anti-VEGF (pegaptanib or ranibizumab) were
more likely to gain 3 or more lines of visual acuity (RR 2.19, 95%
CI 1.36 to 3.53, 497 participants, 3 studies; I2 = 0%) (Analysis
2.1) and less likely to lose 3 or more lines of visual acuity (RR
0.28, 95% CI 0.13 to 0.59, 411 participants, 2 studies; I2 = 44%)
(Analysis 2.2) compared to sham treatment. Effects were larger
for ranibizumab than for pegaptanib, but no significant subgroup
(treatment) effect was detected, although there was little power to
do so with only three studies in the meta-analysis of which one
study was small.
About nine people (95% CI 4 to 29) had to be treated with an-
tiangiogenic therapy to allow one person to markedly improve vi-
sion compared to sham. Although this figure seemed less benefi-
cial than the effect of antiangiogenic therapy versus laser, this may
have been due to differences in study populations as well as to the
fact that rescue laser was allowed in RESOLVE 2010, as previously
explained.
Secondary outcomes at one year
A significant subgroup difference was found between beva-
cizumab, pegaptanib and ranibizumab for mean visual change,
which was less than 1 ETDRS line for pegaptanib in Macugen
2005 and Macugen 2011 versus slightly more than 2 lines for
ranibizumab in RESOLVE 2010 (Analysis 2.3). One small study
comparing bevacizumab with sham treatment at six months
(Ahmadieh 2008) found a mean benefit point estimate of 1.5 vi-
sual acuity lines, but this estimate was imprecise (Analysis 2.3).
A similar trend, although not significant, was also found for the
reduction of retinal thickening with OCT (Analysis 2.4).
Outcome at two years
RISE-RIDE compared monthly ranibizumab injections with
sham treatment and found effects grossly similar to one-year data
and superior toMacugen 2011 (Analysis 2.5; Analysis 2.6; Analysis
2.7; Analysis 2.9).
Quality of life data (NEI-VFQ score) were available in Macugen
2011 and showed a benefit of about 4.5 units at two years, which
was imprecisely estimated (Analysis 2.9; Analysis 2.10).
Quality of life data (NEI-VFQ25 near and distance activity scales)
were available only as mean values in Korobelnik 2014, except for
one significant analysis, and could not be used.
18Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Quality of the evidence
Overall quality of this evidence was high. Risk of bias was low
for most items in the three studies which guided our conclusions
for the primary outcome at about one year (Figure 2). Ahmadieh
2008 provided only mean visual acuity at six months, thus being
subject to selective outcome reporting, and RISE-RIDE reported
only two-year data in detail, although one-year data were also
available. However, as previously stated for the comparison with
grid laser, effects were large and consistent. Although there were
few studies and the ’Optimal InformationSize’ was notmet, results
were consistent with those versus active control and we did not
downgrade the overall quality.
Anti-VEGF plus laser versus laser
Five studies (919 participants) assessed the effect of ranibizumab
additionally to prompt photocoagulation (DRCRnet 2010 (one
study arm); READ2 2009; NCT01131585 (RELATION);
RESPOND 2013; RESTORE 2011) or deferred photocoagula-
tion (one study arm with 188 participants of DRCRnet 2010)
compared with immediate photocoagulation alone. Because the
two arms of DRCRnet 2010 used the same control arm, these
subgroups were not pooled.
Primary outcomes at one year
The amount of relative benefit in combining ranibizumab with
photocoagulation was about the same as that of ranibizumab alone
compared with photocoagulation alone. Regarding gain of vision,
no significant difference (P = 0.33) could be demonstrated be-
tween ranibizumab plus prompt photocoagulation (RR 2.37, 95%
CI 1.76 to 3.21, 919 participants, 4 studies) versus plus deferred
photocoagulation (RR 1.88, 95% CI 1.31 to 2.70, 481 partici-
pants, 1 study) (Analysis 3.1).
Secondary outcomes at one year
About 1 ETDRS line was gained using ranibizumab plus photo-
coagulation compared with photocoagulation alone, which was a
consistent estimate (Analysis 3.3). The reduction of retinal thick-
ness also favoured ranibizumab (Analysis 3.4).
Outcome at two years
Only the DRCRnet 2010 study provided dichotomous and con-
tinous data at this time point and found a significant benefit with
ranibizumab combined therapy (Analysis 3.6; Analysis 3.7). Long-
term OCT data were available from DRCRnet 2010 and showed
no difference in retinal thickness (Analysis 3.9).
Quality of the evidence
The overall qualitywas high. Studieswere also included inprevious
analyses and we used identical criteria for overall judgement.
Adverse events: antiangiogenic therapy versus control
OnlyMacugen 2011, RESOLVE 2010 and RISE-RIDE reported
that the Medical Dictionary for Regulatory Activities (MedDRA)
classification was used to code adverse events and that active safety
data collection was used, whereas this was unclear for the other
studies. We suggest that at least the industry-sponsored studies
must have adopted such methods, to comply with regulatory stan-
dards.
Endophthalmitis and ocular adverse events (per patient
data)
Endophthalmitis can occur within a few days after the intravitreal
injection procedure. The number of intravitreal injections in the
first year was generally 7 to 10 and the total number of injections
in the first two years was 10 to 13 (Table 1). Because the planned
number of injections was 24 in two years, the largest number of
injections was found in RISE-RIDE, which adopted a monthly
schedule (20 to 22 injections across groups). The RESTORE 2011
open-label study extension showed that a mean of 14.2 injections
(median 12 injections) were delivered in the first three years of
treatment in the prior ranibizumab monotherapy study arm. Rates
of endophthalmitis due to intraocular injection were imprecisely
estimated in these relatively small or medium sized RCTs since
this is a rare adverse event (Table 3). There were only zero to three
cases in each interventional study arm. The risk of this type of
adverse event may be preferably studied by means of large non-
comparative studies since it is procedure rather than drug-related,
but the number of cases was very low in the studies included in
this review. Other serious ocular adverse events such as retinal
detachment were also extremely rare and were no longer reported
in this update of the review.
Serious systemic adverse events
In the update of this review, we extracted and meta-analysed all
serious systemic adverse events (SSAEs), as defined by the inves-
tigators, arterial thromboembolic events (including nonfatal my-
ocardial infarction, nonfatal stroke, and death from a vascular or
unknown cause, on the basis of the classification system of the
Antiplatelet Trialists’ Collaboration (ATC 1994)), and also over-
all mortality. Although SSAEsmay be differentially defined across
studies, the International Conference on Harmonisation Good
Clinical Practice (ICH GCP) Guideline identifies SSAEs as med-
ical occurrences that: result in death; are life threatening; require
hospital admission or prolongation of hospital stay; cause persis-
tent or significant disability and incapacity, a congenital anomaly
or birth defect.
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Overall, SSAEs were recorded in up to 20% of participants in the
treatment and control arms, including all controls not using anti-
VEGF drug. Data were extracted for the participants, rather than
eyes, as the unit of analysis and were included in themeta-analysis.
The estimate, based on 441 SSAEs in 2895 participants, excluded
a moderate to large increased risk with anti-VEGF treatments
compared to control (RR 0.98, 95% CI 0.83 to 1.17) (Figure
5; Analysis 4.1). Absolute differences presented in Summary of
findings 2 excluded an increase by more than 3%, according to the
95% CI upper limit, which is below the 5% threshold suggested
to be acceptable in another recently published systematic review
of the safety of antiangiogenic therapy in AMD (Moja 2014).
Figure 5. Forest plot of comparison: 4 Adverse events: Anti-VEGF versus control, outcome: 4.1 Systemic
serious adverse events.
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The diabetic population included in these studies appeared to be
at low risk of arterial thromboembolic events (less than 5% per
year in each study arm). In 14 studies (3034 participants) there
was no difference between anti-VEGF and controls for arterial
thromboembolic events (129 events, RR 0.89, 95% CI 0.63 to
1.25) (Figure 6; Analysis 4.2; Summary of findings 2).
Figure 6. Forest plot of comparison: 4 Adverse events: anti-VEGF versus control, outcome: 4.2 Total ATC
thromboembolic events at 6 to 24 months.
Similarly, no difference was apparent for overall mortality (63
events, RR 0.88, 95% CI 0.52 to 1.47) (Analysis 4.3); and clin-
ically significant differences by more than 1% (Moja 2014) were
excluded by the upper limit of the 95% CI estimate in Summary
of findings 2.
The quality of evidence on adverse events was moderate since
some studies excluded participants with previous cardiovascular
adverse events and there were consistency problems, resolved by
agreement, with extracting data from some studies. As discussed
above, the precision of the estimateswas considered adequatewhen
both RR and absolute differences were jointly considered, thus no
overall quality downgrade was applied despite the relatively small
number of adverse events.
Other comparisons
Monthly ranibizumab dose 0.3 mg and 0.5 mg versus sham:
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efficacy and safety
Monthly 0.3 mg ranibizumab injections are approved in the USA
as a treatment regimen and this was a treatment arm, together
with the 0.5mgmonthly dose, in RISE-RIDE, although the study
was not powered to prove dose equivalence. The effects of the two
doses were very similar in Analysis 2.5; Analysis 2.6; Analysis 2.7;
Analysis 2.8, as acknowledged in RISE-RIDE. Since the safety of
the higher dose (0.5 mg) was a potential problem, particularly for
mortality, which led the Food and Drug Administration (FDA)
to choose the lower ranibizumab dose (0.3 mg), we used logistic
regression to compare the ORs for death with the two doses using
data presented in Table 4. The respective ORs for 0.3 and 0.5 mg
ranibizumab versus sham were 2.37 (95% CI 0.61 to 9.27) and
3.79 (95% CI 1.04 to 13.75) for death, 0.96 (95% CI 0.66 to
1.40) and 1.15 (95% CI 0.80 to 1.66) for SSAEs, and 1.08 (95%
CI 0.50 to 2.35) and 1.41 (95% CI 0.68 to 2.95) for ATC arterial
thromboembolic events. Although the OR for death versus sham
for the 0.5 mg dose was of borderline significance (P = 0.04), no
comparison between doses approached statistical significance.
Direct comparisons of differences in efficacy between anti-
VEGF drugs: bevacizumab versus ranibizumab
Nepomuceno 2013 and Ekinci 2014 compared bevacizumab with
ranibizumab at one year in 45 participants (60 eyes) and 100 par-
ticipants, respectively. Only Nepomuceno 2013 reported our pri-
mary outcomes and did not show a difference regarding gain and
loss of 3 or more lines, but their was little power to do so given
the imprecision (Analysis 5.1; Analysis 5.2). Nepomuceno 2013
reported the difference in mean change of visual acuity but Ekinci
2014 only gave initial and final decimal values, which we con-
verted to logMAR in order to extract the difference (SDs were im-
puted as the mean SD from Nepomuceno 2013). Analysis 5.3 did
not suggest a difference between bevacizumab and ranibizumab
but the calculation approximations regarding Ekinci 2014, the
discordant direction of effects and the low quality of both studies
made estimates unreliable (0.0 logMAR, 95% CI -0.05 to 0.05).
The change in central retinal thickness favoured ranibizumab in
Nepomuceno 2013 but when pooled with Ekinci 2014 no differ-
ence could be shown (MD 27 µm, 95% CI -6 to 60). Although
not an outcome of this review, Nepomuceno 2013 reported the
need for about one more injection with bevacizumab compared
to ranibizumab (9.8 versus 7.7 injections on average, P = 0.005 as
reported by the authors using Wilcoxon rank-sum test).
Exploratory indirect comparisons of differences in efficacy
among anti-VEGF drugs
We used all extracted data for a gain of 3 or more lines (491 events,
2566 participants) at one year in random-effects logistic regres-
sion models to explore differences among antiangiogenic drugs,
considering ranibizumab as the reference as it is widely approved.
The dataset used in this analysis is shown in Table 5.
Ranibizumab approached statistically significant superiority with
respect to pegaptanib (relativeOR1.98, 95%CI 0.99 to 3.95).We
did not find evidence of superiority or equivalence of ranibizumab
versus bevacizumab (relative OR 1.15, 95% CI 0.67 to 2.08) or
aflibercept (relativeOR1.35, 95%CI 0.92 to 2.00) since estimates
were imprecise, regarding a gain of 3 or more lines of vision.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Adverse events: Anti-VEGF compared with control for diabetic macular oedema
Patient or population: people with diabetic macular oedema
Settings:
Intervention: adverse events: anti-VEGF
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Adverse events: anti-
VEGF
Serious systemic ad-
verse events
Follow-up: 6 to 24
months
145 per 1000 142 per 1000
(120 to 170)
RR 0.98
(0.83 to 1.17)
2985
(15 studies)
⊕⊕⊕©
moderate1,2
heterogeneity: I2 = 0%
Total ATC thromboem-
bolic events
Follow-up: 6 to 24
months
42 per 1000 37 per 1000
(26 to 53)
RR 0.89
(0.63 to 1.25)
3034
(14 studies)
⊕⊕⊕©
moderate1,2,3
heterogeneity: I2 = 0%
Death
Follow-up: 6 to 24
months
16 per 1000 14 per 1000
(8 to 24)
RR 0.88
(0.52 to 1.47]
3562
(15 studies)
⊕⊕⊕©
moderate1,2
heterogeneity: I2 = 0%
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Some studies excluded patients with previous cardiovascular adverse events and there were consistency problems, resolved by
agreement, with extracting data from some studies (-1 for indirectness).
2 95% confidence intervals of relative risks are relatively large for death, but absolute differences are small (see text) (no downgrade).
3 Incomplete reporting of Antiplatelet Trialists’ Collaboration (ATC) events in Macugen 2011 and RISE-RIDE , but these should be
balanced across treatment arms (no downgrade).
ATC: Antiplatelet Trialists Collaboration
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D I S C U S S I O N
Summary of main results
We found high quality evidence that antiangiogenic therapy pro-
vides benefit, both as an alternative and as an adjunct, over laser
treatment. Consistently, we also found evidence that intravitreal
injections of antiangiogenic drugs confer a significant benefit over
sham treatment. At one year, about five people need to be treated
to achieve a 3 plus line gain of vision in one person and the mean
gain of vision is about one and a half Snellen lines.We were unable
to estimate subgroup differences in effects, particularly according
to DMO severity of retinal thickness at baseline.
Direct comparisons between different drugs were available only
in two small head-to-head trials comparing bevacizumab and
ranibizumab, which did not show a difference in visual acuity but
did not have the power to show clinically relevant differences, that
is at least 5 ETDRS letters or one Snellen line. The quality of these
studies was low.
When subgroup analyses were used for indirect comparisons
among drugs in meta-analyses, these were based on few trials for
each drug type, and trials were of small size for bevacizumab. For
the visual gain primary outcome, no subgroup differences were
shown between bevacizumab, ranibizumab and aflibercept com-
pared to grid laser. Thiswas confirmedusing random-effectsmodel
logistic regression to fit indirect comparisons (Simmonds 2014)
for the gain of 3 plus lines of vision, but differences were not pre-
cisely estimated. However, in meta-analyses there were significant
subgroup differences regarding mean change of visual acuity and
mean change of central macular thickness, with aflibercept having
the largest effects.
Reported safety was good in the included RCTs since clinically
significant increases in SSAEs, arterial thromboembolic events and
death (Moja 2014) were excluded for patients at low average risk
such as in these studies. However, since some studies excluded pa-
tients with uncontrolled hypertension or previous cardiovascular
events, this could limit generalisability to the real-world diabetic
population, for which we downgraded this evidence to moderate.
Overall completeness and applicability of
evidence
Two-year data were available and reported in only four RCTs in
this review. Studies such as RESTORE 2011 were open-label after
one year. Thus, long-term effects will have to be inferred from
observational trials.
We suggest there are still insufficient data on drug differences.
The possibility of making indirect comparisons between differ-
ent anti-VEGF drugs was limited by the small numbers of trials,
as mentioned above. Two small studies directly comparing beva-
cizumab with ranibizumab provided only very low quality evi-
dence. A large number of RCTs are ongoing in this area of biomed-
ical research (Characteristics of ongoing studies) and can be found
on ClinicalTrial.Gov. The results of these studies will clearly be im-
portant in informing this review, especially regarding differences
among drugs that are being investigated in an ongoing DRCR-
net multicentre study (NCT01627249) entitled ’A Comparative
Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and
Ranibizumab for Diabetic Macular Edema’.
We found no useful data from RCTs, for example from subgroup
analyses, regarding issues that can be of specific interest to clin-
icians, such as patients that are difficult to treat with laser. We
acknowledge that many specialists would not treat people with
CSMO with laser if a thickened and adherent vitreous hyaloid is
found, which is best seen with OCT; or perhaps based on other
clinical and fluorescein angiographic findings, such as macular is-
chaemia, diffuse rather than focal leakage with no exudates, or
OCT findings such as large foveal cysts and loss of photoreceptor
layers. This premise underlines the belief by retina specialists that
laser is not always applicable, and it may be that anti-VEGF may
have wider indications than laser, being less selective.
Regarding the combination of laser and antiangiogenic therapy,
Elman 2012 published a three-year follow-up study of DRCRnet
2010, suggesting that the mean change in visual acuity from base-
line through to the three-year visit was 2.9 letters more (9.7 versus
6.8 letters, MD 2.9 letters, 95% CI 0.4 to 5.4; P = 0.02), about
-0.06 logMAR, in the deferral group compared with the prompt
laser treatment group. However, this evidence regards the addi-
tional use of laser rather than anti-VEGF therapy and we did not
use such data.
We would like to remark that this evidence is obtained in clini-
cal trials with high treatment and monitoring standards. A prag-
matic RCT would be needed assess the real-world effectiveness
of anti-VEGF treatment for DMO, since it could be dependent
on the adequacy of monitoring treatment response, which is also
sensitive to resource constraints, as found for AMD (Pagliarini
2014). DRCRnet 2010 possibly meets this goal in this review,
whereas other registration trials usually adopt strict monitoring
regimens that are not easily implemented in busy clinical practices.
We recognise that this may be more of a problem for age-related
macular degeneration (AMD) than for DMO, which is a more
stable condition.
Quality of the evidence
As remarked above, the overall quality of the evidence in this
review was high for themain question regarding drug class efficacy,
because large effects were precisely measured and did not vary
according to trial quality. The evidence on drug differences is still
limited and of low quality in direct comparisons, and the quality of
our indirect comparisons is difficult to assess formally but should
be low too.
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Potential biases in the review process
Bevacizumab is an off-label drug for treating DMO inmost coun-
tries. Because small RCTs using bevacizumab may have been con-
ducted but not published because no difference was found, we
could have missed small unpublished studies.
Agreements and disagreements with other
studies or reviews
Although we did not systematically search for other reviews on
anti-VEGF treatments for DMO, we retrieved several other re-
views which are described below.
Arevalo 2009,O’Doherty 2008 and Salam 2010 could not include
studies that were published later and are included in our review.
Thus, their conclusions are hard to compare with our review.
Boscia 2010 was a broad purpose review on DMO from its epi-
demiology and pathophysiology to the efficacy of several treat-
ments, finding that preliminary efficacy of anti-VEGF data was
confirmed. The author also provided information on the investi-
gation of other agents targeting VEGF, as well as drugs directed
against TNFa and PKC-b2 which are under study.
Nicholson 2010 included four trials (Ahmadieh 2008; Macugen
2005; READ2 2009; Soheilian 2007) that we included, as well
as RCTs with shorter follow-up and case series. Their conclusions
were in favour of antiangiogenic drugs to treat DMO, and they
stated that “we eagerly await the results of appropriate safety studies
in diabetic populations”.
Goyal 2011 assessed studies on bevacizumab and included
Ahmadieh 2008, DRCRnet 2007 and Soheilian 2007. They
pooled results of comparisons of bevacizumab with sham or laser,
which makes the meta-analysis hard to compare with our data.
They concluded that intravitreal bevacizumab is an effective short-
term treatment for DMO, and that its efficacy wanes after six
weeks.
Manousaridis 2012 assessed RCTs and case series to study the
effect of anti-VEGF drugs on macular ischaemia. They concluded
that “anti-VEGF therapy rarely seems to further compromise the
retinal circulation; however, worsening of macular ischaemia in
the long term cannot be denitely excluded, particularly in eyes
with significant ischaemia at baseline and after repeated intraocular
anti-VEGF injections”.
Zechmeister-Koss 2012 systematically reviewed RCTs as well as
non-randomised studies to investigate safety and reported on in-
dividual study results without pooling them. They included all
studies found by us except for RISE-RIDE and included studies
with shorter follow-up. Using GRADE they found that quality
was mostly moderate, mainly because of unclear randomisation
methods, and that the quality was lower for pegaptanib and be-
vacizumab compared to ranibizumab. They concluded that “in a
proportion of patients (on average 25%), VEGF inhibitors result
in better visual acuity (≥ 15 ETDRS letters or equivalent) than
in patients treated with laser photocoagulation or sham injection.
The number of injections required for long-term improvement as
well as the general long-term efcacy is unknown. The evidence
is not sufficient to conrm safety of the products in patients with
DMO and does not suggest superiority of a single product”. These
conclusions are similar to ours.
Ford 2012 used Bayesian indirect comparisons to compare the
efficacy of bevacizumab and ranibizumab in people with DMO.
They included five studies, also included by us, and found the
OR of a gain of 2 or more lines was 0.95 (95% credible interval
(CrI) 0.23 to 4.32) for bevacizumab compared to ranibizumab,
whereas the MD in change of vision was −0.08 logMAR units
(95% CI−0.19 to 0.04). They concluded that “results suggest no
difference in effectiveness between bevacizumab and ranibizumab,
but the wide credible intervals cannot exclude the possibility that
either drug might be superior” and that “sufficiently powered,
direct head to head trials are needed”.
Wang 2012 conducted a systematic review and meta-analysis in-
cluding four trials also included in our review. They concluded
that ranibizumab and ranibizumab combined with focal or grid
laser is more advantageous than non-drug treatment or focal or
grid laser in improving visual acuity (plus 1.5 lines and plus 1.2
lines at 12 months respectively compared with laser) and reducing
retinal thickness in DMO, and can be well tolerated based on the
safety assessment. They also found that intravitreal ranibizumab
may be equivalent to ranibizumab combined with focal or grid
laser.
Through searching the references of an editorial and review (O’
Malley 2012) we also found MEDCAC 2012, a health technol-
ogy assessment (HTA) conducted by the Institute for Clinical and
Economic Review (ICER) (www.icer-review.org), which prepared
this review for the Medicare Evidence Development & Coverage
Advisory Committee. This review included all studies included
by us plus others assessing comparisons between interventions not
included in our review, such as subthreshold photocoagulation
and intravitreal triamcinolone (total of 15 studies). This HTA
conducted a multiple treatment meta-analysis of all studies, also
linking these treatments that were not considered in our review.
They could not show differences among the antiangiogenic drugs
(ranibizumab, pegaptanib, bevacizumab, aflibercept). Although
95% CIs were narrower, possibly thanks to the larger evidence
network and a visual change cut-off closer to the mean (gain of
10 or more letters), the main comparison between ranibizumab
and bevacizumab found an RR of 0.94 (95% CI 0.47 to 1.85),
which cannot exclude a relevant difference between the two such
as almost twice the risk. This result is not comparable to our ex-
ploratory indirect comparisons since the conduct of a full multiple
treatment meta-analysis was beyond the objective of this review.
The American Academy of Ophthalmology (AAO) has published
an ophthalmic technology assessment which reviewed the litera-
ture available (Ho 2012). All included studies were also included
in our review and no meta-analysis was conducted. They con-
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cluded that “anti-VEGF pharmacotherapy, delivered by intravit-
real injection, is reasonably safe and effective for the treatment of
DME”. They also assessed economic evidence and included only
Smiddy 2011, finding that “the cost of these treatments, however,
is relatively high, and further study is required to evaluate the long-
term cost-effectiveness of these treatments”.
Regnier 2014 used Bayesian network meta-analysis methods to
compare ranibizumab and aflibercept indirectly, using the gain of
10 or more ETDRS letters (2 lines) as an outcome measure. They
found the direction of the effect favoured ranibizumab but dif-
ferences were not statistically significant (OR 1.59, 95% credible
interval 0.61 to 5.37).
Several reviews have been published on the safety of antiangiogenic
therapy in people with AMD, reviewing which is beyond the pur-
pose of our systematic review. Among recent reviews, Schmucker
2012 conducted a systematic review of safety in AMD patients
using direct and indirect comparisons. Using direct comparisons
of bevacizumab and ranibizumab, they found that bevacizumab
increased ocular adverse events (RR 2.8, 95% CI 1.2 to 6.5) as
well as serious infections and gastrointestinal disorders (RR 1.3,
95% CI 1.0 to 1.7), but no difference could be shown for arterial
thromboembolic events. Using indirect comparisons, the authors
found that ranibizumab increased the risk of serious ocular adverse
events (RR 3.1, 95% CI 1.1 to 8.9) as well as non-ocular haem-
orrhage (RR 1.7, 95% CI 1.1 to 2.7) compared with sham treat-
ment. Another review and meta-analysis of RCTs of ranibizumab
in AMD (Bressler 2012) could not find an increase in the risk of
cerebrovascular events, but suggested that these can be increased
in high-risk patients.
Finally, Abouammoh 2013 and Yanagida 2014 conducted safety
meta-analyses of ranibizumab trials in DMO and concluded there
was no safety concern.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is high quality evidence that anti-VEGF drugs are superior
to laser photocoagulation in treating DMO after one year. Less
two-year data confirmed longer-term efficacy. Clinicians and pol-
icy makers should be aware that clinical practice should adhere to
treatment and follow-up standards used in RCTs since undertreat-
ment could limit benefits. This was shown for age-related macular
degeneration in a European observational study of ranibizumab
by Pagliarini 2014.
Differences among drugs were investigated directly only in two
small, low quality trials comparing bevacizumab to ranibizumab
and even indirect comparisons are limited by the number and
types of studies currently available for this purpose.
In the included RCTs the safety of anti-VEGF intravitreal injec-
tion was good, suggesting that a generic indicator such as SSAEs,
mostly including death and hospitalisation, as well as adverse out-
comes such as death and systemic arterial thromboembolic events,
appear unlikely to be increased in the short to medium term in a
sensitive population such as peoplewith diabeticmicroangiopathy.
We cannot exclude that adverse events can be increased in high-
risk populations that differ from those included in our studies,
and questions have been raised about dose dependence of adverse
events.
Implications for research
Treatment of DMO with antiangiogenic therapy is now estab-
lished. Future research should compare different drugs and treat-
ment regimens, as well as investigate effects in the real world. This
review will not be updated in its present form. We recommend
that some of these goals could better be accomplished by a network
meta-analysis comparing the efficacy of antiangiogenic drugs, in-
travitreal steroids, laser and control.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmadieh 2008
Methods Parallel group randomised controlled trial
People were randomly allocated to treatment but in bilateral cases eyes were randomly
allocated to treatment
Participants Country: Iran
Number of people randomised: 101 (115 eyes)
Average age: 60 years (range 39 to 74)
Sex: 51% women
Inclusion criteria:
• CSMO unresponsive to previous macular laser photocoagulation (with the last
session being more than 3 months prior)
Exclusion criteria:
• VA ≥ 20/40
• history of cataract surgery within the past 6 months
• prior intraocular injection or vitrectomy
• glaucoma or ocular hypertension
• PDR with high-risk characteristics
• vitreous haemorrhage
• significant media opacity
• presence of traction on the macula
• monocular
• pregnancy
• serum creatinine level ≥ 3 mg/100ml
Interventions Intervention:
• bevacizumab (1.25 mg) n = ? (41 eyes)
Comparator:
• sham injection n = ? (37 eyes)
“Three consecutive injections were performed at 6-week intervals. Injections were done un-
der sterile conditions with topical anesthesia and insertion of a lid speculum. For the IVB
group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel,
Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a
30-gauge needle through the superotemporal quadrant.” Page 485
“In the control group, a needleless syringe was pressed against the conjunctiva and sclera in
each session.” Page 485
There was another intervention arm that combined bevacizumab with triamcinolone
acetonide, but this is not included in this review (n = 37 eyes)
Outcomes Primary outcome:
• change in CMT
“Central macular thickness was defined by the average thickness of a central macularregion
1,000 ìm in diameter centered on the patient’s foveola.” Page 485
Secondary outcomes:
• change in BCVA (logMAR)
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Ahmadieh 2008 (Continued)
• intraocular pressure
• cataract progression
• intraocular inflammation
• any serious adverse event
Follow-up: 18 and 24 weeks
Notes Date study conducted: November 2005-September 2006
Funding: not reported
Conflict of interest: “The authors have no proprietary interest in this study.”
Trial registration: NCT00370422
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block lengths varied randomly. A random al-
location sequence was performed by a bio-
statistician. Details of the series were un-
known to the investigators.” Page 485
Allocation concealment (selection bias) Low risk “Randomization was performed using a ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block lengths varied randomly. A random al-
location sequence was performed by a bio-
statistician. Details of the series were un-
known to the investigators.” Page 485
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects were masked to the treatment
modality. Visual acuity assessment and OCT
were performed by optometrists who were
masked to the groups.” Page 485
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete outcome data were re-
ported, but number of patients at 24 weeks
follow-up was not specied
Selective reporting (reporting bias) High risk The study protocol is mentioned. How-
ever, dichotomous VA outcomes are not
provided
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Other bias Low risk 28 eyes of 14 patients (14%) with bilateral
CSMO were included in the analysis
Azad 2012
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: India
Number of people randomised: 40 (40 eyes)
Average age: 54 years
Sex: 42% women
Inclusion criteria:
• diffuse DMO on FFA refractory to at least two prior sessions of macular laser
photocoagulation
• CMT > 250 µm on TD-OCT
• no evidence of vitreo-retinal traction
• good metabolic control (HbA1c < 7.0%)
Exclusion criteria:
• history of having received prior intraocular, peribulbar or systemic steroids or
prior anti-VEGF therapy
• uncontrolled diabetes mellitus
• diabetic nephropathy
• uncontrolled hypertension
• history of myocardial infarction, stroke or other thromboembolic
• episode
• monocular
• not available for a follow-up duration of at least 6 months
Interventions Intervention:
• bevacizumab (1.25 mg) n = 20 (20 eyes)
Comparator:
• macular grid augmentation n = 20 (20 eyes)
“IVB [...] injected via pars plana route in the doses mentioned above by a single experienced
investigator using full aseptic precautions. Postinjection, all patients were prescribed topical
moxifloxacin 0.5% qid for 5 days. Macular grid laser augmentation was performed by a
single experienced examiner according to the modified ETDRS protocol with a spot size of 100
µ, pulse duration of 100 ms, and a power of 50-100 mW titrated to produce mild intensity
burns in areas showing diffuse leakage on the FFA in a ‘C’ shaped zone between 500 and
3000µ from the foveal center sparing the papilla-macular bundle.” Page 167
Another intervention arm evaluated triamcinolone acetonide, but is not included in this
review (n = 20 eyes)
Outcomes Outcomes:
• BCVA measured used Snellen chart (mean at follow-up, gain/loss of 3 lines)
• CMT assessed using OCT
• adverse effects (increased IOP, cataract progression, others)
Primary outcome: not specified
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Follow-up: 1, 3 and 6 months
Notes Date study conducted: not reported
Funding: not reported
Conflict of interest: not reported
Trial registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported
Selective reporting (reporting bias) High risk VA data and other outcomes incompletely
reported
Other bias Low risk No other bias identified
BOLT 2010
Methods Parallel group randomised controlled trial
One eye per person, if both eyes were eligible eye with worse VA was selected
Participants Country: UK
Number of people randomised: 80 (80 eyes)
Average age: 64 years (range 40-86)
Sex: 31% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• BCVA in the study eye between 35-69 ETDRS letters at 4 m (Snellen equivalent
6/60 or 6/12)
• centre-involving CSMO with CMT on OCT of ≥ 270 µm
• media clarity, pupillary dilation, and subject co-operation sufficient for adequate
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fundus imaging
• at least 1 prior macular laser therapy
• intraocular pressure < 30 mmHg
• ability to return for regular study visits
• fellow eye ≥ BCVA 3/60
• fellow eye received no anti-VEGF treatment within the past 3 months and there
was no expectation of such treatment during the study
Exclusion criteria: (for study eye)
• macular ischaemia (FAZ ≥ 1000 µm GLD or severe perifoveal intercapillary loss
on FFA)
• macular oedema due to a cause other than DMO
• pre-existing ocular condition that was likely to preclude VA improvement despite
resolution of macular oedema
• ocular condition that may affect macular oedema or alter VA during the course of
the study, any treatment for DMO in the preceding 3 months
• PRP within 3 months of enrollment or anticipated 6 months thereafter
• PDR except for tufts of new vessels elsewhere < 1 disc in area with no vitreous
haemorrhage
• HbA1c > 11.0%
• medical history of chronic renal failure requiring dialysis or kidney transplantation
• BP > 170/100 mmHg
• any thromboembolic event within 6 months
• unstable angina, or evidence of active ischaemia on electrocardiogram at time of
screening
• major surgery within 28 days of randomisation or planned during the subsequent
12 months
• participation in an investigational drug trial within 30 days of randomisation (or
any time during the study)
• systemic anti-VEGF or pro-VEGF treatment within 3 months of enrollment
• pregnancy, breast feeding, or intention to become pregnant within the study
period
• intraocular surgery within 3 months of randomisation
• aphakia
• uncontrolled glaucoma
• significant external ocular disease
Interventions Intervention:
• bevacizumab (1.25 mg) n = 42 (42 eyes)
Comparator:
• macular laser therapy (MLT) n = 38 (38 eyes)
“Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Roche Registration Limited, UK)was prepared
by Moorfields Pharmaceuticals (London, UK) as a prefilled syringe containing 0.13 ml. In
a designated intravitreal treatment room, under sterile conditions, using topical anesthesia
and povidone-iodine 5% into the conjunctival sac and onto the lid margins, and following
application of a drape and insertion of a lid speculum, injections were undertaken with a 30-
gauge needle through the supra- or infratemporal quadrant, with a drop of ofloxacin placed
in the fornix at the end of the procedure. Patency of the central retinal artery was determined
by indirect ophthalmoscopy and VA of hand movements or better. The IOP was checked
30 minutes after the injection, and if the pressure was increased (30 mmHg) appropriate
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treatment was commenced. After the injection, topical ofloxacin was instilled 4 times per day
for 4 days”. Page 1080
“After baseline IVB, patients received 2 further IVB injections (6- and 12-week time points)
. Subsequent IVBinjections were guided by an OCT-based retreatment protocol. In brief, if
the thinnest recorded CMT was less than 270 m at 18 weeks, then treatment was continued
only if macular thickness was not “stable.” If CMT was greater than 270 m at 18 weeks and
subsequent visits, then IVB injections were administered until a “stable” macular thickness
was attained. “Stable macular thickness” was defined as 3 consecutive visits with the CMT
within 20m of the patient’s thinnest recorded CMT. Patients could thereby receive aminimum
of 3 injections and a maximum of 9 injections in the first 12 months.” Page 1080
“Modified ETDRSMLT comprised 50 m argon laser spot size, laser applied only greater than
500 m from the edge of the FAZ, with focal treatment aiming to cause mild blanching of the
retinal pigment epithelium and not darkening/whitening of microaneurysms. Areas of diffuse
leakage or nonperfusion were similarly treated in a grid pattern.” Page 1080
Outcomes Primary outcome:
• mean change in BCVA (EDTRS letters measured at 4 m)
Secondary outcomes:
• mean CMT and mean change in CMT
• gain and loss of 15 and 10 letters of ETDRS
• loss of 30 ETDRS letters
• retinopathy severity (ETDRS grading)
• safety
◦ GLD of the FAZ
◦ area of the FAZ
◦ Retinal Nerve Fibre Layer thickness
◦ other ocular side effects
◦ systemic side effects, including thromboembolic events, BP, and ECG
findings
Follow-up: 12 and 24 months
Notes Date study conducted: May 2007 to August 2009
Funding:“Supported by grants from Moorfields Special Trustees and the National Institute
for Health Research UK to the Biomedical Research Center for Ophthalmology based at
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.”
Conflict of interest: “The author(s) have no proprietary or commercial interest in any ma-
terials discussed in this article”
Trial registration: eudract.ema.europa.eu Identifier: 2007-000847-89
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized into 2 groups by
means of an in-house computerized random-
ization program. The research investigator
was not involved in the randomization pro-
cess. Patients were stratified for BCVA, with
the aim being that both groups would have
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comparable mean baseline BCVAs.” Page
1080
Allocation concealment (selection bias) Low risk The doctor had to phone the Clinical Trial
Unit in order to obtain a randomisation
from the statistician [personal communica-
tion from investigators]
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Although the patient and the study physician
were not masked to the therapeutic modal-
ity, the study optometrist, OCT technician,
photographer, graders performing assessment
of the FAZ and ETDRS retinopathy grading,
and study statistician were all masked to the
patient randomization.” Page 1080
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two patients in the laser group did not com-
plete 12months of follow-up (1 patientmoved
away, and 1 patient could not be contacted)
. They were last reviewed at the 32-week
time point,with these data being carried for-
ward and an intention-to-treat analysis un-
dertaken. All 42 patients in the IVBgroup
completed the study.” Page 1082
Selective reporting (reporting bias) Low risk We could not find a protocol but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other bias identified
DA VINCI 2011
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: USA, Canada and Austria
Number of people randomised: 221 (221 eyes)
Average age: 64 years (range 40-86)
Sex: 31% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• DMO involving the central macula defined as CRT ≥ 250 µm in the central
subfield based on Stratus OCT
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• BCVA letter score at 4 m of 73-24 (Snellen equivalent: 20/40-20/320) measured
by the ETDRS protocol
• women of childbearing potential were included only if they were willing to not
become pregnant and to use a reliable form of birth control during the study period
Exclusion criteria:
(for study eye)
• history of vitreoretinal surgery
• PRP or macular laser photocoagulation or use of intraocular or periocular
corticosteroids or anti-angiogenic drugs within 3 months of screening
• vision decrease due to causes other than DMO
• PDR (unless regressed and currently inactive)
• ocular inflammation
• cataract or other intraocular surgery within 3 months of screening
• laser capsulotomy within 2 months of screening
• aphakia
• spherical equivalent of > -8 diopters or any concurrent disease that would
compromise VA or require medical or surgical intervention during the study period
(in either eye)
• active iris neovascularisation
• vitreous haemorrhage
• traction retinal detachment
• preretinal fibrosis involving the macula
• visually significant vitreomacular traction or epiretinal membrane evident
biomicroscopically or on OCT
• history of idiopathic or autoimmune uveitis
• structural damage to the center of the macula that is likely to preclude
improvement in VA after the resolution of macular oedema
• uncontrolled glaucoma or previous filtration surgery
• infectious blepharitis, keratitis, scleritis, or conjunctivitis
• current treatment for serious systemic infection
(systemic)
• uncontrolled diabetes mellitus
• uncontrolled hypertension
• history of cerebral vascular accident or myocardial infarction within 6 months
• renal failure requiring dialysis or renal transplant
• pregnancy or lactation
• history of allergy to fluorescein or povidone iodine
• only 1 functional eye
• ocular condition in the fellow eye with a poorer prognosis than the study eye
Interventions Intervention:
• VEGF Trap-Eye n = 177 (177 eyes)
Comparator
• laser photocoagulation n = 44 (44 eyes)
“Patients were randomly assigned in a 1:1:1:1:1 ratio to 1 of 5 treatment regimens in 1 eye
only: 0.5 mg VEGF Trap-Eye every 4 weeks (0.5q4); 2 mg VEGF Trap-Eye every 4 weeks
(2q4); 2 mg VEGF Trap-Eye for 3 initial monthly doses and then every 8 weeks, (2q8); 2 mg
VEGF Trap-Eye for 3 initial monthly doses and then on an as-needed (PRN) basis (2 PRN)
; or macular laser treatment by the modified ETDRS protocol” Page 1820
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Outcomes Primary outcome:
• change in BCVA from baseline to week 24 (ETDRS chart at 4 m)
Secondary outcomes:
• retinal thickness assessed by OCT
• safety and tolerability
• change in BCVA from baseline at week 52
• proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with
baseline at weeks 24 and 52
• the change in CRT (central subeld on OCT) from baseline to weeks 24 and 52
• number of focal laser treatments given
Follow-up: 24 and 52 weeks
Notes Date study conducted: December 2008-June 2009
Funding: “Sponsored by Regeneron Pharmaceuticals, Inc., Tarrytown, New York.”
Conflict of interest: “The author(s) have made the following disclosure (s): Diana V.
Do: Genentech (financial support), Regeneron Pharmaceuticals (financial support). Ursula
Schmidt-Erfuth: Alcon Labs (consultant, lecturer), Bayer Healthcare (consultant, lecturer),
Novartis (consultant, lecturer), Regeneron Pharmaceuticals (lecturer), Pfizer (lecturer). Victor
H.Gonzalez: Pfizer (consultant, lecturer), Genentech (lecturer), Eyetech (consultant, lecturer)
, Regeneron (lecturer). CarmelinaM. Gordon: Allergan (consultant), Regeneron Pharmaceu-
ticals (lecturer), Novartis (consultant, lecturer). Michael Tolentino: Genentech (consultant,
lecturer), Eyetech (consultant, lecturer), Regeneron Pharmaceuticals (consultant, lecturer).
Alyson J Berliner: Regeneron Pharmaceuticals (employee, equity owner). Robert Vitti: Re-
generon Pharmaceuticals (employee, equity owner). Rene Rückert: Bayer Schering Pharma
(employee). Rupert Sandbrink: Bayer Schering Pharma (employee). David Stein: Regeneron
Pharmaceuticals (employee,equity owner). Ke Yang: Regeneron Pharmaceuticals (employee,
equity owner). Karola Beckmann: Bayer Schering Pharma (employee). Jeff S.Heier: Genen-
tech (consultant, lecturer), Regeneron Pharmaceuticals (consultant,lecturer), Fovea (consul-
tant).
Trial registration:NCT00789477
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomizationwas handled by an IVRS
vendor. The study statistician at REGEN-
ERONprovided the randomization plan and
reviewed and approved the dummy rand ta-
ble. Study Data Management at REGEN-
ERON tested the randomization function ex-
tensively along with the Clinical team.“
Allocation concealment (selection bias) Low risk ”Sites called into IVRS to randomize patients
and received the randomization number and
drug kit assignment at the completion of the
call. The site also received a confirmation
email. Neither of these contained the actual
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randomization assignment. The randomiza-
tion assignments were kept by the IVRS ven-
dor in a secure, access-controlled database and
were delivered to REGENERONby the IVRS
vendor at the primary endpoint database lock.
“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”To maintain participant masking, sham in-
jections were performed on visits when an ac-
tive dose was not given, and a sham laser was
given to the VEGF Trap-Eye groups at week
1. Study drug and sham injections and laser
and sham laser treatments were performed by
an unmasked
physician who had no other role in the study
except to assess adverse events (AEs) immedi-
ately posttreatment. Sham injections followed
the active treatment protocol with the excep-
tion that no needle was attached to the sy-
ringe, and the syringe hub was gently applied
to the sclera to mimic an injection. Sham laser
consisted of placing a contact lens on the study
eye and positioning the patient in front of the
laser machine for the approximate duration
of a laser treatment.“ Page 1820-1
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A separate masked physician was assigned to
assess adverse events (AEs) and retreatment
and rescue criteria and to supervise themasked
assessment of efficacy. Every effort was made
to ensure that all other study site personnel
remained masked to treatment assignment to
facilitate an unbiased assessment of efficacy
and safety.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two randomized patients did not receive
treatment and 19 patients discontinued the
study after receiving at least 1 treatment for
the following reasons: lost to follow-up (6 pa-
tients), withdrew consent (6 patients), death
(3 patients), treatment failures (2 patients)
, AE (1 patient), and protocol deviation (1
patient). Discontinuations were evenly dis-
tributed among the 5 treatment groups.” Page
1821
Comment: LOCF used
Selective reporting (reporting bias) Low risk Primary outcome declared and consistent
with our review
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Other bias Low risk No other bias identified
DRCRnet 2010
Methods Parallel group and within-person randomised controlled trial
One or two study eyes per person. If both eyes eligible, right eye randomised first and
then left eye assigned to “sham plus prompt laser group”. If right eye already assigned to
this group then left eye assigned randomly to 1 of the other 3 groups
Participants Country: USA
Number of people randomised: 691 (854 eyes)
Average age: 63 years
Sex: 44% women
Inclusion criteria:
• 18 years and older
• diabetes
(in study eye)
• best-corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-
ETDRS Visual Acuity Test11) VA letter score 78-24 (20/32-20/320)
• definite retinal thickening due to DMO on clinical examination involving the
centre of the macula assessed to be the main cause of visual loss
• retinal thickness measured on TD-OCT ≥ 250 micron in the central subfield
Exclusion criteria:
• treatment for DMO within previous 4 months
• PRP within the previous 4 months or anticipated need for PRP within the next 6
months
• major ocular surgery within the previous 4 months
• history of open-angle glaucoma or steroid-induced IOP elevation that required
IOP-lowering treatment
• IOP ≥ 25 mmHg
(patient)
• systolic BP was 180 mmHg or diastolic BP was 110 mmHg, or if a myocardial
infarction, other cardiac event requiring hospitalisation, cerebrovascular accident,
transient ischaemic attack, or treatment for acute congestive heart failure occurred
within 4 months before randomisation
Interventions Intervention:
• ranibizumab (0.5 mg) and laser photocoagulation n = ? (375 eyes)
Comparator:
• sham injection and laser photocoagulation n = ? (293 eyes)
Ranibizumab group was also randomly allocated to prompt laser photocoagulation (187
eyes) which occurred within 3-10 days of the injection and deferred laser photocoag-
ulation (188 eyes) which happened after 24 weeks. All eyes in comparator group were
treated within 3-10 days of the sham injection
Complex retreatment algorithm using web-based, real-time data-entry system (page
1066)
There was another intervention arm that combined triamcinolone with prompt laser
photocoagulation, but this was not included in this review. n = ? (186 eyes)
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Outcomes Primary outcome:
• BCVA and safety at 12 months
Secondary outcomes:
Follow-up: every 4 weeks for 12 months. After 12 months, the trial was unmasked and
follow-up continued to 3 years
Notes Dates participants enrolled: March 2007-December 2008
Funding:“Supported through a cooperative agreement from the National Eye Institute and
the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Department of Health and Human Services EY14231, EY14229, and EY018817.
The funding organization (National Institutes of Health) participated in oversight oversight
of the conduct of the study and review of the manuscript but not directly in the design or
conduct of the study; the collection, management, analysis, or interpretation of the data; or
the preparation of the manuscript. Genentech provided the ranibizumab for the study, and
Allergan, Inc., provided the triamcinolone for the study. In addition, Genentech and Allergan,
Inc., provided funds to the DRCR.net to defray the study’s clinical site costs. As described in
the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.
net had complete control over the design of the protocol, the ownership of the data, and all
editorial content of presentations and publications related to the protocol.”
Conflict of interest: “A complete list of all DRCR.net investigator financial disclosures can
be found at www.drcr.net”
Trial registration: NCT00445003
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was com-
puter-generated by the DRCR.net co-ordi-
nating centre
“...study participants with 1 study eye were as-
signed randomly on theDRCR.net studyweb-
site (using a permuted blocks design stratified
by study eye visual acuity)” Page 1065
Allocation concealment (selection bias) Low risk Randomisation assignments were obtained
through the DRCR.net study website,
therefore no study personnel had access to
the list or to the next assignment before it
was assigned
“study participants with 1 study eye were as-
signed randomly on theDRCR.net studyweb-
site (using a permuted blocks design stratified
by study eye visual acuity)” Page 1065
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Study participants in the 3 groups receiving
laser were masked to treatment assignment
through the primary outcome visit, whereas
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the ranibizumab deferred laser group was not
masked.” Page 1065-6
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Visual acuity examiners and OCT techni-
cians were masked to treatment group assign-
ment before and at the 1-year primary out-
come visit.” Page 1066
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patients randomised in each group were:
293 laser, 187 ranibizumab + prompt laser,
188 ranibizumab + deferred laser and 186
IVTA + laser. At 1 year complete patients
were 274, 171, 178, 176 respectively (91%-
95%)
At 2 years complete patients were 211, 136,
139, 142 respectively (72%-76%)
Causes ofmissingdatawere balanced across
groups
Selective reporting (reporting bias) Low risk We could not find a protocol but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other source of bias identified
Ekinci 2014
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: Turkey
Number of people randomised unclear: 100 (100 eyes) completed follow-up
Average age: 67 years (range 50-89)
Sex: 68% women
Inclusion criteria:
• clinically significant DMO (CMT >300 mm), as found through FFA and OCT
evaluations and dilate fundus examination, after 1-year follow-up period
Exclusion criteria:
• patients who received intravitreal treatment at another centre
• additional diseases that might have an effect on sight (age related macular
degeneration, uveitis, occlusion on the vein root or branch, hereditary macular diseases)
• PRP, grid or focal laser photocoagulation application or intraocular surgery within
6 months
• participants with acute ocular infection, stroke, myocardial infarction,
uncontrolled hypertension, pregnancy, renal failure and cataract formation during the
follow-up period were excluded from the study
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Interventions Intervention:
• bevacizumab (1.25 mg) n = 50 (50 eyes)
Comparator:
• ranibizumab (0.05 mg) n = 50 (50 eyes)
“Topical anesthetic drops were instilled, and a drape application and blepharostat attachment
were applied. Afterward, fornix lavage was applied using diluted povidone iodine. For Group
1, 1.25 mg (0.05 ml) of bevacizumab was injected into the eye that needed treatment, using
a 30 gauge needle; for Group 2, 0.05 mg (0.05 cc) of ranibizumab was injected into the
vitreous humor through the lower temporal quadrant, 3.5-4 mm behind the limbus. After
the treatment, all patients were treated with topical antibiotics four-times a day for 1 week.”
Page 140
Bevacizumab and ranibizumab injections were applied, with an interval of 1 month for
the first three doses. Retreatment criteria. “After the third dose of bevacizumab/ranibizumab
for patients in Groups 1 and 2, an additional three consecutive bevacizumab/ranibizumab
injections were applied if the central macular thickness was greater than 275 µm or if there
was an increase in BCVA of at least three letters compared with baseline. After the sixth
intravitreal injection, if the central macular thickness was greater than 275 mm or if ther was
an increase in BCVA of at least two letters, additional intravitreal injections were performed
until stable visual acuity was obtained.“ Page 140
Outcomes Outcomes:
• BCVA using the Snellen chart
• CMT assessed with OCT
• IOP assessed with applanation tonometry
Primary outcome not specified
Follow-up: monthly intervals after treatment to 12 months
Notes Dates participants enrolled: 2011-2014
Funding: not reported
Conflict of interest:”The authors have no relevant affiliations or financial involvement with
any organization or entity with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript. This includes employment, consultancies,
honoraria, stock ownership or options, expert testimony, grants or patents received or pending,
or royalties.” Page 142
Trial registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if participants, care providers or
outcome assessors were masked to treat-
ment method
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants, care providers or
outcome assessors were masked to treat-
ment method
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusion after randomisation: 15 patients
excluded
“Patients with acute ocular infection (en-
dophthalmitis after intravitreal injection, n
= 3), stroke, myocardial infarction (n = 2),
uncontrolled hypertension (n = 4), pregnancy
(n = 1), renal failure (n = 1) and cataract
formation during follow-up period (n = 4)
were excluded from the study.” Page 140
Selective reporting (reporting bias) High risk We could not find a protocol and our pri-
mary outcomes were not reported
Other bias Low risk No other bias identified
Korobelnik 2014
Methods Parallel group randomised controlled trial
Eyes: 862 eyes from 862 patients. One eye per patient. “For patients who met eligibility
criteria in both eyes, the eye with the worst BCVA was selected as the study eye. If a patient
had DME with similar BCVA in both eyes, the eye with the clearest media was selected as
the study eye. If the ocular media of the both eyes were similar in clarity, the patient’s non-
dominant eye (if identifiable) was selected as the study eye. If neither eye is dominant, the
right eye was designated as the study eye.” (Appendix 2)
Participants Country: 54 centres in USA (VISTA study, 446 participants) and 73 centres in Europe,
Japan, and Australia (VIVID study, 406 participants)
Number of people randomised: 852 (852 eyes)
Average age: 63 years
Sex: 42% women
Inclusion criteria:
• adults ≥ 18 years with type 1 or 2 diabetes mellitus
• central DMO involvement (defined as retinal thickening involving the 1 mm
central (OCT) subfield thickness)
• retinal thickness ≥ 300 µm (assessed by OCT)
• decrease in vision determined to be primarily the result of DME in the study eye
• BCVA ETDRS letter score of 73-24 (20/40-20/320) in the study eye
Exclusion criteria:
• laser photocoagulation (panretinal or macular) in the study eye within 90 days of
day 1
• more than 2 previous macular laser treatments in the study eye
• previous use of intraocular or periocular corticosteroids in the study eye within
120 days of day 1
• previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium,
51Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Korobelnik 2014 (Continued)
bevacizumab, ranibizumab etc.) within 90 days of day 1
• active PDR in the study eye, with the exception of inactive, regressed PDR
• uncontrolled diabetes mellitus, as defined by HbA1c > 12%
• only 1 functional eye even if that eye is otherwise eligible for the study
See paper for details
Interventions Intervention:
• aflibercept 2q4 n = 290 (290 eyes): aflibercept 2 mg every 4 weeks
• aflibercept 2q8 n = 286 (286 eyes): aflibercept 2 mg monthly for 5 months, then
every 8 weeks
Comparator
• laser photocoagulation and sham monthly injection = 286 (286 eyes)
“Eyes were randomized in a 1:1:1 ratio to receive either 2 mg IAI every 4 weeks (2q4), 2
mg IAI every 8 weeks after 5 initial monthly doses (from baseline to week 16) with sham
injections on non-treatment visits (2q8), or macular laser photocoagulation at baseline and
sham injections at every visit (laser control group)” Page 2
Outcomes Primary outcome:
• change in BCVA from baseline to week 52 (ETDRS chart at 4 m)
Secondary outcomes:
• proportion of eyes that gained at least 10 ETDRS letters in BCVA at week 52
compared with baseline
• proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with
baseline
• change in CRT (central subfield on OCT) from baseline to week 52
• proportion of eyes with a 2-step improvement in the ETDRS Diabetic
Retinopathy Severity Scale (DRSS) score
• change from baseline in the National Eye Institute Visual Function
Questionnaire-25 (NEI VFQ-25) near activities subscale score
• change from baseline in the NEI VFQ-25 distance activities subscale score
Follow-up: 52 weeks
Notes Date study conducted: May 2011-June 2013
Funding: “The VISTA and VIVID studies were funded by Regeneron Pharmaceuticals, Inc.
, Tarrytown, NY and Bayer HealthCare, Berlin, Germany. The sponsors participated in the
design and conduct of the study, analysis of the data, and preparation of the manuscript.”
Conflict of interest: “Assistance with the study design and conduct and data analysis was
provided by Karen Chu, MS, and Xiaoping Zhu, PhD, Regeneron Pharmaceuticals, Inc.
(VISTA), and Jana Sachsinger, PhD, and Christiane Norenberg, MS, Bayer HealthCare
(VIVID). Editorial and administrative assistance to the authors was provided byHadiMoini,
PhD, and S. Balachandra Dass, PhD, Regeneron Pharmaceuticals, Inc.” Other conflicts of
interest reported in the paper.
Trial registration: VISTA NCT01363440, VIVID NCT01331681
Risk of bias
Bias Authors’ judgement Support for judgement
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Korobelnik 2014 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details available
Allocation concealment (selection bias) Unclear risk No details available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A masked investigator assessed safety and ef-
ficacy and decided on the need for laser re-
treatment and additional treatment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Masked graders at independent central read-
ing centers evaluated OCT images for central
retinal thickness (center subfield))”
Incomplete outcome data (attrition bias)
All outcomes
Low risk About 93% participants completed 52
week follow-up in each arm and causes of
loss to follow-upwere balanced across arms.
Slightly higher loss to follow-up in laser
group in VIVID - approx 15% compared
to 8% and 11% in aflibercept groups
Selective reporting (reporting bias) Unclear risk Some differences between trial registration
and final reports
Other bias Low risk No other bias identified
LUCIDATE 2014
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
“One eye per participant was included to avoid exposure of both eyes to the study drug.
If both eyes were eligible, the eye with worse visual acuity became the study eye. Subjects
were randomized with 2:1 probability to receive the intervention or standard care (ETDRS
macular laser). The randomization list was created using permuted blocks of varying sizes,
held by the trial statistician and concealed from the researcher who enrolled, assessed, and
allocated treatment to participants.” (Page 961)
Participants Country: UK
Number of people randomised: 37 (37 eyes)
Average age: 66 years
Sex: 36% women
Inclusion criteria:
• adult patients with type 1 or 2 diabetes
• BCVA of 55-79 ETDRS letters (Snellen equivalent, 20/30-20/80) resulting from
centre-involving DMO , with Spectralis OCT (Heidelberg Engineering GmbH,
Heidelberg, Germany) central subfield thickness of 300 mm or more in the study eye
Exclusion criteria:
• uncontrolled glaucoma
• aphakia
53Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
LUCIDATE 2014 (Continued)
• cataract precluding fundus photography
• external ocular infections
• previous anti-VEGF or laser treatment in the preceding 3 months in both eyes
• angiographic evidence of macular ischaemia defined as FAZ GLD of >1000 mm
or severe perifoveal capillary loss
• other causes for macular oedema, for example, after cataract surgery
• other causes of visual loss in the study eye; other diseases that may affect the
course of macular oedema in the study eye
• PDR, either active or treated within the previous 3 months
• systemic conditions that precluded trial enrollment included HbA1c > 11.0%;
past medical history of chronic renal failure requiring either dialysis or kidney
transplantation; BP > 170/100 mmHg; an arteriothrombotic event within 6 months
before randomisation, including myocardial infarction, acute congestive heart failure or
other cardiac event, and stroke or transient ischaemic attack
• planned surgery
• pregnancy or breastfeeding
Interventions Intervention:
• ranibizumab (0.5 mg) n = 25
Comparator:
• laser photocoagulation n = 12
“Subjects were randomized with 2:1 probability to receive the intervention or standard care
(ETDRS macular laser).” (page 961) “Intravitreal injections of ranibizumab (Lucentis, 0.5
mg in 0.05 mL solution for injection; Novartis Pharmaceuticals UK Ltd., Frimley, United
Kingdom) at baseline, 4 weeks, and 8 weeks then every 4 weeks as required according to
predefined retreatment criteria to amaximum of 12 injections. Retreatment occurred if BCVA
was reduced by 5 letters or more from maximum acuity or if OCT central subfield thickness
was more than 300 mm. Subjects in the laser arm received ETDRS macular laser at baseline
guided by fluorescein angiography,OCT, and clinical examination. Laser retreatment occurred
at 12, 24, and 36 weeks if clinically significantmacular edemawas still present, in accordance
with standard clinical practice at the time; this was guided by the most recent fluorescein
angiogram, OCT, and clinical examination results” (page 961)
Outcomes Outcomes:
• change in ETDRS BCVA
• retinal sensitivity
• colour vision
• electrophysiologic parameters
• macular thickness and volume
• change in ETDRS severity grade of diabetic retinopathy from fundus photographs
Follow-up: 48 weeks
Notes Date study conducted: November 2010-July 2011
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Conflict of interest: “Dr Comyn receives travel support from Novartis. Dr Sivaprasad is a
consult for and receives payment for lectures or speaker bureaus and travel support fromNovar-
tis, Allergan, and Bayer, and receives payment for development of educational materials from
Allergan. Dr Holder is a consultant to Servier. Dr Patel receives grant support from Allergan,
Heidelberg United Kingdom, and Topcon United Kingdom and is a consultant to Bayer,
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Novartis, and Thrombogenics. Dr Hykin is a consultant to and receives grant support from
Novartis, Allergan, and Bayer. Drs Comyn, Sivaprasad, Peto, Patel, Egan, Bainbridge, and
Hykin have received a proportion of their funding from the Department of Health’s National
Institute for Health Research Biomedical Research Centre for Ophthalmology at Moorfields
Eye Hospital and University College London, Institute of Ophthalmology. Dr Bainbridge is
supported by a National Institute for Health Research Professorship. Supported by an unre-
stricted research grant from Novartis and the National Institute for Health Research Biomed-
ical Research Centre based at Moorfields Eye Hospital National Health Service Foundation
Trust and University College London Institute of Ophthalmology.” (page 970)
Trial registration: NCT01223612
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list was created using
permuted blocks of varying sizes, held by the
trial statistician and concealed from the re-
searcher who enrolled, assessed, and allocated
treatment to participants.” Page 96
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatments were different
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The microperimetry and electrophysiologic
assessors were masked to the patient treatment
arm. Evaluation of OCT scans, fundus pho-
tographs and fluorescein angiograms was per-
formed by masked Reading Centre graders.
The protocol states that the visual acuity asses-
sors were also masked to the patient treatment
arm but due to a protocol deviation they had
access to the source notes and were potentially
unmasked.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 22/25 (88%) of anti-VEGF group com-
pared to 11/12 (92%) laser group followed
up
Selective reporting (reporting bias) Unclear risk Unclear risk
Other bias Low risk No other source of bias identified
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Methods Parallel group randomised controlled trial
One eye per person, chosen by patient and physician. In 81% of cases the eye with the
worse VA was chosen
Participants Country: USA
Number of people randomised: 172 (172 eyes)
Average age: 62 years (range 27-89)
Sex: 49% women
Inclusion criteria:
• 18 years or older
• diabetes
(study eyes)
• macular oedema involving the centre of the macula demonstrated on OCT with
corresponding leakage from microaneurysms, retinal telangiectasis, or both on
fluorescein angiography
• an area of retinal thickening of at least half a disc area involving the central macula
as confirmed by graders at an independent fundus photograph and angiogram reading
center (University of Wisconsin, Madison, Wisconsin)
• clear ocular media and adequate pupillary dilation to permit good stereoscopic
fundus photographs
(patients)
• BCVA letter scores between 68-25 inclusive (approximate Snellen equivalent, 20/
50-20/320) in the study eye and at least 35 (20/100 or better) in the fellow eye
• IOP ≤ 23 mmHg
• assessment by the treating ophthalmologist that focal photocoagulation could be
deferred safely for 16 weeks
• an electrocardiogram that demonstrated no abnormalities judged to be clinically
relevant and serological test results that suggested no clinically meaningful
haematological, liver, or renal abnormalities
• women enrolling in the study were required to be postmenopausal for 12 months
before the study, surgically sterile, or not pregnant and on 2 forms of effective
contraception
Exclusion criteria:
• history of PRP or focal photocoagulation
• neodymium:yttrium-aluminum-garnet laser or peripheral retinal cryoablation
within the previous 6 months
• any abnormality thought likely to confound VA assessments or fundus
photography, including cataract; vitreoretinal traction within 1 disc diameter of the
fovea confirmed either clinically or on OCT
• vitreous incarceration in a previous wound or incision
• any retinal vein occlusion involving the macula; and atrophy/scarring/fibrosis or
hard exudates involving the centre of the macula that would preclude improvement in
VA
• a history of any intraocular surgery within the previous 12 months, myopia of ≥
8 diopters, axial length of ≥ 25 mm, and the likelihood of requiring either scatter
(panretinal) photocoagulation within the ensuing 9 months or cataract surgery within
12 months
• active ocular or periocular infection
• previous therapeutic radiation to the eye, head, or neck
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• any treatment with an investigational agent for any condition in the 60 days
before enrollment. known serious allergies to fluorescein dye
• glycosylated haemoglobin (GHb) levels of ≥ 13%
• 3 episodes of severe hypoglycemia within 3 months of study entry
• 2 episodes of ketoacidosis within 1 year of baseline
• any episode of ketoacidosis within 3 months of baseline
• evidence of severe cardiac disease
• clinically significant peripheral vascular disease (previous surgery, amputation, or
symptoms of claudication)
• uncontrolled hypertension (treated systolic BP 155 or diastolic BP 95), or stroke
within the preceding 12 months
Interventions Intervention:
• pegaptanib (0.3 mg, 1 mg, or 3 mg) n = 130 (130 eyes)
Comparator:
• sham injection n = 42 (42 eyes)
“Intravitreous pegaptanib or sham injections were administered at entry, week 6, and week
12, for a minimum of 3 injections. Thereafter, additional injections were administered every
6 weeks at the discretion of investigators if judged indicated, to a maximum of 6 injections
up to week 30. [...] Pegaptanib was formulated for intravitreous injection at 0.3 mg/90 µl,
1 mg/90 µl, and 3 mg/90 µl concentrations in preservative-free phosphate-buffered saline
(pH 5-7). Pegaptanib was packaged in sterile, single-use, United States Pharmacopeia type
1 graduated glass 1-ml syringes with preattached 27-gauge needles” Page 1748
Outcomes Outcomes:
• BCVA (measured using ETDRS chart)
• CRT on OCT
• change in retinal thickness derived by comparing measurements at baseline with
those at week 36 or nal examination if before week 36
• focal photocoagulation applied at week 12 or later
• size of the area of retinal thickness measured by photography
• macular capillary leakage and cystoid spaces
• adverse events
• laboratory test abnormalities
Follow-up: 36 weeks
Notes Dates participants enrolled: not reported, study published 2005
Funding:“The study was sponsored by Eyetech Pharmaceuticals, Inc., New York, New York,
and Pfizer Inc., New York, New York.” Page 1747
Conflict of interest: not reported
Trial registration: NCT00040313
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were allocated [...] by a dynamic
minimization procedure using a stochastic
treatment allocation algorithm based on the
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variance method. Randomization was strati-
fied by study site, size of the thickened retina
area [...] and baseline VA [...]”. Page 1748
Allocation concealment (selection bias) Low risk “An independent fundus photograph and an-
giogram reading center confirmed eligibility
and appropriate retinal thickness classifica-
tion both for study entry and for randomiza-
tion and stratification using baseline fluores-
cein angiography and OCT.” Page 1748
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study subjects receiving sham or study med-
ication were treated identically in all regards,
including ocular antisepsis procedures and
subconjunctival anesthetic, except that sub-
jects receiving active treatment had pegap-
tanib injected into the vitreous, whereas those
receiving sham had a needleless syringe pressed
against the conjunctiva and sclera. The in-
jection procedure prevented subjects from see-
ing the syringe and needle, to minimize the
risk of unmasking. In all but 3 subjects, injec-
tion was administered by a staff member other
than the study ophthalmologist responsible for
all other aspects of the protocol, to maintain
investigator masking.” Page 1748
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Study subjects receiving sham or study med-
ication were treated identically in all regards,
including ocular antisepsis procedures and
subconjunctival anesthetic, except that sub-
jects receiving active treatment had pegap-
tanib injected into the vitreous, whereas those
receiving sham had a needleless syringe pressed
against the conjunctiva and sclera. The in-
jection procedure prevented subjects from see-
ing the syringe and needle, to minimize the
risk of unmasking. In all but 3 subjects, in-
jection was administered by a staff member
other than the study ophthalmologist respon-
sible for all other aspects of the protocol, to
maintain investigator masking. Visual acuity
was determined by a separate VA examiner
masked to treatment.” Page 1748
“At baseline and at each study visit thereafter,
refraction and VAwere determined andOCT
was performed by certified examiners masked
both to randomization and to findings of the
previous measurement.” Page 1749
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine participants were discontinued from
the study before week 36. None in pegap-
tanib groups 0.3 mg and 1 mg, 3 in pegap-
tanib 3 mg group (3 mg subgroup: 2 pa-
tients by request at weeks 12 and 16 and 1
by other reason at week 1), 6 in sham group
(5 patients by request at weeks 6, 11, 18,
30, and 33 and 1 due to death at week 8)
Selective reporting (reporting bias) Low risk The study protocol is available and all (pri-
mary and secondary) outcomes that are of
interest in the study have been reported in
the pre-specied way
Other bias Low risk No other source of bias identified
Macugen 2011
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: Australia, Europe, India, North America, and South America
Number of people randomised: 288 (288 eyes)
Average age: 62 years (20-83)
Sex: 43% women
Inclusion criteria:
• 18 years or older
• diabetes
• DMO involving the centre of the macula not associated with ischaemia
(study eye)
• foveal thickness of ≥ 250 µm (centre point thickness measured on OCT)
• BCVA with a letter score of 65-35 (20/50-20/200 Snellen equivalents)
• IOP ≤ 21 mmHg
• clear ocular media and adequate pupillary dilation to allow good quality
stereoscopic fundus photography
• focal or grid laser photocoagulation could be deferred for 18 weeks in the opinion
of the treating ophthalmologist
Exclusion criteria:
• yttrium-aluminum-garnet laser, peripheral retinal cryoablation, laser retinopexy
for retinal tears, or focal or grid photocoagulation within the prior 16 weeks or scatter
(panretinal) photocoagulation 6 months before baseline or likely to be needed within 9
months
• macular ischaemia if a nonperfusion area of > 1 disc area involving the foveal
avascular zone (2 quadrants centred around the FAZ)
Interventions Intervention:
• pegaptanib sodium (0.3 mg) n = 145 (145 eyes)
Comparator:
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• sham injection n = 143 (143 eyes)
Patients received pegaptanib 0.3 mg or sham injections every 6 weeks in year 1 (total 9
injections) and could receive focal/grid photocoagulation beginning at week 18. During
year 2, patients received injections as often as every 6 weeks according to pre-specified
criteria
Outcomes Primary outcome:
• 10-letter (2-line) improvement from baseline at 12 months (ETDRS chart)
Secondary outcomes: (at 12 and 24 months unless otherwise specified)
• 10-letter improvement from baseline at 24 months
• changes from baseline in mean VA
• 15-letter (3-line) improvement in VA
• change in degree of retinopathy of 2 steps based on the 12-step scale of retinopathy
• decrease in retinal thickness at the centre point by 25% and 50%
• focal or grid laser
• change in NEI VFQ-25 and EQ-5D
Follow-up: 12 and 24 months
Notes Dates participants enrolled: September 2005-July 2009
Funding:“Sponsored by Pfizer Inc, New York, New York. The sponsor participated in the
design of the study, in the management, analysis, and interpretation of the data, and in the
preparation and review of the manuscript.” Page 12
Conflict of interest: The authors were employees of Pfizer, the sponsor
Trial registration: NCT00605280
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[...] subjects were centrally allocated to re-
ceive either pegaptanib 0.3 mg or sham in-
jections (1:1) using a dynamic minimization
procedure stratified by the site, hemoglobin
A1c (<7.6% vs >=7.6%), systolic blood pres-
sure (<140 vs >=140mmHg), diastolic blood
pressure (80 vs 80
mmHg), and baseline BCVA (<54 vs >=
54 letters); the dynamic minimization used
a stochastic treatment allocation algorithm
based on the variance method.” Page 3
Allocation concealment (selection bias) Low risk “...subjects were centrally allocated...” Page 3
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To maintain masking, the intravitreal pro-
cedure was identical between the sham and
comparator arms, with the difference lying
only in the application of an empty barrel of
a needleless syringe in the sham procedure de-
signed to mimic the intravitreal injection.”
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Page 3
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Throughout the study, BCVA was measured
at 4 m by the study refractionist/ophthalmol-
ogist, who was masked to the subject’s treat-
ment and to the subject’s previous visual acu-
ity (VA) assessments”. Page 3
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk At 1 year 116/144 (81%) pegaptanib
treated participants and 114/142 (80%)
controls completed the 54 week visit. Ad-
verse events led to discontinuation of 5
treated and 7 control participants
At 2 years 66 participants in each group
completed the 102 week visit
ITT analysis with LOCF was used leading
to the analysis of 133 treated and 127 con-
trol participants
Selective reporting (reporting bias) Low risk All primary outcomes reported
Other bias Low risk No other biases identified
NCT01131585 (RELATION)
Methods Parallel group randomised controlled trial
One eye per person, eye with worse VA selected
Participants Country: Germany
Number of people randomised: 128 (128 eyes)
Average age: 64 years (range 31-79)
Sex: 37% women
Inclusion criteria:
• 18 years or older
• diabetes
• visual impairment (BCVA between 78-39 letters, testing distance 4 m) due to
focal or diffuse DMO in at least one eye eligible for laser treatment in the opinion of
the investigator
Exclusion criteria:
• other eye diseases and conditions that might affect VA
• other eye and systemic treatments
• pregnancy or possibility of being pregnant
• Inability to comply with follow-up
Interventions Intervention:
• ranibizumab (0.5 mg) plus laser n = 85 (85 eyes)
• laser plus sham injection n = 43 (43 eyes)
Ranibizumabwas applied at baseline, 30, 60, 90 days and reapplied at intervals no shorter
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than 28 days and laser was applied at baseline and re-applied if needed at intervals no
shorter than 3 months
Outcomes Primary outcome:
• mean change in BCVA from baseline to month 12 (ETDRS chart, 4 m)
Secondary outcomes:
• adverse events
Notes Dates participants enrolled: July 2010-May 2011, terminated early
Funding: Novartis
Conflict of interest: Novartis
Trial registration: NCT01131585
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-blind, but no details
given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-blind, but no details
given
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing
data: combined laser and ranibizumab: 7/
85 (7%), laser 11/43 (26%)
Selective reporting (reporting bias) High risk Only mean change of VA and harms re-
ported
Other bias Low risk Study terminated early due to European
Medicine Agency approval of ranibizumab
for DMO but this is independent of effect
estimates
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Methods Parallel group randomised controlled trial and within-person study
People randomised to treatment but two eyes sometimes included. If two eyes included
then fellow eye randomised to other treatment
Participants Country: Brazil
Number of people randomised: 48 (63 eyes)
Average age 64 years
Sex: 55% women (based on eyes included in analyses)
Inclusion criteria:
• centre-involved DMO defined as a central subfield thickness > 300 mm on
Spectral Domain-OCT, despite at least 1 session of macular laser photocoagulation
performed at least 3 months previously
• BCVA ETDRS measurement between 0.3 logMAR (Snellen equivalent: 20/40)
and 1.6 logMAR (Snellen equivalent: 20/800)
Exclusion criteria:
• vitreomacular traction on SD-OCT
• PDR needing PRP or anticipated to need PRP in the next 12 months
• macular capillary dropout on fluorescein angiography
• history of glaucoma or ocular hypertension (defined as an intraocular pressure >
22 mmHg)
• an ocular condition (other than diabetes) that, in the opinion of the investigator,
might affect macular oedema or alter VA during the course of the study (eg retinal vein
occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc)
• systemic corticosteroid therapy
• any condition that, in the opinion of the investigator, might preclude follow-up
throughout the study period
Interventions Intervention:
• bevacizumab (1.5 mg) n = ? (32 eyes)
Comparator:
• ranibizumab (0.5 mg) n = ? (28 eyes)
“Retreatment with the originally assigned treatment was performedmonthly if central subfield
thickness was greater than 275 mm.”
“If, after 3 consecutive injections, there was not a reduction in central subfield thickness of at
least 10%or an increase in BCVA of at least 5 letters comparedwith baseline, the patient could,
at the discretion of the treating ophthalmologist, receive focal/grid laser photocoagulation or
continue to receive the same intravitreal medication for an additional 3 consecutive visits.”
Page 503
Outcomes Outcomes reported in publication (primary outcome not specified):
• BCVA (standardised ETDRS refraction protocol)
• retinal thickness (using OCT)
On clinical trials.gov following outcomes listed:
• Primary outcome measures: CSFT change (time frame: monthly from baseline to
week 48; not designated as a safety issue); CSFT measured with SD-OCT
• Secondary outcome measures: BCVA change (time frame: monthly from baseline
to week 48; not designated as a safety issue); BCVA using ETDRS charts
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Notes Dates participants enrolled: July 2010-August 2011
Funding:“Fundac¸ a~o de Amparo a‘ Pesquisa do Estado de Sa~o Paulo (FAPESP), grant
number 2010/013368; and Fundac¸ a~o Apoio ao Ensino, Pesquisa e Assistencia (FAEPA)
do Hospital das Cl ´ nicas da Faculdade de Medicina de Ribeira~o Preto da Universidade
de Sa~o Paulo.”
Conflict of interest: Rodrigo Jorge received travel support from Novartis to attend the
2012 American Society of Retina Specialists (ASRS) meeting
Trial registration: NCT01487629
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “.... received the randomized treatment ac-
cording to a computer-generated sequence”
Page 503
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Examiners (E.T., F.P.P.A., R.P.) weremasked
regarding which treatment drug was used for
each patient. Throughout the study, a single
masked, certified examiner performed BCVA
measurements prior to any other study proce-
dure. Patients, OCT technicians, and fundus
photographers were also masked to treatment
group”. Page 504
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Examiners (E.T., F.P.P.A., R.P.) weremasked
regarding which treatment drug was used for
each patient. Throughout the study, a single
masked, certified examiner performed BCVA
measurements prior to any other study proce-
dure. Patients, OCT technicians, and fundus
photographers were also masked to treatment
group”. Page 504
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The 3 patients excluded from the outcomes
analyses consisted of 1 patient in the IV
ranibizumab group who developed Staphylo-
coccus aureus endophthalmitis after the first
injection (this patient chose to exit the study
and he did not complete any further study
visits); 1 patient in the IV bevacizumab
group who developed advanced posterior sub-
capsular cataract, which precluded adequate
SDOCT images, after the ninth follow-up
visit; and 1 patient from the IV bevacizumab
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group who missed 3 consecutive follow-up vis-
its.” Page 504
Selective reporting (reporting bias) Low risk Both outcomes listed on trial registration
reported
Other bias Low risk No other bias identified
READ2 2009
Methods Parallel group randomised controlled trial
One eye per person, if both eyes were eligible, the eye with the greater centre subfield
thickness was entered
Participants Country: USA
Number of people randomised:126 (126 eyes)
Average age: 62 years
Sex: 59% women
Inclusion criteria:
• 18 years and older
• diabetes
• DMO
• reduction in VA between 20/40-20/320
• centre subfield thickness measured by OCT ≥ 250 µm
• HbA1c ≥ 6% within 12 months before randomisation
• no potential contributing causes to reduced VA other than DMO
• reasonable expectation that scatter laser photocoagulation would not be required
for the next 6 months
Exclusion criteria:
• received focal/grid laser treatment within 3 months
• intraocular injection of steroid within 3 months
• intraocular injection of a VEGF antagonist within 2 months
Interventions Intervention:
• ranibizumab 0.5 mg n = 42 (42 eyes)
• ranibizumab 0.5 mg plus laser photocoagulation n = 42 (42 eyes)
Comparator:
• laser photocoagulation n = 42 (42 eyes)
Patients were randomised 1:1:1 to receive 0.5 mg ranibizumab at baseline and months
1, 3, and 5 (group 1), focal or grid laser photocoagulation at baseline and month 3 if
needed (group 2), or a combination of 0.5 mg ranibizumab and focal or grid laser at
baseline and month 3 (group 3). Starting at month 6, if retreatment criteria were met,
all participants could be treated with ranibizumab
Duration: primary outcome at 6 months, extension to 24 and 36 months
Outcomes As reported in publications:
Primary outcome:
• change in BCVA between baseline and follow-up
Secondary outcomes:
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• change in BCVA between baseline and month 24
• 3 or more lines or 2 or more lines improvement at month 24
• change in foveal thickness between baseline and month 24
• elimination of 90% or 50% excess foveal thickness
On clinical trials.gov
“Primary Outcome Measures: Improvement in vision of 15 or more letters, or achieve a final
vision of 50 letters (20/25) or better if baseline VA was 40 letters (20/40) [Time Frame: 6
mos, 12 mos and 24 mos. Study Extended to 36 mos.] [Designated as safety issue: Yes]
SecondaryOutcomeMeasures: Several outcomes related toOCTmeasurements and fluorescein
angiography. [TimeFrame: 6mos, 12mos and 24mos, study extended to 36mos.] [Designated
as safety issue: Yes]”
Follow-up: 6 months and 24 months.
Notes Dates participants enrolled: not reported
Funding: “Sponsored by the Juvenile Diabetes Research Foundation and Genentech, Inc.”
Conflict of interest: “QDN and PAC have served as members of Expert Panels for Genentech,
Inc. without receiving an honorarium during the time of this study, but JHU has recently
negotiated a contract through which JHU receives compensation. QDN is a consultant for
Bausch and Lomb and has research support from Genentech, Inc., and Regeneron, Inc. PAC
serves on the data and safety monitoring committee for a phase III trial sponsored by Regen-
eron, Inc., and has research support from Genentech, Alimera, and CoMentis for diabetic
macular edema trials. Diana Do receives research support from Genentech. These activites are
being managed by the Conflict of Interest Committee of the Johns Hopkins University School
of Medicine. JSH is a consultant for Genentech, Alcon, Allergan, Bausch and Lomb, Eye-
maginations, Fovea, Genzyme, Heidelburg, IScience, ISTA, Jerini, LPath, NeoVista, Nodal
Vision, Novagali, Novartis, Optherion, Oxigene, Paloma, Pfizer, Regeneron, Resolvyx, Scher-
ing Plough, Scyfix, and VisionCare and has received honoriaria from Genentech, Heidelberg,
Jerini, NeoVista, Optimedica, and Regeneron. JL has received honoriaria from Genentech.
DB is a consultant and has received honoraria from Genentech, Novartis, Alcon, Allergan,
and Pfizer. PA is a consultant for Genentech” (page 2181)
Trial registration: NCT00407381
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear method of sequence generation
and information could not be obtained
from the authors
Allocation concealment (selection bias) Unclear risk Unclear method of allocation concealment
and information could not be obtained
from the authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unclear ifmasked andwhowasmasked and
information could not be obtained from
the authors
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unclear ifmasked andwhowasmasked and
information could not be obtained from
the authors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants randomised to each group: 33
ranibizumab, 34 ranibizumab + laser, 34
laser
Completed particpants at 1 year: 29, 29,
30 (85%-88%)
Completed particpants at 2 years: 24, 26,
24 (71%-76%)
Causes ofmissingdatawere balanced across
groups
Selective reporting (reporting bias) High risk The primary outcome differed in the pro-
tocol and the final report
Other bias Unclear risk No other source of bias identified
RESOLVE 2010
Methods Parallel group randomised controlled trial
One eye per person, eye with worse VA selected
Participants Country: unclear exactly where conducted. Investigators from Australia, Denmark, Aus-
tria, France, Germany, Italy, Korea, Portugal, Spain, Switzerland, UK
Number of people randomised: 151 (151 eyes)
Average age: 64 years (range 32-85)
Sex: 46% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus,
• stable HbA1c levels (≤ 12%)
• DMO with centre involvement in at least one eye
(study eye)
• CRT ≥ 300 µm (Stratus Zeiss Meditec)
• BCVA score between 73-39 letters inclusively, using ETDRS charts at a testing
distance of 4 m (approximate Snellen equivalent of 20/40-20/160)
• decreased vision attributed to foveal thickening from DMO, that was not
explained by any other causes in the opinion of the investigator
• laser photocoagulation, additional or first treatment, could be withheld for at least
3 months after randomisation
Exclusion criteria:
• PRP (focal peripheral laser photocoagulation) performed within 6 months prior
to study entry. Grid/central laser photocoagulation was excluded except for patients
with only mild laser burns at least 1000 µm from the center of the fovea performed
more than 6 months before the trial commenced
• proliferative diabetic retinopathy in the study eye, with the exception of tufts of
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neovascularization < 1 disc area with no vitreous haemorrhage. As well as those with
area of retinal ischaemia ≥ 500 µm and located ≤ 500 µm from the center of the
macula of the study eye as assessed by fluorescein angiography at visit 1 and confirmed
by a central reading centre
• patients with unstable medical conditions such as poor glycaemic or BPcontrol
• patients with hypertension for whom a change in antihypertensive treatment was
initiated within 2 months preceding start of trial were not enrolled unless BP was
maintained below 160/100 mmHg for at least 1 month prior to the first day of the trial
by antihypertensive treatment
• history of treatment with systemic corticosteroids within 4 months prior to
randomisation or topical, rectal or inhaled corticosteroids in current use more than 2
times per week
• previous participation in a study on antiangiogenic drugs
• ocular disorders and history of any condition that might confound the
interpretation of study results or might render patient at high-risk for treatment
complications
• ocular inflammation in either eye or history of cataract surgery in the study eye
within 6 months before study initiation
• pre-menopausal women not using adequate contraception and pregnant or
nursing women
Interventions Intervention:
• ranibizumab (0.3 mg or 0.5 mg) n = 102 (102 eyes)
Comparator:
• sham injection n = 49 (49 eyes)
Outcomes Primary outcome:
• mean change in BCVA from baseline at 1 month and 12 months
Secondary outcomes:
• mean change in BCVA and CMT from baseline at 12 months
• categorised BCVA outcome
• safety
Notes Dates participants enrolled: not reported
Funding: Novartis
Conflict of interest: authors served on advisory boards forNovartis and receivedhonoraria
and travel and accommodation payments; Novartis employees assisted with the analysis,
interpretation and writing
Trial registration:NCT00284050
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomised 1:1:1 to
either ranibizumab (0.3 mg or 0.5 mg) or
sham treatment according to a computer-gen-
erated randomised allocation schedule” On-
line appendix page 1
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Allocation concealment (selection bias) Low risk “...allocation schedule (kept at a secure site
and accessible only to the injecting physician”
Online appendix page 1
“Based on the patient strata the injecting
physician would take the treatment allocation
card and tear-off the cover and follow instruc-
tions to choose vial from the box as indicated
(3 boxes, randomisation block size 3). The
randomisation data were kept strictly confi-
dential until database
lock; not accessible to anyone involved in the
study with the exception of injecting physician
(s) and drug accountability monitor.”Online
appendix page 1
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Sham injection for masking patients
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Masking was maintained through appoint-
ment of a minimum of 2 investigators at each
study site; unmasked injecting physician and a
masked evaluating physician (roles could not
be switched).” Online appendix page 1
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who completed the trial at 1
year: 92/102 ranibizumab and40/49 sham.
Causes of missingness were balanced
ITT analysis with LOCF was used
Selective reporting (reporting bias) Low risk We could not find a protocol, but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Low risk No other source of bias identified
RESPOND 2013
Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: Canada
Number of people randomised: 239 (239 eyes)
Average age: 62 years (range 26-87)
Sex: 40% women
Inclusion criteria:
• 18 years or older
• stable type 1 or type 2 diabetes with HbA1c ≤ 10%)
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• visual impairment due to focal or diffuse DMO in at least one eye eligible for laser
treatment in the opinion of the investigator
Exclusion criteria:
• active conditions in study eye that could prevent improvement in VA
• active eye infection or inflammation
• history of stroke, renal failure or active hypertension
Interventions Intervention:
• ranibizumab (0.5 mg) n = 80 (80 eyes)
• ranibizumab (0.5 mg) plus laser n = 78 (78 eyes)
Comparator:
• laser n = 81 (81 eyes)
For combination and monotherapy, ranibizumab was administered as 3 monthly injec-
tions, then 10 months PRN injections given/withheld based on DME stability criteria.
Laser was administered according to ETDRS guidelines at intervals of > 3 months
Outcomes On clinical trials.gov
Primary Outcome Measures: Measure: mean change from baseline in Best Correct Visual
Acuity (BCVA) [Time Frame: 12 months] [Designated as safety issue: No]
Secondary Outcome Measures: Measure: number of patients with visual acuity above 73
letters [Time Frame: 3, 6, 9 and 12 months]
Measure: number of patients with improvement in BCVA [Time Frame: 3, 6, 9 and 12
months]
Measure: time course of BCVA changes [Time Frame: 3, 6, 9 and 12 months]
Measure: change in central retinal thickness and other anatomical changes [Time Frame: 3,
6, 9 and 12 months]
Measure: 15-letter (3-line) gain in BCVA [Time Frame: 3, 6, 9 and 12 months]
Notes Dates participants enrolled: July 2010-March 2013
Funding: Novartis
Conflict of interest:
Trial registration: NCT01135914
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unmasked study (described as open-label)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unmasked study (described as open-label)
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Incomplete outcome data (attrition bias)
All outcomes
High risk More missing data in the laser arm (27%)
, mainly due to lack of efficacy, compared
to the 2 ranibizumab arms (5%-6%)
Selective reporting (reporting bias) Low risk VA, OCT data and harms adequately re-
ported (only loss of vision not reported)
Other bias Low risk No other bias identified
RESTORE 2011
Methods Parallel group randomised controlled trial
One eye per person, eye with worse VA selected unless other eye more suitable for
treatment
Participants Country: 10 European countries, Australia, Canada, Turkey
Number of people randomised: 345 (345 eyes)
Average age: 63 years
Sex: 42% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus (according to the American Diabetes Association or World
Health Organization guidelines)
• HbA1c ≤ 10%
• visual impairment due to DMO
• stable medication for the management of diabetes within 3 months before
randomisation and expected to remain stable during the study
• visual impairment due to focal or diffuse DMO in at least 1 eye that was eligible
for laser treatment in the opinion of the investigator
• BCVA letter score between 78-39, both inclusive, based on ETDRS-like VA
testing charts administered at a starting distance of 4 m (approximate Snellen
equivalent 20/32-20/160)
• decreased vision due to DMO and not other causes, in the investigator’s opinion
(at visit 1)
Exclusion criteria:
• concomitant conditions in the study eye that could prevent the improvement in
VA on the study treatment in the investigator’s opinion
• active intraocular inflammation or infection in either eye
• uncontrolled glaucoma in either eye (e.g. IOP > 24 mmHg on medication, or
from the investigator’s judgement)
• laser PRP (within 6 months) or focal/grid laser photocoagulation (within 3
months) before study entry
• treatment with antiangiogenic drugs in the study eye within 3 months before
randomisation
• history of stroke
• systolic BP > 160 mmHg or diastolic BP > 100 mmHg
• untreated hypertension
• change in antihypertensive treatment within 3 months preceding baseline
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Interventions Intervention:
• ranibizumab (0.5 mg) plus sham laser n = 116 (116 eyes)
• ranibizumab (0.5 mg) plus laser n = 118 (118 eyes)
Comparator
• laser treatment plus sham injections n = 111 (111 eyes)
Outcomes Primary outcome:
• mean average change in BCVA from baseline over 12 months
Secondary outcomes:
• VA improvement
• BCVA letter score 73 (20/40 Snellen equivalent) at month 12
• mean change in BCVA letter score
• mean change in central retinal (subfield) thickness
• patient-reported outcomes
• safety
Follow-up: 12 months
Notes Dates participants enrolled: not reported
Funding: Novartis
Conflict of interest: authors reported financial support of Novartis or were Novartis
employees
Trial registration: NCT00906464
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was produced by, or un-
der the responsibility of, Novartis Drug Sup-
plyManagement using a validated system that
automated the random assignment of treat-
ment arms to randomization numbers in the
specified ratio.” Appendix 1
Allocation concealment (selection bias) Low risk Central randomisation using an electronic
Case Report Form after each patient was
included by study investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The masked BCVA assessor evaluated the vi-
sual acuity of the patient and provided the
results to the evaluating investigator who also
was masked to the treatment assignment. The
evaluating investigator was responsible for all
other aspects of the study, excluding the injec-
tion procedures. Based on all the performed
clinical assessments and the visual acuity (VA)
results received from the BCVA assessor, the
evaluating investigator had to decide on the
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treatment requirements for the patient each
month and communicated this decision to the
treating investigator. The treating investiga-
tor was unmasked to the treatment assignment
and performed all injections or laser treat-
ment as well as the corresponding sham treat-
ments. He/she was required not be involved
in any other aspect of the study and not to
divulge the patient’s treatment assignment to
anyone. Once the designated roles were de-
termined, the roles could not be switched at
any time during the conduct of the study. Ev-
ery effort was made to limit the number of
unmasked study personnel to ensure the in-
tegrity of this masked study. An independent
review and standardized grading of fundus
photography, fluorescein angiography, and op-
tical coherence tomography (OCT) images for
the patients screened and enrolled in the study
was performed at a central reading center that
did not have access to any other data of the
patients.” Appendix 1
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patients randomised in each group were:
116 ranibizumab, 118 ranibizumab + laser,
111 laser
At 1 year complete patients were 87.9%,
87.3% and 88.3% respectively
There were 2 deaths in each of the 3 treat-
ment arms
Used ITT analysis with LOCF
Selective reporting (reporting bias) Low risk We could not find a protocol, but primary
outcomes were stated in the methods and
were those routinely used in the field
Other bias Unclear risk No other source of bias identified
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Methods Parallel group randomised controlled trial
One eye per person, unclear how eye selected
Participants Country: USA and South America
Number of people randomised: 759 (759 eyes)
Average age: 62 years
Sex: 43% women
Inclusion criteria:
• 18 years or older
• diabetes mellitus
• decreased vision from DMO (study eye BCVA, 20/40-20/320 Snellen equivalent
using ETDRS testing)
• macular oedema (TD-OCT) central subfield thickness ≥ 275 µm
Exclusion criteria:
• prior vitreoretinal surgery
• recent history (within 3 months of screening) of panretinal or macular laser in the
study eye
• intraocular corticosteroids antiangiogenic drugs
• uncontrolled hypertension
• uncontrolled diabetes (HbA1c >12%)
• recent (within 3 months) cerebrovascular accident, or myocardial infarction
Interventions Intervention:
• ranibizumab (0.3 mg or 0.5 mg) n = 244 (244 eyes)
Comparator:
• sham injection n = 122 (122 eyes)
“The median number of ranibizumab injections was 24. The mean number of macular
laser treatments over 24 months was 1.8 and 1.6 in the sham groups and 0.3 to 0.8 in
the ranibizumab groups. Substantially more sham-treated patients received macular laser
under the protocol-specied criteria or underwent panretinal photocoagulation for proliferative
diabetic retinopathy.” (page 5)
Outcomes Primary outcome:
• gain of 15 or more ETDRS letters in BCVA score from baseline at 24 months
(corresponding to 3 lines on the eye chart)
Secondary outcomes: (at 24 months)
• mean change from baseline BCVA score over time
• proportion of participants with BCVA Snellen equivalent of 20/40
• mean change from baseline BCVA score over time in participants with focal
oedema as assessed on fluorescein angiography
• proportion of participants losing 15 letters in BCVA score from baseline
• mean change from baseline in OCT CFT over time
• proportion of participants with a 3-step progression from baseline in ETDRS
retinopathy severity on fundus photography
• proportion of participants with resolution of leakage on FA
• mean number of macular laser treatments
Follow-up: 24 months
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Notes Dates participants enrolled: June 2007-January 2009
Funding:“This study was supported by Genentech Inc. Support for third-party writing assis-
tance by Ivo Stoilov, MD, CMPP, of Envision Scientific Solutions was provided by Genentech
Inc.” “The sponsor participated in the design and conduct of the study; collection, manage-
ment, analysis, and interpretation of the data; and preparation and review of the manuscript.
” (page 1121)
Conflict of interest: “Dr Ip is a consultant/advisor for Eye Technology Ltd, Genentech Inc,
NicOx, Notal Vision, QLT Phototherapeutics Inc, Regeneron, and Sirion and has received
grant support from Allergan Inc. Drs Hopkins and Ehrlich and Ms Wong are employees of
Genentech Inc, a member of the Roche Group. Drs Hopkins and Ehrlich hold equity and/or
options in Roche.” (page 1121)
Trial registration: RIDE NCT00473382 RISE NCT00473330
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified by study eye
BCVA (55 vs 55 ETDRS letters), baseline
HbA1c (<=8% vs >8%), priorDME therapy
in the study eye (yes vs no), and study site. Dy-
namic randomization was used to obtain ap-
proximately a 1:1:1 ratio among groups (Fig
1). Randomization was done via interactive
phone system. The sponsor developed the spec-
ifications for the randomization, and a third
party programmed and held the randomiza-
tion algorithm.” Page 3, Nguyen et al
Allocation concealment (selection bias) Low risk “Randomization was stratified by study eye
BCVA (55 vs 55 ETDRS letters), baseline
HbA1c (<=8% vs >8%), priorDME therapy
in the study eye (yes vs no), and study site. Dy-
namic randomization was used to obtain ap-
proximately a 1:1:1 ratio among groups (Fig
1). Randomization was done via interactive
phone system. The sponsor developed the spec-
ifications for the randomization, and a third
party programmed and held the randomiza-
tion algorithm.” Page 3, Nguyen et al
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Ocular assessments, including the need for
macular laser, were made by evaluating
ophthalmologists masked to patients’ treat-
ment assignments. Study treatments were ad-
ministered by treating ophthalmologists un-
masked to treatment assignments but masked
to ranibizumab dose. To improve patient
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masking, all patients received subconjuncti-
val anesthesia before sham or active injections
(performed as previously described).22 Study
site personnel (except treating physicians and
assistants), central reading center personnel,
and the sponsor and its agents (except drug ac-
countability monitors) were masked to treat-
ment assignment. Treating physicians were
masked to the assigned dose of ranibizumab.
” Page 3, Nguyen et al
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The 2-year study period was completed by
83.3% of participants in RISE and by 84.
6% in RIDE Causes of missingness not re-
ported
Selective reporting (reporting bias) Low risk All VA cut-offs and secondary outcomes
available at 2 years, although not at 1 year,
as pre-planned
Other bias Low risk No other bias identified
Soheilian 2007
Methods Parallel group randomised controlled trial
One or two eyes per person, in bilateral cases unclear how the second eye allocated
Participants Country: Iran
Number of people randomised: 129 (150 eyes)
Average age: 61 years
Sex: 49% women
Inclusion criteria:
• clinically significant DMO based on ETDRS criteria
Exclusion criteria:
• previous PRP or focal laser photocoagulation
• prior intraocular surgery or injection
• history of glaucoma or ocular hypertension
• VA of 20/40 or better, or worse than 20/300
• presence of iris neovascularisation
• high-risk PDR
• significant media opacity
• monocularity
• pregnancy
• serum creatinine ≥ 3 mg/dL
• uncontrolled diabetes mellitus
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Interventions Intervention:
• bevacizumab (1.25 mg) n = ? (50 eyes)
Comparator:
• laser photocoagulation n = ? (50 eyes)
Re-treatment was performed at 12-week intervals whenever indicated
There was another intervention arm which combined bevacizumab with triamcinolone,
but this is not included in this review (n = 50 eyes)
Outcomes Primary outcome:
• change in BCVA (logMAR) at week 24 (data available at 36 weeks)
Secondary outcomes:
• VA change
• CMT change assessed by OCT
• injection-related complications
Notes Dates participants enrolled: September 2005-May 2007
Funding: “Supported by the Ophthalmic Research Center of Shahid Beheshti University
(MC) Tehran, Iran.” (page 1150)
Conflict of interest: “The author(s) have no proprietary or commercial interest in any ma-
terials discussed in this article” (page 1150)
Trial registration: NCT00370669
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block length varied randomly (6, 12). Ran-
dom allocation sequence was performed by a
biostatistician. The detail of series was un-
known by the study investigators.” Page 2 So-
heilian 2009
Allocation concealment (selection bias) Low risk “Randomization was performed using ran-
domblock permutationmethod according to a
computer-generated randomization list. The
block length varied randomly (6, 12). Ran-
dom allocation sequence was performed by a
biostatistician. The detail of series was un-
known by the study investigators.” Page 2 So-
heilian 2009
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A sham laser procedure (20 seconds) was per-
formed by aiming the laser beam on the mac-
ula for the eyes in the IVB and IVB/IVT
groups. In the MPC group, a sham injection
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was done by a needleless syringe pressed against
the conjunctiva. To keep the masking process,
patients were prevented from seeing the sy-
ringes. All procedures were run by staff mem-
bers other than the study investigators to pre-
serve investigator masking. Best-corrected VA
measurement and OCT were performed by
certified examiners masked both to the ran-
domization and to the findings of previous
measurements.” Page 2-3 Soheilian 2009
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were 6 missing eyes out of 50 at 36
weeks in the IVB group and 12 out of 50
in the photocoagulation group and causes
were not clearly unrelated to VA outcome,
except for 2 deaths. In a subsequent pub-
lication in 2012 the authors reported 39
(78%) and 38 (76%) eyes in the two arms;
8 participants (12 eyes) missing were dead
for causes unrelated to treatment, but other
causes of death were not reported
Selective reporting (reporting bias) Low risk The primary outcomes are continuous
measures and no arbitrary cut-points were
used
Other bias High risk There was an imbalance of baseline VA
in the IVB and photocoagulation groups
: 0.71 logMAR versus 0.55 logMAR. Al-
though there was a potential unit of anal-
ysis issue (150 eyes of 129 patients, 16%
of participants had both eyes included),
comparisons were made in a marginal re-
gression model (based on generalised esti-
mating equation methods) adjusted for the
baseline values and to eliminate any pos-
sible correlation effects between the 2 eyes
of participants in bilateral enrolled cases.
However, we could not take correlation
into account when analysing dichotomous
VA definitions
Abbreviations
BCVA: best-corrected visual acuity
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BP: blood pressure
CMT: central macular thickness
CRT: central retinal thickness
CSFT: central subfield macular thickness
CSMO: clinically significant macular oedema
DMO: diabetic macular oedema (DME: US spelling edema)
ECG: electrocardiogram
EQ-5D: EuroQol 5D
ETDRS: Early Treatment Diabetic Retinopathy Study
FAZ: foveal avascular zone
FFA: fundus fluorescein angiography
GLD: greatest linear dimension
HbA1c: glycated haemoglobin
IOP: intraocular pressure
ITT: intention-to-treat
iv: intravenous
IV: intravitreal injection
IVB: intravitreal bevacizumab
IVT: intravitreal triamcinolone
LOCF: last observation carried forward
NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25
OCT: optical coherence tomography
PDR: proliferative diabetic retinopathy
PFCL: perifoveal capillary loss
PRP: panretinal photocoagulation
SD-OCT: spectral-domain optical coherence tomography
TD-OCT: time-domain optical coherence tomography
VA: visual acuity
VEGF: vascular endothelial growth factor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmadieh 2013 Not an RCT
CRFB002DFR08 (LUDIC) Single-arm study
CRFB002DGB14 (RELIGHT) Single-arm study
CRFB002DNO02 (PTIMAL) Single-arm study
DRCRnet 2007 Follow-up at 12 weeks only
DRCRnet 2011 Follow-up at 14 weeks only. RCT comparing ranibizumab (2 injections), triamcinolone (1 injec-
tion) to sham in patients with DMO undergoing grid and panretinal laser photocoagulation
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DRCRnet 2012 Follow-up of DRCRnet 2010 comparing prompt to deferred laser in patients treated for
ranibizumab for DMO: does not report on comparison of ranibizumab with laser
Faghihi 2008 Follow-up at 16 weeks only
Lim 2012 Bevacizumab compared to intravitreal triamcinolone
Paccola 2008 Single injection of intravitreal triamcinolone acetonide (4mg/0.1mL) compared to single injection
of intravitreal bevacizumab (1.5 mg/0.06 mL). Duration: 24 weeks
Solaiman 2010 Single intravitreal injection of bevacizumab (inadequate dose); follow-up 6 months
Zehetner 2013 Physiological study of anti-VEGF levels only
Zhang 2013 Bevacizumab was combined with triamcinolone
Abbreviations
DMO: diabetic macular oedema
RCT: randomised controlled trial
VEGF: vascular endothelial growth factor
Characteristics of studies awaiting assessment [ordered by study ID]
NCT01171976 (RETAIN)
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: single masked (investigator)
Participants 374 at 52 centres in Europe
Interventions Experimental: 0.5 mg ranibizumab TE + laser
Experimental: 0.5 mg ranibizumab TE alone
Active comparator: 0.5 mg ranibizumab alone given PRN
Outcomes Primary outcome:
Mean average change from baseline in BCVA over a 12-month treatment period
Secondary outcomes:
Evaluate whether the mean average change from baseline in BCVA obtained with either a 0.5 mg ranibizumab TE
with adjunctive laser, or with 0.5 mg ranibizumab TE is non-inferior to 0.5 mg ranibizumab PRN
Investigate, within the TE dosing concepts, the impact of laser treatment on the number of re-treatments
Investigate the efficacy of 0.5 mg ranibizumab TE with adjunctive laser, 0.5 mg ranibizumab TE and 0.5 mg
ranibizumab PRN measured by the overall score assessed by VFQ-25 and EQ-5D
Time course of mean BCVA change from baseline to month 12, and up to month 24 obtained with either a 0.5 mg
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ranibizumab TE with adjunctive laser, or with 0.5 mg ranibizumab TE and with 0.5 mg ranibizumab PRN
Tocompare the changes in development ofCSFTof 0.5mg ranibizumabTEwith adjunctive laser, 0.5mg ranibizumab
TE and 0.5 mg ranibizumab PRN over time
Notes Sponsor: Novartis Pharmaceuticals
Trial ID: NCT01171976
Abbreviations
BCVA: best-corrected visual acuity
CFST: central subfield macular thickness
EQ-5D: EuroQol 5D
PRN: Pro Re Nata
TE: treat and extend
VFQ-25: Visual Function Questionnaire 25-item
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-TRC-12002417
Trial name or title A randomized controlled trial to compare the efficacy and safety of 1) macular laser vs 2) repeated intravitreal
bevacizumab vs 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema
Methods Parallel group RCT
Participants People with type 2 diabetes and diabetic macular oedema
Interventions Group 1 (Control): macular laser photocoagulation performed every 4 months unless the deferral criteria are
met. Group 2: intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months and repeated en
bloc every 4 months unless the deferral criteria are met
Group 3: Intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months, followed by macular
laser photocoagulation at month 3; and repeated en bloc every 4 months unless the deferral criteria are met
Outcomes BCVA at 2 years
Starting date Unknown; trial registered 13 August 2013
Contact information joycekung@cuhk.edu.hk
Notes
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NCT00387582
Trial name or title Lucentis in the treatment of macular edema - a phase II, single center, randomized study to evaluate the
efficacy of ranibizumab versus focal laser treatment in subjects with diabetic macular edema
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants 49, country: USA
Interventions Experimental: I
Lucentis injections for the first 3 months of the study and then according to the protocol for the duration of
the trial
Active comparator: II
Argon laser treatment at enrolment and then according to the protocol for the duration of the study
Outcomes Primary outcome (time frame: 6 and 12 months):
Prevention of vision loss at 1 year as evidenced by ETDRS visual acuity
Secondary outcome:
Reduction in retinal thickening based on OCT
Starting date Study start date: July 2006
Study completion date: February 2009
Contact information Roy A Goodart, MD, Principal Investigator, Rocky Mountain Retina Consultants
Notes Investigator contacted
NCT00901186
Trial name or title A randomized, open label, multicenter, laser-controlled phase II study assessing the efficacy and safety of
ranibizumab (intravitreal injections) vs laser treatment in patients with visual impairment due to diabetic
macular edema
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants 84, country: Spain
Interventions Drug: ranibizumab
Procedure: laser
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Outcomes Primary outcome:
Change BCVA with ranibizumab 0.5 mg versus laser 12-month
Secondary outcomes:
Improvement in BCVA with ranibizumab (0.5 mg) versus laser 12-month measure
Mean BCVA change with ranibizumab (0.5 mg) versus laser
% of participants with VA > 73 letters with ranibizumab (0.5 mg) versus laser
Time and mean change in central retinal thickness by OCT with ranibizumab (0.5 mg) versus laser
Monitoring and registry of all adverse events, serious adverse events, VA, concomitant medications, ophthal-
mologic exams (including count of fingers and movement of the hands), IOP, vital constants and analytical
parameters
Starting date Study first received: 11 May 2009
Last updated: 16 November 2011
Study completion date: August 2012
Contact information Novartis (Novartis Pharmaceuticals)
Notes Sponsor: Novartis (Novartis Pharmaceuticals)
NCT00989989 (REVEAL)
Trial name or title Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic
macular edema (REVEAL)
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: double masked (patient, investigator)
Primary purpose: treatment
Participants 395, country: China, Hong Kong, Korea, Japan, Singapore, Taiwan
Interventions Experimental Group 1 (adjunctive group): drug, ranibizumab; procedure, laser photocoagulation
Experimental Group 2 (monotherapy group): drug, ranibizumab
Active comparator Group 3 (laser control group): procedure, laser photocoagulation
Outcomes Primary Outcome Measures:
· Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
Secondary Outcome Measures:
· Change From Baseline on Central Retinal Subfield Thickness (CRST) at Month 12
Central Retinal Subfield Thickness (CRST) was measured using Optical Coherence Tomography (OCT) in
micrometers. A negative change from baseline of CRST indicates improvement
· Percent of Participants With Anatomical Changes in Intra-retinal Cysts at End of Study Compared to
Baseline
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Presence or absence of intra-retinal cysts in any of the 6 sections of the study eye was measured using Optical
CoherenceTomography (OCT). A complete resolutionor decrease frombaseline of intra-retinal cysts indicates
improvement
· Percent of ParticipantsWith Anatomical Changes in Sub-retinal Fluid at End of Study Compared to Baseline
Presence or absence of sub-retinal fluid in any of the 6 sections of the study eye was measured using Optical
Coherence Tomography (OCT). A complete resolution or decrease from baseline of sub-retinal fluid indicates
improvement
· Percent of Participants With Visual Acuity Above 73 Letters at Month 12
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study
(ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance
of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 indicates a positive
outcome
· Percent of Participants Who Gained >= 10 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A gain of 10 or more BCVA letters from baseline indicates improvement.
A BCVA of 84 letters or more at Month 12 indicates improvement
· Percent of Participants Who Lost >= 10 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A loss of 10 or more BCVA letters from baseline indicates worsening
· Percent of Participants Who Gained >= 15 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A gain of 15 or more BCVA letters from baseline indicates improvement.
A BCVA of 84 letters or more at Month 12 indicates improvement
· Percent of Participants Who Lost >= 15 Letters at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A loss of 15 or more BCVA letters from baseline indicates worsening
· Best-Corrected Visual Acuity (BCVA) Mean Change From Baseline at Month
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy
Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The
range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement
· Patient Outcome Measure Euro Quality of Life Questionnaire (EQ-5D)
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health
outcomes related to mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Participants
self-rate their health on a visual, vertical analogue scale from 0 to 100 where the endpoints are labeled “Best
imaginable health state” (100) and “worst imaginable health state” (0)
Starting date Study start date: September 2009
Study completion date: August 2011
Contact information Novartis
Notes Results posted on clinical trials.gov
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NCT00997191 (IBeTA)
Trial name or title Intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation for diabetic
macular edema (IBeTA)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants 12, country: Brazil
Interventions Procedure: laser photocoagulation
Drug: intravitreal triamcinolone
Drug: intravitreal bevacizumab
Outcomes Primary outcome (time frame: 1 year):
BCVA
Secondary outcomes:
Macular mapping test
Multifocal electroretinogram
CMT
Starting date Study start date: October 2009
Estimated study completion date: October 2011
Contact information Bianka Yukari Nakase Yamasato Katayama, Faculdade de Medicina de Ribeirão Preto da Universidade de São
Paulo
Notes
NCT01100307
Trial name or title A phase 3 study to compare the efficacy and safety of 0.3 mg pegaptanib sodium to sham injections in subjects
with diabetic macular edema
Methods Allocation: randomised endpoint classification; safety/efficacy study intervention model; parallel assignment
Masking: double masked
Participants 243, country: Japan
Interventions Drug: pegaptanib sodium
Other: sham injection
Outcomes Number of participants who experience a ≥ 10 letter improvement of VA in ETDRS chart from baseline to
week 24: Double masked phase (time frame: baseline and week 24; designated as safety issue: no)
• Change from baseline in VA: double masked phase (time frame: baseline, weeks 6, 12, 18, and 24)
(designated as safety issue: no) changes in VA were monitored through refraction and BCVA measurements
using retro-illuminated, modified Ferris-Bailey ETDRS charts
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• Number of participants underwent focal/grid laser, or vitrectomy: double masked phase (time frame:
up to 24 weeks; designated as safety issue: no) Included focal laser photocoagulation, grid laser
photocoagulation, and vitrectomy
• Number of participants who experience a ≥ 10 letter improvement of VA in ETDRS chart from
baseline at week 54: open phase (time frame: baseline and week 54; designated as safety issue: no) BCVA
measurements performed using retro-illuminated, modified Ferris-Bailey ETDRS charts
• Change from baseline in VA: open phase (time frame: baseline, weeks 30, 36, 42, 48 and 54;
designated as safety issue: no) changes in VA were monitored through refraction and BCVA measurements
using retro-illuminated, modified Ferris-Bailey ETDRS charts
• Number of participants who underwent focal/grid laser, or vitrectomy: ppen phase (time frame: weeks
24 to 54; designated as safety issue: no) Included focal laser photocoagulation, grid laser photocoagulation,
and vitrectomy
Starting date Study start date: May 2010
Estimated study completion date: August 2012
Contact information See http://clinicaltrials.gov/ct2/show/NCT01100307
Notes Sponsor: Pfizer
NCT01100401 (READ3)
Trial name or title Ranibizumab for edema of the macula in diabetes: Protocol 3 with high dose - the READ 3 study
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double masked
Participants 92, country: USA
Interventions Drug: pegaptanib sodium
Other: sham injection
Outcomes Adverse events (time frame: 3, 6, 9 and 12 months; designated as safety issue: yes). The primary outcomes for
safety and tolerability include: incidence and severity of systemic and ocular adverse events associated with
repeated intravitreal injections of 2 doses of ranibizumab in subjects with DMO such as cardiovascular events,
intraocular reactions (inflammation), vitreous haemorrhage, retinal detachment, endophthalmitis (intraocular
infection), increased IOP, and cataract formation, among others
Secondary outcomes: VA (time frame: 3, 6, 9 and 12 months; designated as safety issue: no) mean change in
BCVA (ETDRS) at 4 m in the study eye over time through month 12
Anatomic retinal changes (time frame: 3, 6, 9 and 12 months; designated as safety issue: yes) anatomic retinal
changes in the study eye as assessed by colour fundus photography, fluorescein angiography, and OCT, from
baseline to months 6 and 12, including: extent of fluorescein leakage fromCSMO progression to proliferative
diabetic retinopathy by ETDRS grade. Change in CRT, as assessed by OCT. Change in central retinal volume,
as assessed by OCT
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Starting date Starting date: February 2010
Study completion date: March 2013
Contact information Jennifer Denton jdenton2@jhmi.edu
Notes
NCT01112085 (MINIMA-2)
Trial name or title MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: single masked (patient)
Participants Estimated enrolment: 72, country: Mexico
Interventions Experimental: ranibizumab 0.05 mg (low dose). Intravitreal injections of 0.05 mg ranibizumab over 6months
then additional treatment with ranibizumab 0.05 mg as needed (according to re-treatment criteria)
Experimental: ranibizumab 0.5 mg (high dose). Intravitreal injections of 0.5 mg ranibizumab over 6 months
then additional treatment with ranibizumab 0.5 mg as needed (according to re-treatment criteria)
Outcomes Primary outcome (time frame: 6 months and 12 months):
BCVA: Improvement in vision of BCVA of 15 or more letters, or a final vision of 20/25 (50 letters) or better
if BCVA was 20/40 (40 letters)
Secondary outcomes (time frame: 6 months and 12 months):
Mean change in CRT and volume by OCT
Changes in CRT and volume assessed by OCT
Starting date Study start date: April 2010
Estimated study completion date: December 2011
Estimated primary completion date: September 2011 (final data collection date for primary outcomemeasure)
Contact information Fundación Mexicana de Retina
Notes Sponsor: Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Investigators contacted
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NCT01445899 (MATISSE)
Trial name or title An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized,
double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655
alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema (MATISSE
STUDY)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double masked (subject, caregiver, investigator)
Participants 264, countries: USA, Israel
Interventions Drug: PF-04523655 (Stratum I)
Drug: PF-04523655 and ranibizumab
Drug: ranibizumab
Drug: PF-04523655 (Stratum II)
Outcomes Primary outcomes:
Safety and dose-limiting toxicities (Stratum I): to determine the safety and dose-limiting toxicities of a single
intravitreal (IVT) injection of PF-04523655 in people with low vision
Pharmacokinetics (Stratum I): to determine the pharmacokinetics (PK) of a single IVT injection of PF-
04523655 in people with low vision
Safety and tolerability (Stratum II): to evaluate the safety and tolerability of PF-04523655 alone and in
combination with ranibizumab in patients with DMO
Efficacy (Stratum II): to evaluate the ability of PF-04523655 alone and in combination with ranibizumab to
improve visual acuity compared to ranibizumab alone in people with DMO
Starting date Study start date: February 2012
Estimated study completion date: July 2014
Contact information Quark Pharmaceuticals
Notes Sponsor: Quark Pharmaceuticals
Consider putting in excluded studies
NCT01476449
Trial name or title Monthly ranibizumab versus treat and extend ranibizumab for diabetic macular edema
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: open-label
Participants 20, country: USA
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Interventions Active comparator: monthly intravitreal injections of ranibizumab for the duration of the study
Experimental (TE ranibizumab): intravitreal injections of ranibizumab administered until participants’ mac-
ulae are anatomically ’dry’, at which point the evaluation and injection interval will be extended
Outcomes Not available
Starting date Study start date: November 2011
Estimated study completion date: June 2013
Contact information Retina Vitreous Associates of Florida
Notes
NCT01487629 (IBERA-DME)
Trial name or title Bevacizumab versus ranibizumab for the treatment of diabetic macular edema (IBERA-DME)
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Participants 53, country: Brazil
Interventions Drug: bevacizumab 1.5 mg, intravitreal, throughout the study
Drug: ranibizumab 0.5 mg, intravitreal, throughout the study
Outcomes Primary outcomes:
CSFT change
CSFT measured with spectral-domain OCT
Secondary outcomes:
BCVA change
BCVA using ETDRS charts
Starting date Study start date: April 2010
Estimated study completion date: September 2012
Contact information Rodrigo Jorge, Principal Investigator, University of Sao Paulo
Notes Sponsor: University of Sao Paulo
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NCT01552408 (DAVE)
Trial name or title A phase I/II, randomized, study for diabeticmacular edema using 0.5mg ranibizumab combinedwith targeted
PRPmonthly for 4 months,then PRN vs 0.5mg ranibizumab 4months monotherapy, then as needed (DME-
AntiVEgf ) DAVE
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: single group assignment
Masking: Open Label
Participants 40, country: USA
Interventions Active Comparator: 0.50mg ranibizumab
4 mandatory monthly injections of 0.50mg ranibizumab, retreatment will be as needed
Experimental: Targeted PRP with 0.50mg ranibizumab
4 mandatory monthly injections of 0.50mg ranibizumab, and at V3 (day7) will receive Targeted PRP, then
treatment with ranibizumab will be PRN
Outcomes NA
Starting date Study Start date: March 2012
Estimated Study completion date: March 2014
Contact information David M Brown, MD, Director Greater Houston Retina Research, Greater Houston Retina Research
Notes Sponsor: David M Brown, MD
Collaborator: Genentech
NCT01565148 (IDEAL)
Trial name or title A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal
Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in
the Treatment of Diabetic Macular Edema (the iDEAL Study)
Methods Allocation: Randomised
Endpoint classification: Safety/efficacy study
Intervention model: Factorial assignment
Masking: open-label
Participants 208, country: USA
Interventions Experimental Group 1: drug: iCo-007 350 µg as an intravitreal injection at baseline followed by another iCo-
007 dose (350 µg) at month 4
Experimental Group 2: drug: iCo-007 700 µg as an intravitreal injection at baseline followed by another iCo-
007 dose (700 µg) at month 4
Experimental Group 3: drug: iCo-007 350 µg as an intravitreal injection at baseline followed 7 days later by
laser photocoagulation. At month 4, intravitreal injection of iCo-007 (350 µg) will be given as mandatory
treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Experimental Group 4: drug: ranibizumab 0.5 mg intravitreal injection at baseline followed by iCo-007 350
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µg intravitreal injection 2 weeks later; re-treatment with ranibizumab 0.5 mgmandatory at month 4 followed
by iCo-007 350 µg 2 weeks later
Outcomes Primary outcome:
Change in VA from baseline to month 8
Secondary outcomes:
Number of participants in a given study arm experiencing the same drug-related serious adverse event as a
measure of safety and tolerability
Safety of repeated iCo-007 intravitreal injections in treatment of people with DMO as monotherapy and in
combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more
patients in a particular treatment arm experience the same drug-related serious adverse event
Change in VA from baseline to month 12
Change in retinal thickness measured by OCT from baseline to month 8
Change in retinal thickness measured by OCT from baseline to month 12
Duration of iCo-007 treatment effect during the 12 month follow-up period as measured by VA and OCT
thickness
Peak plasma concentration (Cmax) of iCo-007 after multiple injections
Starting date Study start date: February 2012
Estimated study completion date: December 2013
Contact information Quan Dong Nguyen, MD, Johns Hopkins University
Notes Sponsors and Collaborators
Quan Dong Nguyen
Juvenile Diabetes Research Foundation
iCo Therapeutics Inc
Consider moving to excluded studies
NCT01572350 (ALBA)
Trial name or title Safety and efficacy of triamcinolone acetonide combined with laser, bevacizumab combined with laser versus
laser alone for the treatment of diffuse non-tractional diabetic macular edema (ALBA)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: factorial assignment
Masking: open-label
Participants 105, country: Spain
Interventions Grid laser
Triamcinolone acetonide
Bevacizumab
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Outcomes Primary outcome: BCVA (time frame: 12 months; designated as safety issue: yes) Type of adverse events,
severity and number of participants with adverse events at baseline, 3, 6 and 12 months in order to assess
safety and tolerability of intravitreal Triesence (r) (designated as safety issue: yes)
Secondary outcomes:
To assess the safety of intravitreal Triesence (time frame: baseline, 3, 6 and 12 months; designated as safety
issue: yes) Type of adverse events, severity and number of participants with adverse events as a measure of
safety and tolerability
Average change in mean CMT in each group (time frame: baseline and 3, 6 and 12 months after initiation
of treatment; designated as safety issue: no), measured in µm by OCT at each follow-up visit, compared to
the baseline visit in each of the 3 groups
To assess the safety of intravitreal Avastin (time frame: baseline, 3, 6 and 12 months; designated as safety
issue: yes) Type of adverse events, severity and number of participants with adverse events as a measure of
safety and tolerability
To assess the safety of intravitreal grid photocoagulation (time frame: baseline, 3, 6 and 12months; designated
as safety issue: yes) Type of adverse events, severity and number of participants with adverse events as a measure
of safety and tolerability
Starting date Starting date: October 2010
Study completion date: October 2012
Contact information Alicia Pareja, MD, Hospital Universitario de Canarias
Notes
NCT01610557 (CADME)
Trial name or title A phase II randomized study to compare anti-VEGF agents in the treatment of diabetic macular edema
(CADME)
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: cross-over assignment
Masking: double-masked
Participants 60, country: USA
Interventions Drug: ranibizumab and bevacizumab
Eyes are randomly assigned to receive a set sequence of monthly eye injections; all eyes receive ranibizumab
at some time points and bevacizumab at others during the cross-over study
Outcomes Primary outcome:
Mean change in BCVA
Secondary outcome:
Retinal thickness on OCT
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Starting date Study start date: May 2012
Estimated study completion date: August 2014
Contact information Henry E Wiley IV, National Eye Institute, National Institutes of Health
Notes Sponsor: National Eye Institute (NEI)
NCT01627249
Trial name or title Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (protocol
T)
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: single-masked (patient)
Participants 660
Interventions Drug: 0.5 mg intravitreal injection of ranibizumab (Lucentis™) at baseline and up to every 4 weeks using
defined retreatment criteria
Experimental: 2.0 mg intravitreal injection of aflibercept at baseline and up to every 4 weeks using defined
re-treatment criteria
Experimental: 1.25 mg intravitreal injection of bevacizumab at baseline and up to every 4 weeks using defined
re-treatment criteria
Outcomes Endpoint classification: Safety/efficacy study
Starting date Study start date: August 2012
Estimated study completion date: September 2015
Contact information Diabetic Retinopathy Clinical Research Network
Notes Sponsor: Diabetic Retinopathy Clinical Research Network
NCT01635790 (BRDME)
Trial name or title Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular
edema (BRDME)
Methods Parallel group RCT
Participants 246 people with DMO
Interventions Ranibizumab compared to bevacizumab
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Outcomes From clinical trials record:
Primary outcome: change in BCVA in the study eye from baseline to month 6 (designated as safety issue: no)
Secondary outcome measures:
Proportion of patients with a gain or loss of 15 letters or more at 6 months compared to baseline BCVA
(designated as safety issue: no)
Change in leakage on fluorescein angiography, baseline compared to 6 month exit visit (designated as safety
issue: no)
Change in foveal thickness (central retinal area) by OCT, 6 month exit visit compared to baseline (designated
as safety issue: no)
Total number of adverse events that occured during the 6 month study, with secondary a classification of the
types of adverse events (designated as safety issue: yes)
Costs per quality adjusted life-year of the 2 treatments (time frame: 6 months; designated as safety issue: no)
, results will be based on the use of standardised health questionnaires (EQ-5D or Health Utility Index Mark
3)
{roportion of patients with a BCVA of 20/40 or more at 6 months compared to baseline BCVA (designated
as safety issue: no)
Starting date June 2012
Contact information r.schlingemann@amc.uva.nl
Notes http://clinicaltrials.gov/show/NCT01635790
NCT01845844 (ROTATE)
Trial name or title Ranibizumab for persistent diabetic macular edema after bevacizumab (ROTATE)
Methods Parallel group RCT
Participants 30 people with persistent DMO after treatment with bevacizumab
Interventions Ranibizumab versus control
Outcomes From clinical trials record:
Primary outcomes:
Incidence of ocular and systemic adverse events will be compared between experimental and active com-
parator groups (time frame: 1 year; designated as safety issue: yes). Examples include worsened acuity of >
30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous haemorrhage, new PDR or
neovascularisation of the iris or angle, incidence and severity of other adverse events, as identified by physical
examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths
and systemic serious adverse events
Severity of ocular and systemic adverse events will be compared between experimental and active comparator
groups (time frame: 1 year; designated as safety issue: yes). Examples include worsened acuity of > 30 letters,
retinal detachment, endophthalmitis, cataract progression, vitreous haemorrhage, new PDR or neovasculari-
sation of the iris or angle, incidence and severity of other adverse events, as identified by physical examination,
subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic
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serious adverse events
Secondary outcome:
Proportion of eyes with absence of fluorescein angiographic macular leakage at 12 months; proportion of
eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline at 1,
6 and 12 months; proportion of eyes with unchanged, worsened, or improved fundus photographic DMO
appearance from baseline at 1, 6 and 12 months; proportion of eyes with new vitreous hemorrhage or traction
retinal detachment secondary to PDR; proportion of eyes with progression from baseline non-PDR to PDR
Other outcomes:
Mean BCVA letter changes from baseline at 1, 3, 6, 9 and 12 months (designated as safety issue: yes)
OCTCSF thickness and macular volume mean changes from baseline at 1, 3, 6, 9 and 12 months (designated
as safety issue: yes)
Starting date April 2013
Contact information dmarcus@southeastretina.com
Notes http://clinicaltrials.gov/ct2/show/NCT01845844?term=NCT01845844&rank=1
Abbreviations
BCVA: best-corrected visual acuity
CMT: central macular thickness
CRT: central retinal thickness
CSMO: clinically significant macular oedema
DMO: diabetic macular oedema (DME: US spelling edema)
ETDRS: Early Treatment Diabetic Retinopathy Study
IOP: intraocular pressure
NA: not available
OCT: optical coherence tomography
PDR: proliferative diabetic retinopathy
PRN: pro re nata (as required in the circumstances)
PRP: panretinal photocoagulation
VA: visual acuity
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-VEGF versus laser
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gain 3+ lines of visual acuity at
1 year
9 1333 Risk Ratio (M-H, Fixed, 95% CI) 3.60 [2.70, 4.80]
1.1 Bevacizumab 3 207 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [1.42, 5.91]
1.2 Ranibizumab 4 465 Risk Ratio (M-H, Fixed, 95% CI) 3.59 [2.03, 6.33]
1.3 Aflibercept 2 661 Risk Ratio (M-H, Fixed, 95% CI) 3.81 [2.61, 5.56]
2 Loss 3+ lines of visual acuity at 1
year
6 1086 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.05, 0.24]
2.1 Bevacizumab 2 167 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.05, 0.51]
2.2 Ranibizumab 2 258 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.05, 0.91]
2.3 Aflibercept 2 661 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.23]
3 Visual acuity at 1 year 8 1292 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.18, -0.14]
3.1 Bevacizumab 2 165 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.28, -0.12]
3.2 Ranibizumab 4 466 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.15, -0.08]
3.3 Aflibercept 2 661 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.24, -0.17]
4 Central macular thickness at 1
year
7 1215 Mean Difference (IV, Fixed, 95% CI) -78.83 [-94.55, -63.
12]
4.1 Bevacizumab 2 165 Mean Difference (IV, Fixed, 95% CI) -43.61 [-82.11, -5.
11]
4.2 Ranibizumab 3 390 Mean Difference (IV, Fixed, 95% CI) -47.94 [-73.15, -22.
73]
4.3 Aflibercept 2 660 Mean Difference (IV, Fixed, 95% CI) -119.02 [-142.58, -
95.45]
5 Quality of life at 1 year 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Ranibizumab 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Gain 3+ lines of visual acuity at
2 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Bevacizumab 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Loss 3+ lines of visual acuity at 2
years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Bevacizumab 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Visual acuity at 2 years 2 142 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.24, -0.05]
8.1 Bevacizumab 2 142 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.24, -0.05]
9 Central macular thickness at 2
years
2 142 Mean Difference (IV, Fixed, 95% CI) -18.35 [-62.23, 25.
52]
9.1 Bevacizumab 2 142 Mean Difference (IV, Fixed, 95% CI) -18.35 [-62.23, 25.
52]
10 Quality of life (near activities)
at 1 year
1 195 Mean Difference (IV, Fixed, 95% CI) 4.4 [1.33, 7.47]
10.1 Ranibizumab 1 195 Mean Difference (IV, Fixed, 95% CI) 4.4 [1.33, 7.47]
11 Quality of life (far activities) at
1 year
1 195 Mean Difference (IV, Fixed, 95% CI) 4.4 [1.33, 7.47]
11.1 Ranibizumab 1 195 Mean Difference (IV, Fixed, 95% CI) 4.4 [1.33, 7.47]
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Comparison 2. Anti-VEGF versus sham
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gain 3+ lines of visual acuity at
1 year
3 497 Risk Ratio (M-H, Fixed, 95% CI) 2.19 [1.36, 3.53]
1.1 Pegaptanib 2 346 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.01, 3.16]
1.2 Ranibizumab 1 151 Risk Ratio (M-H, Fixed, 95% CI) 3.17 [1.32, 7.62]
2 Loss 3+ lines of visual acuity at 1
year
2 411 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.13, 0.59]
2.1 Pegaptanib 1 260 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.16, 1.21]
2.2 Ranibizumab 1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.50]
3 Visual acuity at 1 year 4 575 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.17, -0.08]
3.1 Bevacizumab 1 78 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.26, -0.04]
3.2 Pegaptanib 2 346 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.13, -0.03]
3.3 Ranibizumab 1 151 Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.32, -0.15]
4 Central macular thickness at 1
year
3 315 Mean Difference (IV, Fixed, 95% CI) -126.38 [-160.27, -
92.49]
4.1 Bevacizumab 1 78 Mean Difference (IV, Fixed, 95% CI) -130.6 [-187.27, -
73.93]
4.2 Pegaptanib 1 86 Mean Difference (IV, Fixed, 95% CI) -71.7 [-149.71, 6.
31]
4.3 Ranibizumab 1 151 Mean Difference (IV, Fixed, 95% CI) -145.80 [-196.12, -
95.48]
5 Gain 3+ lines of visual acuity at
2 years
2 1223 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [2.02, 3.09]
5.1 Pegaptanib 1 207 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.87, 2.78]
5.2 Ranibizumab 0.5 mg
monthly.
1 509 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [2.03, 3.86]
5.3 Ranibizumab 0.3 mg
monthly
1 507 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [1.86, 3.58]
6 Loss 3+ lines of visual acuity at 2
years
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Pegaptanib 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Ranibizumab 0.5 mg
monthly
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Ranibizumab 0.3 mg
monthly
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Visual acuity at 2 years 2 1223 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.20, -0.15]
7.1 Pegaptanib 1 207 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.17, -0.02]
7.2 Ranibizumab 0.5 mg
monthly
1 509 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.23, -0.14]
7.3 Ranibizumab 0.3 mg
monthly
1 507 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.24, -0.15]
8 Central macular thickness at 2
years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Ranibizumab 0.5 mg
monthly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Ranibizumab 0.3 mg
monthly
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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9 Quality of life at 1 year 1 Mean Difference (Fixed, 95% CI) Totals not selected
10 Quality of life at 2 years 1 Mean Difference (Fixed, 95% CI) Totals not selected
Comparison 3. Anti-VEGF plus laser versus laser alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gain 3+ lines of visual acuity at
1 year
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Prompt photocoagulation 4 919 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [1.76, 3.21]
1.2 Deferred
photocoagulation
1 481 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [1.31, 2.70]
2 Loss 3+ lines of visual acuity at 1
year
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Prompt photocoagulation 2 708 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.13, 0.67]
2.2 Deferred
photocoagulation
1 481 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.10, 0.77]
3 Visual acuity at 1 year 5 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Prompt photocoagulation 5 1045 Mean Difference (IV, Random, 95% CI) -0.11 [-0.13, -0.08]
3.2 Deferred
photocoagulation
1 481 Mean Difference (IV, Random, 95% CI) -0.12 [-0.17, -0.07]
4 Central macular thickness at 1
year
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Prompt photocoagulation 3 801 Mean Difference (IV, Fixed, 95% CI) -50.66 [-66.71, -34.
61]
4.2 Deferred
photocoagulation
1 446 Mean Difference (IV, Fixed, 95% CI) -35.0 [-62.00, -6.00]
5 Quality of life at 1 year 1 200 Mean Difference (IV, Fixed, 95% CI) 4.80 [1.85, 7.75]
5.1 Prompt photocoagulation 1 200 Mean Difference (IV, Fixed, 95% CI) 4.80 [1.85, 7.75]
6 Gain 3+ lines of visual acuity at
2 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Prompt photocoagulation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Deferred
photocoagulation
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Loss 3+ lines of visual acuity at 2
years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Prompt photocoagulation 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Deferred
photocoagulation
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Visual acuity at 2 years 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Prompt photocoagulation 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Deferred
photocoagulation
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Central macular thickness at 2
years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Prompt photocoagulation 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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9.2 Deferred
photocoagulation
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Adverse events: anti-VEGF versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systemic serious adverse events 15 2985 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.83, 1.17]
1.1 Follow-up 6-12 months 11 1879 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.81, 1.28]
1.2 Follow-up 24 months 4 1106 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.73, 1.23]
2 Total ATC thromboembolic
events at 6 to 24 months
14 3034 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.63, 1.25]
2.1 Follow-up 6 to 12 months 10 1663 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.67, 2.64]
2.2 Follow-up 24 months 4 1371 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.38]
3 Death 15 3562 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.52, 1.47]
3.1 Follow-up 6 to 12 months 12 2271 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.29, 1.81]
3.2 Follow-up 24 months 3 1291 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.36, 3.45]
Comparison 5. Bevacizumab versus ranibizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gain 3+ lines of visual acuity at
1 year
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.44, 1.47]
2 Loss 3+ lines of visual acuity at 1
year
1 60 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [0.11, 62.23]
3 Visual acuity at 1 year 2 160 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.05, 0.05]
4 Central macular thickness at 1
year
2 160 Mean Difference (IV, Fixed, 95% CI) 27.02 [-5.70, 59.73]
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Analysis 1.1. Comparison 1 Anti-VEGF versus laser, Outcome 1 Gain 3+ lines of visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 1 Gain 3+ lines of visual acuity at 1 year
Study or subgroup AntiVEGF Photocoagulation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bevacizumab
Azad 2012 4/20 0/20 1.0 % 9.00 [ 0.52, 156.91 ]
BOLT 2010 5/42 2/38 4.1 % 2.26 [ 0.47, 10.98 ]
Soheilian 2007 16/44 6/43 11.7 % 2.61 [ 1.13, 6.03 ]
Subtotal (95% CI) 106 101 16.8 % 2.89 [ 1.42, 5.91 ]
Total events: 25 (AntiVEGF), 8 (Photocoagulation)
Heterogeneity: Chi2 = 0.76, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
2 Ranibizumab
LUCIDATE 2014 0/22 0/11 Not estimable
READ2 2009 (1) 8/37 0/38 1.0 % 17.45 [ 1.04, 291.82 ]
RESPOND 2013 17/70 4/62 8.2 % 3.76 [ 1.34, 10.59 ]
RESTORE 2011 26/115 9/110 17.8 % 2.76 [ 1.36, 5.63 ]
Subtotal (95% CI) 244 221 27.0 % 3.59 [ 2.03, 6.33 ]
Total events: 51 (AntiVEGF), 13 (Photocoagulation)
Heterogeneity: Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.41 (P = 0.000010)
3 Aflibercept
DA VINCI 2011 19/45 5/44 9.8 % 3.72 [ 1.52, 9.08 ]
Korobelnik 2014 (2) 47/151 12/154 23.0 % 3.99 [ 2.21, 7.23 ]
Korobelnik 2014 (3) 45/135 12/132 23.5 % 3.67 [ 2.03, 6.61 ]
Subtotal (95% CI) 331 330 56.3 % 3.81 [ 2.61, 5.56 ]
Total events: 111 (AntiVEGF), 29 (Photocoagulation)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 6.92 (P < 0.00001)
Total (95% CI) 681 652 100.0 % 3.60 [ 2.70, 4.80 ]
Total events: 187 (AntiVEGF), 50 (Photocoagulation)
Heterogeneity: Chi2 = 3.16, df = 8 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.45, df = 2 (P = 0.80), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours photocoagulation Favours antiVEGF
(1) follow-up: 6 months
(2) VISTA study
(3) VIVID study
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Analysis 1.2. Comparison 1 Anti-VEGF versus laser, Outcome 2 Loss 3+ lines of visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 2 Loss 3+ lines of visual acuity at 1 year
Study or subgroup AntiVEGF Photocoagulation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bevacizumab
BOLT 2010 1/42 10/38 16.5 % 0.09 [ 0.01, 0.67 ]
Soheilian 2007 (1) 2/44 8/43 12.7 % 0.24 [ 0.05, 1.09 ]
Subtotal (95% CI) 86 81 29.3 % 0.16 [ 0.05, 0.51 ]
Total events: 3 (AntiVEGF), 18 (Photocoagulation)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
2 Ranibizumab
LUCIDATE 2014 1/22 0/11 1.0 % 1.57 [ 0.07, 35.57 ]
RESTORE 2011 1/115 9/110 14.5 % 0.11 [ 0.01, 0.83 ]
Subtotal (95% CI) 137 121 15.5 % 0.20 [ 0.05, 0.91 ]
Total events: 2 (AntiVEGF), 9 (Photocoagulation)
Heterogeneity: Chi2 = 2.02, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 2.08 (P = 0.037)
3 Aflibercept
DA VINCI 2011 0/45 6/44 10.3 % 0.08 [ 0.00, 1.30 ]
Korobelnik 2014 (2) 1/151 14/154 21.8 % 0.07 [ 0.01, 0.55 ]
Korobelnik 2014 (3) 0/135 14/132 23.1 % 0.03 [ 0.00, 0.56 ]
Subtotal (95% CI) 331 330 55.2 % 0.06 [ 0.01, 0.23 ]
Total events: 1 (AntiVEGF), 34 (Photocoagulation)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000072)
Total (95% CI) 554 532 100.0 % 0.11 [ 0.05, 0.24 ]
Total events: 6 (AntiVEGF), 61 (Photocoagulation)
Heterogeneity: Chi2 = 4.84, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.65 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.74, df = 2 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
Favours antiVEGF Favours photocoagulation
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(1) Data reported at 9 months
(2) VISTA study
(3) VIVID study
Analysis 1.3. Comparison 1 Anti-VEGF versus laser, Outcome 3 Visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 3 Visual acuity at 1 year
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
BOLT 2010 -0.1128571 (0.1528794) 42 38 0.09 (0.2631054) 5.2 % -0.20 [ -0.30, -0.11 ]
Soheilian 2007 43 -0.21 (0.27) 42 -0.02 (0.34) 2.8 % -0.19 [ -0.32, -0.06 ]
Subtotal (95% CI) 85 80 8.0 % -0.20 [ -0.28, -0.12 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 5.07 (P < 0.00001)
2 Ranibizumab
LUCIDATE 2014 22 -0.12 (0.17) 11 0.02 (0.212) 2.3 % -0.14 [ -0.28, 0.01 ]
READ2 2009 (1) 37 -0.1322 (0.182) 38 -0.05 (0.185) 6.9 % -0.08 [ -0.17, 0.00 ]
RESPOND 2013 71 -0.178 (0.15906) 62 -0.01 (0.25712) 8.7 % -0.17 [ -0.25, -0.10 ]
RESTORE 2011 115 -0.122 (0.1286) 110 -0.02 (0.1712) 30.0 % -0.11 [ -0.15, -0.07 ]
Subtotal (95% CI) 245 221 47.8 % -0.12 [ -0.15, -0.08 ]
Heterogeneity: Chi2 = 3.09, df = 3 (P = 0.38); I2 =3%
Test for overall effect: Z = 7.25 (P < 0.00001)
3 Aflibercept
DA VINCI 2011 45 -0.24 (0.2218) 44 0.03 (0.4144) 2.5 % -0.27 [ -0.40, -0.13 ]
Korobelnik 2014 (2) 151 -0.214 (0.164) 154 0 (0.25) 21.1 % -0.21 [ -0.26, -0.16 ]
Korobelnik 2014 (3) 135 -0.214 (0.186) 132 -0.02 (0.212) 20.6 % -0.19 [ -0.24, -0.14 ]
Subtotal (95% CI) 331 330 44.2 % -0.20 [ -0.24, -0.17 ]
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 12.21 (P < 0.00001)
-0.5 -0.25 0 0.25 0.5
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(. . . Continued)
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 661 631 100.0 % -0.16 [ -0.18, -0.14 ]
Heterogeneity: Chi2 = 19.53, df = 8 (P = 0.01); I2 =59%
Test for overall effect: Z = 14.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.25, df = 2 (P = 0.00), I2 =87%
-0.5 -0.25 0 0.25 0.5
Favours antiVEGF Favours photocoagulation
(1) Follow-up: 6 months; standard deviations derived from a figure
(2) VISTA study
(3) VIVID study
Analysis 1.4. Comparison 1 Anti-VEGF versus laser, Outcome 4 Central macular thickness at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 4 Central macular thickness at 1 year
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
BOLT 2010 42 -130 (122) 38 -68 (171) 5.7 % -62.00 [ -127.71, 3.71 ]
Soheilian 2007 43 -40 (133) 42 -6 (86) 10.9 % -34.00 [ -81.51, 13.51 ]
Subtotal (95% CI) 85 80 16.7 % -43.61 [ -82.11, -5.11 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
2 Ranibizumab
LUCIDATE 2014 22 -131.5 (98) 11 -102.9 (88.4) 5.6 % -28.60 [ -94.98, 37.78 ]
RESPOND 2013 71 -143.5 (146.38) 61 -107.1 (146.84) 9.8 % -36.40 [ -86.57, 13.77 ]
RESTORE 2011 115 -118.7 (115.07) 110 -61.3 (132.29) 23.4 % -57.40 [ -89.86, -24.94 ]
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(. . . Continued)
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 208 182 38.9 % -47.94 [ -73.15, -22.73 ]
Heterogeneity: Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
3 Aflibercept
DA VINCI 2011 44 -180.3 (124.43) 43 -58.4 (177.6) 5.9 % -121.90 [ -186.47, -57.33 ]
Korobelnik 2014 (1) 136 -192.4 (149.9) 132 -66.2 (139) 20.6 % -126.20 [ -160.80, -91.60 ]
Korobelnik 2014 (2) 151 -183.1 (153.5) 154 -73.3 (176.7) 17.9 % -109.80 [ -146.93, -72.67 ]
Subtotal (95% CI) 331 329 44.5 % -119.02 [ -142.58, -95.45 ]
Heterogeneity: Chi2 = 0.41, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 9.90 (P < 0.00001)
Total (95% CI) 624 591 100.0 % -78.83 [ -94.55, -63.12 ]
Heterogeneity: Chi2 = 21.88, df = 7 (P = 0.003); I2 =68%
Test for overall effect: Z = 9.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 20.15, df = 2 (P = 0.00), I2 =90%
-200 -100 0 100 200
Favours antiVEGF Favours photocoagulation
(1) VIVID study
(2) VISTA study
Analysis 1.5. Comparison 1 Anti-VEGF versus laser, Outcome 5 Quality of life at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 5 Quality of life at 1 year
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference
Mean
Difference
N
Mean(SD)[
score] N
Mean(SD)[
score] IV,Fixed,95% CI IV,Fixed,95% CI
1 Ranibizumab
RESTORE 2011 99 5 (11.0102) 96 0.6 (10.84209) 4.40 [ 1.33, 7.47 ]
-10 -5 0 5 10
Favours laser Favours anti-VEGF
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Analysis 1.6. Comparison 1 Anti-VEGF versus laser, Outcome 6 Gain 3+ lines of visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 6 Gain 3+ lines of visual acuity at 2 years
Study or subgroup AntiVEGF Photocoagulation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bevacizumab
BOLT 2010 12/37 1/28 9.08 [ 1.25, 65.77 ]
0.1 0.2 0.5 1 2 5 10
Favours photocoagulation Favours antiVEGF
Analysis 1.7. Comparison 1 Anti-VEGF versus laser, Outcome 7 Loss 3+ lines of visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 7 Loss 3+ lines of visual acuity at 2 years
Study or subgroup AntiVEGF Photocoagulation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bevacizumab
BOLT 2010 0/37 4/28 0.08 [ 0.00, 1.51 ]
0.01 0.1 1 10 100
Favours antiVEGF Favours photocoagulation
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Analysis 1.8. Comparison 1 Anti-VEGF versus laser, Outcome 8 Visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 8 Visual acuity at 2 years
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
BOLT 2010 37 0.412 (0.266) 28 0.6 (0.252) 60.4 % -0.19 [ -0.32, -0.07 ]
Soheilian 2007 (1) 39 -0.1 (0.37) 38 -0.03 (0.33) 39.6 % -0.07 [ -0.23, 0.09 ]
Total (95% CI) 76 66 100.0 % -0.14 [ -0.24, -0.05 ]
Heterogeneity: Chi2 = 1.41, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 2.86 (P = 0.0042)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours antiVEGF Favours photocoagulation
(1) Change in visual acuity from baseline
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Analysis 1.9. Comparison 1 Anti-VEGF versus laser, Outcome 9 Central macular thickness at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 9 Central macular thickness at 2 years
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
BOLT 2010 37 355 (174) 28 360 (125) 36.4 % -5.00 [ -77.71, 67.71 ]
Soheilian 2007 (1) 39 -24 (137) 38 2 (108) 63.6 % -26.00 [ -81.03, 29.03 ]
Total (95% CI) 76 66 100.0 % -18.35 [ -62.23, 25.52 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours antiVEGF Favours photocoagulation
(1) Change in central macular thickness from baseline
Analysis 1.10. Comparison 1 Anti-VEGF versus laser, Outcome 10 Quality of life (near activities) at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 10 Quality of life (near activities) at 1 year
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
score] N
Mean(SD)[
score] IV,Fixed,95% CI IV,Fixed,95% CI
1 Ranibizumab
RESTORE 2011 99 5 (11.0102) 96 0.6 (10.84209) 100.0 % 4.40 [ 1.33, 7.47 ]
Total (95% CI) 99 96 100.0 % 4.40 [ 1.33, 7.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours laser Favours anti-VEGF
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Analysis 1.11. Comparison 1 Anti-VEGF versus laser, Outcome 11 Quality of life (far activities) at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 1 Anti-VEGF versus laser
Outcome: 11 Quality of life (far activities) at 1 year
Study or subgroup AntiVEGF Photocoagulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
score] N
Mean(SD)[
score] IV,Fixed,95% CI IV,Fixed,95% CI
1 Ranibizumab
RESTORE 2011 99 5 (11.0102) 96 0.6 (10.84209) 100.0 % 4.40 [ 1.33, 7.47 ]
Total (95% CI) 99 96 100.0 % 4.40 [ 1.33, 7.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours laser Favours anti-VEGF
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Analysis 2.1. Comparison 2 Anti-VEGF versus sham, Outcome 1 Gain 3+ lines of visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 1 Gain 3+ lines of visual acuity at 1 year
Study or subgroup AntiVEGF Sham Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pegaptanib
Macugen 2005 (1) 8/44 3/42 13.3 % 2.55 [ 0.72, 8.95 ]
Macugen 2011 22/133 13/127 57.5 % 1.62 [ 0.85, 3.07 ]
Subtotal (95% CI) 177 169 70.8 % 1.79 [ 1.01, 3.16 ]
Total events: 30 (AntiVEGF), 16 (Sham)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
2 Ranibizumab
RESOLVE 2010 33/102 5/49 29.2 % 3.17 [ 1.32, 7.62 ]
Subtotal (95% CI) 102 49 29.2 % 3.17 [ 1.32, 7.62 ]
Total events: 33 (AntiVEGF), 5 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0099)
Total (95% CI) 279 218 100.0 % 2.19 [ 1.36, 3.53 ]
Total events: 63 (AntiVEGF), 21 (Sham)
Heterogeneity: Chi2 = 1.60, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Chi2 = 1.15, df = 1 (P = 0.28), I2 =13%
0.1 0.2 0.5 1 2 5 10
Favours sham Favours antiVEGF
(1) Follow-up: 36 weeks
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Analysis 2.2. Comparison 2 Anti-VEGF versus sham, Outcome 2 Loss 3+ lines of visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 2 Loss 3+ lines of visual acuity at 1 year
Study or subgroup AntiVEGF Sham Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pegaptanib
Macugen 2011 5/133 11/127 45.4 % 0.43 [ 0.16, 1.21 ]
Subtotal (95% CI) 133 127 45.4 % 0.43 [ 0.16, 1.21 ]
Total events: 5 (AntiVEGF), 11 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
2 Ranibizumab
RESOLVE 2010 3/102 10/49 54.6 % 0.14 [ 0.04, 0.50 ]
Subtotal (95% CI) 102 49 54.6 % 0.14 [ 0.04, 0.50 ]
Total events: 3 (AntiVEGF), 10 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
Total (95% CI) 235 176 100.0 % 0.28 [ 0.13, 0.59 ]
Total events: 8 (AntiVEGF), 21 (Sham)
Heterogeneity: Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 3.30 (P = 0.00096)
Test for subgroup differences: Chi2 = 1.79, df = 1 (P = 0.18), I2 =44%
0.05 0.2 1 5 20
Favours antiVEGF Favours sham
110Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Anti-VEGF versus sham, Outcome 3 Visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 3 Visual acuity at 1 year
Study or subgroup AntiVEGF Sham
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
Ahmadieh 2008 (1) 41 -0.18 (0.26) 37 -0.03 (0.24) 13.4 % -0.15 [ -0.26, -0.04 ]
Subtotal (95% CI) 41 37 13.4 % -0.15 [ -0.26, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.65 (P = 0.0081)
2 Pegaptanib
Macugen 2005 (2) 44 -0.094 (0.182) 42 0 (0.284) 16.1 % -0.09 [ -0.20, 0.01 ]
Macugen 2011 133 -0.104 (0.182) 127 -0.02 (0.284) 48.7 % -0.08 [ -0.14, -0.02 ]
Subtotal (95% CI) 177 169 64.8 % -0.08 [ -0.13, -0.03 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0012)
3 Ranibizumab
RESOLVE 2010 102 -0.206 (0.182) 49 0.03 (0.284) 21.8 % -0.23 [ -0.32, -0.15 ]
Subtotal (95% CI) 102 49 21.8 % -0.23 [ -0.32, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.27 (P < 0.00001)
Total (95% CI) 320 255 100.0 % -0.13 [ -0.17, -0.08 ]
Heterogeneity: Chi2 = 8.85, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 6.05 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.79, df = 2 (P = 0.01), I2 =77%
-0.2 -0.1 0 0.1 0.2
Favours antiVEGF Favours sham
(1) Follow-up: 24 weeks
(2) Follow-up: 36 weeks
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Analysis 2.4. Comparison 2 Anti-VEGF versus sham, Outcome 4 Central macular thickness at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 4 Central macular thickness at 1 year
Study or subgroup AntiVEGF Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Bevacizumab
Ahmadieh 2008 (1) 41 -95.7 (172.5) 37 34.9 (63.9) 35.8 % -130.60 [ -187.27, -73.93 ]
Subtotal (95% CI) 41 37 35.8 % -130.60 [ -187.27, -73.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.52 (P < 0.00001)
2 Pegaptanib
Macugen 2005 (2) 44 -68 (184.5) 42 3.7 (184.5) 18.9 % -71.70 [ -149.71, 6.31 ]
Subtotal (95% CI) 44 42 18.9 % -71.70 [ -149.71, 6.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
3 Ranibizumab
RESOLVE 2010 102 -194.2 (135.1) 49 -48.4 (153.4) 45.4 % -145.80 [ -196.12, -95.48 ]
Subtotal (95% CI) 102 49 45.4 % -145.80 [ -196.12, -95.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.68 (P < 0.00001)
Total (95% CI) 187 128 100.0 % -126.38 [ -160.27, -92.49 ]
Heterogeneity: Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 7.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.48, df = 2 (P = 0.29), I2 =19%
-200 -100 0 100 200
Favours antiVEGF Favours sham
(1) Follow-up: 24 weeks
(2) Follow-up: 36 weeks.
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Analysis 2.5. Comparison 2 Anti-VEGF versus sham, Outcome 5 Gain 3+ lines of visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 5 Gain 3+ lines of visual acuity at 2 years
Study or subgroup AntiVEGF Sham Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pegaptanib
Macugen 2011 25/107 15/100 16.7 % 1.56 [ 0.87, 2.78 ]
Subtotal (95% CI) 107 100 16.7 % 1.56 [ 0.87, 2.78 ]
Total events: 25 (AntiVEGF), 15 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
2 Ranibizumab 0.5 mg monthly.
RISE-RIDE 107/252 39/257 41.7 % 2.80 [ 2.03, 3.86 ]
Subtotal (95% CI) 252 257 41.7 % 2.80 [ 2.03, 3.86 ]
Total events: 107 (AntiVEGF), 39 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 6.25 (P < 0.00001)
3 Ranibizumab 0.3 mg monthly
RISE-RIDE 98/250 39/257 41.5 % 2.58 [ 1.86, 3.58 ]
Subtotal (95% CI) 250 257 41.5 % 2.58 [ 1.86, 3.58 ]
Total events: 98 (AntiVEGF), 39 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 5.68 (P < 0.00001)
Total (95% CI) 609 614 100.0 % 2.50 [ 2.02, 3.09 ]
Total events: 230 (AntiVEGF), 93 (Sham)
Heterogeneity: Chi2 = 3.07, df = 2 (P = 0.22); I2 =35%
Test for overall effect: Z = 8.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.07, df = 2 (P = 0.22), I2 =35%
0.1 0.2 0.5 1 2 5 10
Favours sham Favours antiVEGF
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Analysis 2.6. Comparison 2 Anti-VEGF versus sham, Outcome 6 Loss 3+ lines of visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 6 Loss 3+ lines of visual acuity at 2 years
Study or subgroup AntiVEGF Sham Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pegaptanib
Macugen 2011 4/107 9/100 0.42 [ 0.13, 1.31 ]
2 Ranibizumab 0.5 mg monthly
RISE-RIDE 7/252 24/257 0.30 [ 0.13, 0.68 ]
3 Ranibizumab 0.3 mg monthly
RISE-RIDE 5/250 24/257 0.21 [ 0.08, 0.55 ]
0.05 0.2 1 5 20
Favours antiVEGF Favours sham
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Analysis 2.7. Comparison 2 Anti-VEGF versus sham, Outcome 7 Visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 7 Visual acuity at 2 years
Study or subgroup AntiVEGF Sham
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Pegaptanib
Macugen 2011 107 -0.122 (0.242) 100 -0.03 (0.278) 17.0 % -0.10 [ -0.17, -0.02 ]
Subtotal (95% CI) 107 100 17.0 % -0.10 [ -0.17, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
2 Ranibizumab 0.5 mg monthly
RISE-RIDE 252 -0.238 (0.242) 257 -0.05 (0.278) 42.0 % -0.19 [ -0.23, -0.14 ]
Subtotal (95% CI) 252 257 42.0 % -0.19 [ -0.23, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.06 (P < 0.00001)
3 Ranibizumab 0.3 mg monthly
RISE-RIDE 250 -0.25 (0.2478) 257 -0.05 (0.278) 41.0 % -0.20 [ -0.24, -0.15 ]
Subtotal (95% CI) 250 257 41.0 % -0.20 [ -0.24, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.47 (P < 0.00001)
Total (95% CI) 609 614 100.0 % -0.18 [ -0.20, -0.15 ]
Heterogeneity: Chi2 = 5.92, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 11.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.92, df = 2 (P = 0.05), I2 =66%
-0.2 -0.1 0 0.1 0.2
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Analysis 2.8. Comparison 2 Anti-VEGF versus sham, Outcome 8 Central macular thickness at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 8 Central macular thickness at 2 years
Study or subgroup antiVEGF sham
Mean
Difference
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Ranibizumab 0.5 mg monthly
RISE-RIDE 250 -261.08 (192.93) 257 -129.4 (203.7) -131.68 [ -166.21, -97.15 ]
2 Ranibizumab 0.3 mg monthly
RISE-RIDE 250 -256.22 (191.95) 257 -129.4 (203.7) -126.82 [ -161.26, -92.38 ]
-200 -100 0 100 200
Favours antiVEGF Favours sham
Analysis 2.9. Comparison 2 Anti-VEGF versus sham, Outcome 9 Quality of life at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 9 Quality of life at 1 year
Study or subgroup sham pegaptanib Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Macugen 2011 (1) 133 127 2.92 (1.653) 2.92 [ -0.32, 6.16 ]
-10 -5 0 5 10
Favours sham Favours pegaptanib
(1) Change in NEI-VFQ 25 composite score
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Analysis 2.10. Comparison 2 Anti-VEGF versus sham, Outcome 10 Quality of life at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 2 Anti-VEGF versus sham
Outcome: 10 Quality of life at 2 years
Study or subgroup sham pegaptanib Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Macugen 2011 (1) 107 100 4.47 (2.148) 4.47 [ 0.26, 8.68 ]
-10 -5 0 5 10
Favours sham Favours pegaptanib
(1) Change in NEI-VFQ 25 composite score
Analysis 3.1. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 1 Gain 3+ lines of visual
acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 1 Gain 3+ lines of visual acuity at 1 year
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 57/187 43/293 70.4 % 2.08 [ 1.46, 2.95 ]
READ2 2009 (1) 3/40 0/38 1.1 % 6.66 [ 0.36, 124.77 ]
RESPOND 2013 15/71 4/62 9.0 % 3.27 [ 1.15, 9.35 ]
RESTORE 2011 27/118 9/110 19.6 % 2.80 [ 1.38, 5.68 ]
Subtotal (95% CI) 416 503 100.0 % 2.37 [ 1.76, 3.21 ]
Total events: 102 (ranibizumab + photocoag.), 56 (laser photocoagulation)
Heterogeneity: Chi2 = 1.60, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.62 (P < 0.00001)
2 Deferred photocoagulation
0.1 0.2 0.5 1 2 5 10
Favours photocoagulation Favours ranibizumab+laser
(Continued . . . )
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(. . . Continued)
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DRCRnet 2010 52/188 43/293 100.0 % 1.88 [ 1.31, 2.70 ]
Subtotal (95% CI) 188 293 100.0 % 1.88 [ 1.31, 2.70 ]
Total events: 52 (ranibizumab + photocoag.), 43 (laser photocoagulation)
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.33), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours photocoagulation Favours ranibizumab+laser
(1) follow-up: 6 months
Analysis 3.2. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 2 Loss 3+ lines of visual
acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 2 Loss 3+ lines of visual acuity at 1 year
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Prompt photocoagulation
DRCRnet 2010 3/187 23/293 48.3 % 0.20 [ 0.06, 0.67 ]
RESTORE 2011 4/118 9/110 51.7 % 0.41 [ 0.13, 1.31 ]
Subtotal (95% CI) 305 403 100.0 % 0.29 [ 0.13, 0.67 ]
Total events: 7 (ranibizumab + photocoag.), 32 (laser photocoagulation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0037)
2 Deferred photocoagulation
DRCRnet 2010 4/188 23/293 100.0 % 0.27 [ 0.10, 0.77 ]
Subtotal (95% CI) 188 293 100.0 % 0.27 [ 0.10, 0.77 ]
0.05 0.2 1 5 20
Favours ranibiz. + laser Favours laser
(Continued . . . )
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(. . . Continued)
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 4 (ranibizumab + photocoag.), 23 (laser photocoagulation)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
0.05 0.2 1 5 20
Favours ranibiz. + laser Favours laser
Analysis 3.3. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 3 Visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 3 Visual acuity at 1 year
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Random,95% CI IV,Random,95% CI
1 Prompt photocoagulation
DRCRnet 2010 187 -0.18 (0.22) 293 -0.06 (0.26) 31.3 % -0.12 [ -0.16, -0.08 ]
NCT01131585 ˙x0028˙RELATION˙x0029˙ 85 -0.13 (0.172) 43 -0.03 (0.146) 18.2 % -0.10 [ -0.16, -0.04 ]
READ2 2009 (1) 40 -0.0962 (0.189) 37 -0.05 (0.182) 8.6 % -0.05 [ -0.13, 0.03 ]
RESPOND 2013 70 -0.164 (0.18782) 62 -0.01 (0.25712) 9.8 % -0.16 [ -0.24, -0.08 ]
RESTORE 2011 118 -0.118 (0.1584) 110 -0.02 (0.1712) 32.0 % -0.10 [ -0.14, -0.06 ]
Subtotal (95% CI) 500 545 100.0 % -0.11 [ -0.13, -0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.02, df = 4 (P = 0.40); I2 =1%
Test for overall effect: Z = 8.69 (P < 0.00001)
2 Deferred photocoagulation
DRCRnet 2010 188 -0.18 (0.24) 293 -0.06 (0.26) 100.0 % -0.12 [ -0.17, -0.07 ]
Subtotal (95% CI) 188 293 100.0 % -0.12 [ -0.17, -0.07 ]
-0.2 -0.1 0 0.1 0.2
Favours ranibiz. + laser Favours laser
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(. . . Continued)
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 5.18 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours ranibiz. + laser Favours laser
(1) Follow-up: 6 months; standard deviations derived from a figure
Analysis 3.4. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 4 Central macular thickness
at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 4 Central macular thickness at 1 year
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 171 -131 (129) 271 -102 (151) 37.0 % -29.00 [ -55.40, -2.60 ]
RESPOND 2013 70 -152.2 (141.93) 61 -107.1 (146.84) 10.5 % -45.10 [ -94.73, 4.53 ]
RESTORE 2011 118 -128.3 (114.34) 110 -61.3 (43) 52.6 % -67.00 [ -89.14, -44.86 ]
Subtotal (95% CI) 359 442 100.0 % -50.66 [ -66.71, -34.61 ]
Heterogeneity: Chi2 = 4.73, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 6.19 (P < 0.00001)
2 Deferred photocoagulation
DRCRnet 2010 175 -137 (136) 271 -102 (151) 100.0 % -35.00 [ -62.00, -8.00 ]
Subtotal (95% CI) 175 271 100.0 % -35.00 [ -62.00, -8.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Chi2 = 0.95, df = 1 (P = 0.33), I2 =0.0%
-200 -100 0 100 200
Favours ranibiz. + laser Favours laser
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Analysis 3.5. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 5 Quality of life at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 5 Quality of life at 1 year
Study or subgroup AntiVEGF plus laser Laser alone
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
score] N
Mean(SD)[
score] IV,Fixed,95% CI IV,Fixed,95% CI
1 Prompt photocoagulation
RESTORE 2011 104 5.4 (10.42955) 96 0.6 (10.84209) 100.0 % 4.80 [ 1.85, 7.75 ]
Total (95% CI) 104 96 100.0 % 4.80 [ 1.85, 7.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours laser alone Favours anti-VEGF % laser
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Analysis 3.6. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 6 Gain 3+ lines of visual
acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 6 Gain 3+ lines of visual acuity at 2 years
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 39/136 37/211 1.64 [ 1.10, 2.43 ]
2 Deferred photocoagulation
DRCRnet 2010 39/139 37/211 1.60 [ 1.08, 2.38 ]
0.1 0.2 0.5 1 2 5 10
Favours laser Favours ranibizumab+laser
Analysis 3.7. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 7 Loss 3+ lines of visual
acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 7 Loss 3+ lines of visual acuity at 2 years
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 6/136 21/211 0.44 [ 0.18, 1.07 ]
2 Deferred photocoagulation
DRCRnet 2010 3/139 21/211 0.22 [ 0.07, 0.71 ]
0.05 0.2 1 5 20
Favours ranibizumab+laser Favours laser
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Analysis 3.8. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 8 Visual acuity at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 8 Visual acuity at 2 years
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation
Mean
Difference
Mean
Difference
N
Mean(SD)[
logMAR] N
Mean(SD)[
logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 136 -0.14 (0.26) 211 -0.06 (0.3) -0.08 [ -0.14, -0.02 ]
2 Deferred photocoagulation
DRCRnet 2010 139 -0.18 (0.28) 211 -0.06 (0.3) -0.12 [ -0.18, -0.06 ]
-0.2 -0.1 0 0.1 0.2
Favours ranibizumab+laser Favours laser
Analysis 3.9. Comparison 3 Anti-VEGF plus laser versus laser alone, Outcome 9 Central macular thickness
at 2 years.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 3 Anti-VEGF plus laser versus laser alone
Outcome: 9 Central macular thickness at 2 years
Study or subgroup
ranibizumab
+
photocoag.
laser
photocoag-
ulation
Mean
Difference
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
1 Prompt photocoagulation
DRCRnet 2010 136 -141 (155) 211 -138 (149) -3.00 [ -35.91, 29.91 ]
2 Deferred photocoagulation
DRCRnet 2010 136 -150 (143) 211 -138 (149) -12.00 [ -43.33, 19.33 ]
-200 -100 0 100 200
Favours ranibizumab+laser Favours laser
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Analysis 4.1. Comparison 4 Adverse events: anti-VEGF versus control, Outcome 1 Systemic serious adverse
events.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 4 Adverse events: anti-VEGF versus control
Outcome: 1 Systemic serious adverse events
Study or subgroup antiVEGF control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Follow-up 6-12 months
Azad 2012 0/20 0/20 Not estimable
DA VINCI 2011 6/45 10/44 3.5 % 0.59 [ 0.23, 1.48 ]
Ekinci 2014 0/50 0/50 Not estimable
Korobelnik 2014 65/287 64/287 32.5 % 1.02 [ 0.75, 1.38 ]
LUCIDATE 2014 2/22 1/11 0.6 % 1.00 [ 0.10, 9.86 ]
Macugen 2005 0/42 0/44 Not estimable
NCT01131585 ˙x0028˙RELATION˙x0029˙ 13/85 3/43 2.1 % 2.19 [ 0.66, 7.28 ]
RESOLVE 2010 14/102 8/49 4.7 % 0.84 [ 0.38, 1.87 ]
RESPOND 2013 20/158 6/79 4.0 % 1.67 [ 0.70, 3.98 ]
RESTORE 2011 30/235 15/110 9.0 % 0.94 [ 0.53, 1.67 ]
Soheilian 2007 0/48 0/48 Not estimable
Subtotal (95% CI) 1094 785 56.3 % 1.02 [ 0.81, 1.28 ]
Total events: 150 (antiVEGF), 107 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.49, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Follow-up 24 months
BOLT 2010 6/42 4/38 2.1 % 1.36 [ 0.41, 4.45 ]
DRCRnet 2010 48/166 24/74 18.2 % 0.89 [ 0.59, 1.34 ]
Macugen 2011 28/144 27/142 13.3 % 1.02 [ 0.64, 1.64 ]
RISE-RIDE 22/250 25/250 10.1 % 0.88 [ 0.51, 1.52 ]
Subtotal (95% CI) 602 504 43.7 % 0.95 [ 0.73, 1.23 ]
Total events: 104 (antiVEGF), 80 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 1696 1289 100.0 % 0.98 [ 0.83, 1.17 ]
0.2 0.5 1 2 5
Favours antiVEGF Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup antiVEGF control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 254 (antiVEGF), 187 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.26, df = 10 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
0.2 0.5 1 2 5
Favours antiVEGF Favours control
Analysis 4.2. Comparison 4 Adverse events: anti-VEGF versus control, Outcome 2 Total ATC
thromboembolic events at 6 to 24 months.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 4 Adverse events: anti-VEGF versus control
Outcome: 2 Total ATC thromboembolic events at 6 to 24 months
Study or subgroup antiVEGF control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Follow-up 6 to 12 months
Azad 2012 0/20 0/20 Not estimable
DA VINCI 2011 1/44 1/45 1.6 % 1.02 [ 0.07, 15.85 ]
Ekinci 2014 0/50 0/50 Not estimable
Korobelnik 2014 10/287 8/287 14.0 % 1.25 [ 0.50, 3.12 ]
LUCIDATE 2014 0/22 0/11 Not estimable
Macugen 2005 0/44 0/42 Not estimable
NCT01131585 ˙x0028˙RELATION˙x0029˙ 1/85 1/43 1.6 % 0.51 [ 0.03, 7.89 ]
READ2 2009 (1) 1/79 0/38 1.2 % 1.46 [ 0.06, 35.09 ]
RESOLVE 2010 2/49 3/102 3.8 % 1.39 [ 0.24, 8.04 ]
RESTORE 2011 7/235 1/110 2.7 % 3.28 [ 0.41, 26.31 ]
Subtotal (95% CI) 915 748 24.8 % 1.33 [ 0.67, 2.64 ]
0.1 0.2 0.5 1 2 5 10
Favours antiVEGF Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup antiVEGF control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 22 (antiVEGF), 14 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Follow-up 24 months
BOLT 2010 2/42 2/38 3.2 % 0.90 [ 0.13, 6.11 ]
DRCRnet 2010 25/375 17/130 34.6 % 0.51 [ 0.28, 0.91 ]
Macugen 2011 7/144 9/142 12.8 % 0.77 [ 0.29, 2.00 ]
RISE-RIDE 18/250 13/250 24.6 % 1.38 [ 0.69, 2.76 ]
Subtotal (95% CI) 811 560 75.2 % 0.80 [ 0.47, 1.38 ]
Total events: 52 (antiVEGF), 41 (control)
Heterogeneity: Tau2 = 0.11; Chi2 = 4.74, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 1726 1308 100.0 % 0.89 [ 0.63, 1.25 ]
Total events: 74 (antiVEGF), 55 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.81, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =20%
0.1 0.2 0.5 1 2 5 10
Favours antiVEGF Favours control
(1) ranibizumab and ranibizumab plus laser groups were cumulated
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Analysis 4.3. Comparison 4 Adverse events: anti-VEGF versus control, Outcome 3 Death.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 4 Adverse events: anti-VEGF versus control
Outcome: 3 Death
Study or subgroup Favours antiVEGF control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Follow-up 6 to 12 months
Azad 2012 0/20 0/20 Not estimable
BOLT 2010 0/42 0/38 Not estimable
DA VINCI 2011 0/44 1/45 2.6 % 0.34 [ 0.01, 8.15 ]
Ekinci 2014 0/50 0/50 Not estimable
Korobelnik 2014 2/287 6/578 10.5 % 0.67 [ 0.14, 3.31 ]
LUCIDATE 2014 1/22 1/11 3.7 % 0.50 [ 0.03, 7.26 ]
Macugen 2005 0/44 0/42 Not estimable
NCT01131585 ˙x0028˙RELATION˙x0029˙ 0/85 0/43 Not estimable
READ2 2009 (1) 1/79 0/38 2.6 % 1.46 [ 0.06, 35.09 ]
RESOLVE 2010 0/49 1/102 2.6 % 0.69 [ 0.03, 16.56 ]
RESPOND 2013 0/158 0/79 Not estimable
RESTORE 2011 4/235 2/110 9.4 % 0.94 [ 0.17, 5.03 ]
Subtotal (95% CI) 1115 1156 31.4 % 0.72 [ 0.29, 1.81 ]
Total events: 8 (Favours antiVEGF), 11 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Follow-up 24 months
DRCRnet 2010 13/375 8/130 36.1 % 0.56 [ 0.24, 1.33 ]
Macugen 2011 4/144 5/142 15.9 % 0.79 [ 0.22, 2.88 ]
RISE-RIDE 11/250 3/250 16.6 % 3.67 [ 1.04, 12.98 ]
Subtotal (95% CI) 769 522 68.6 % 1.11 [ 0.36, 3.45 ]
Total events: 28 (Favours antiVEGF), 16 (control)
Heterogeneity: Tau2 = 0.67; Chi2 = 6.04, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 1884 1678 100.0 % 0.88 [ 0.52, 1.47 ]
Total events: 36 (Favours antiVEGF), 27 (control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.82, df = 8 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.56), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours antiVEGF Favours control
(1) ranibizumab and ranibizumab plus laser groups were cumulated
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Analysis 5.1. Comparison 5 Bevacizumab versus ranibizumab, Outcome 1 Gain 3+ lines of visual acuity at 1
year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 5 Bevacizumab versus ranibizumab
Outcome: 1 Gain 3+ lines of visual acuity at 1 year
Study or subgroup Favours ranibizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nepomuceno 2013 (1) 12/32 13/28 100.0 % 0.81 [ 0.44, 1.47 ]
Total (95% CI) 32 28 100.0 % 0.81 [ 0.44, 1.47 ]
Total events: 12 (Favours ranibizumab), 13 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours ranibizumab Favours bevacizumab
(1) Follow-up: 48 weeks
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Analysis 5.2. Comparison 5 Bevacizumab versus ranibizumab, Outcome 2 Loss 3+ lines of visual acuity at 1
year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 5 Bevacizumab versus ranibizumab
Outcome: 2 Loss 3+ lines of visual acuity at 1 year
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nepomuceno 2013 (1) 1/32 0/28 100.0 % 2.64 [ 0.11, 62.23 ]
Total (95% CI) 32 28 100.0 % 2.64 [ 0.11, 62.23 ]
Total events: 1 (Bevacizumab), 0 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours bevacizumab Favours ranzibizumab
(1) Follow-up: 36 weeks
Analysis 5.3. Comparison 5 Bevacizumab versus ranibizumab, Outcome 3 Visual acuity at 1 year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 5 Bevacizumab versus ranibizumab
Outcome: 3 Visual acuity at 1 year
Study or subgroup Bevacizumab Ranibizumab
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
Ekinci 2014 50 -0.23736 (0.16) 50 -0.21 (0.16) 66.1 % -0.03 [ -0.09, 0.04 ]
Nepomuceno 2013 (1) 32 -0.23 (0.113137) 28 -0.29 (0.21166) 33.9 % 0.06 [ -0.03, 0.15 ]
Total (95% CI) 82 78 100.0 % 0.00 [ -0.05, 0.05 ]
Heterogeneity: Chi2 = 2.47, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours bevacizumab Favours ranibizumab
(1) Follow-up: 48 weeks
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Analysis 5.4. Comparison 5 Bevacizumab versus ranibizumab, Outcome 4 Central macular thickness at 1
year.
Review: Anti-vascular endothelial growth factor for diabetic macular oedema
Comparison: 5 Bevacizumab versus ranibizumab
Outcome: 4 Central macular thickness at 1 year
Study or subgroup Bevacizumab Ranibizumab
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ m] N Mean(SD)[ m] IV,Fixed,95% CI IV,Fixed,95% CI
Ekinci 2014 50 342.3 (121) 50 339.3 (121) 47.6 % 3.00 [ -44.43, 50.43 ]
Nepomuceno 2013 (1) 32 329.7 (109.1773) 28 280.9 (66.67293) 52.4 % 48.80 [ 3.63, 93.97 ]
Total (95% CI) 82 78 100.0 % 27.02 [ -5.70, 59.73 ]
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours bevacizumab Favours ranibizumab
(1) Follow-up: 48 weeks
A D D I T I O N A L T A B L E S
Table 1. Mean (SD) or median (*) number of intravitreal injections in studies
Study Follow-up Sham
Ranibizumab
Beva-
cizumab
Pegap-
tanib
Sham
+ laser
An-
tiVEGF
+ laser
(prompt)
Ranibizumab
+ laser
(deferred)
Aflibercep
Macugen
2005
36
weeks (re-
ported at
30 weeks)
4.5 (1.5) 5 (1.2)
Soheilian
2007
2 years 3.1 (1.6) 1 (0.1)
Ahmadieh
2008
24 weeks 3 3
DRCRnet
2010
1 year 8 (7,11)* 9 (7,11)*
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Table 1. Mean (SD) or median (*) number of intravitreal injections in studies (Continued)
DRCRnet
2010
year 2 only 2 (0,4)* 3 (1,7)*
RE-
STORE
2011
1 year 7 (2.81) 7.3 (3.22) 6.8 (2.95)
RE-
SOLVE
2010
1 year 8.9 (3.5) 10.2 (2.5)
READ2
2009
1.5 years 5.3 4.4 2.9
BOLT
2010
1 year 9 (8,9)* 3 (2, 4)*
Macugen
2011
1 year 8.4 (1.4) 8.3 (1.7)
Macugen
2011
2 years 12.9 (4.4) 12.7 (4.6)
RISE-
RIDE
(two stud-
ies)
2 years 20 (7.5)
20.8 (7.1)
20.9 (6.3)
21.9 (5.8)
DA
VINCI
2011§
6 months Not
reported
3.8 to 5.6
Azad 2012 6 months 2.7 (0.4)
Nepomu-
ceno
2013
1 year 7.7 (2.9) 9.8 (3.4)
Ekinci
2014
1 year 5.1 (0.74) 6.5 (0.85)
NCT01131585
(RELA-
TION)
1 year Not
reported
Not
reported
RE-
SPOND
2013
1 year Not
reported
Not
reported
Not
reported
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Table 1. Mean (SD) or median (*) number of intravitreal injections in studies (Continued)
LUCI-
DATE
2014
48 weeks 9
Korobel-
nik
2014
(VISTA
and
VIVID)#
1 year Not
reported
8.4 (1.3)
8.7 (1.2)
(*): median (interquartile range) number of injection; mean otherwise
(#): only one aflibercept regimen was selected, based on similarity to current clinical practice
Table 2. Outcome reporting grid: visual acuity
Outcome Gain 3+ lines Loss 3+ lines Gain 3+ lines Loss 3+ lines
Study Antiangiogenic
drug
6 to 12 months 2 years
Soheilian 2007 Bevacizumab Yes Yes Yes Yes
Ahmadieh 2008 Bevacizumab E E E E
BOLT 2010 Bevacizumab Yes Yes NA NA
Macugen 2005 Pegaptanib Yes E NA NA
Macugen 2011 Pegaptanib Yes Yes Yes Yes
DRCRnet 2010 Ranibizumab Yes Yes Yes Yes
READ2 2009 Ranibizumab Yes E NA NA
RESOLVE 2010 Ranibizumab Yes Yes NA NA
RESTORE 2011 Ranibizumab Yes Yes NA NA
RISE-RIDE Ranibizumab E E Yes Yes
DA VINCI 2011 Aflibercept Yes Yes NA NA
Nepomuceno 2013 Bevacizumab,
ranibizumab
yes yes NA NA
Ekinci 2014 Bevacizumab,
ranibizumab
Yes Yes NA NA
132Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Outcome reporting grid: visual acuity (Continued)
NCT01131585
(RELATION)
Ranibizumab E E NA NA
RESPOND 2013 Ranibizumab Yes E NA NA
LUCIDATE 2014 Ranibizumab E E NA NA
Korobelnik
2014 (VISTA and
VIVID)
Aflibercept Yes Yes NA NA
Yes: outcome analysed and fully reported allowing its inclusion in the meta-analysis.
E: clear that outcome was measured (for example, includes structurally related outcomes) but not necessarily analysed (adapted from
list provided by Paula Williamson at Cochrane training workshop on selective outcome reporting bias, Edinburgh March 2009).
NA: not applicable, since follow-up less than 2 years
Table 3. Ocular adverse events: endophthalmitis
Study Follow-up Sham
Ranibizumab
Beva-
cizumab
Pegap-
tanib
Laser
Ranibizumab
+ laser
(prompt)
Ranibizumab
+ laser
(deferred)
Aflibercept
Macugen
2005
36 weeks 0/42 1/44
Soheilian
2007 *
2 years 0/48 0/48
Ahmadieh
2008(#)
24 weeks 0 0
DRCRnet
2010
2 years 1/293 2/187 2/188
RE-
STORE
2011
1 year 0/115 0/110 0/120
RE-
SOLVE
2010
1 year 0/49 2/102
READ2
2009
2 years
BOLT
2010
2 years 0/42 0/38
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Table 3. Ocular adverse events: endophthalmitis (Continued)
Macugen
2011
2 years 0/127 0/133
RISE-
RIDE
2 years 0/250 3/250*
DA
VINCI
2011§
1 year 0/44 1/45
Azad 2012 6 months 0/20 0/20
Nepomu-
ceno
2013
1 year 2/28 0/32
Ekinci
2014
1 year 0/60 0/60
NCT01131585
(RELA-
TION)
1 year NA NA
RE-
SPOND
2013
1 year NA NA NA
LUCI-
DATE
2014
48 weeks 0/11 0/22
Korobel-
nik
2014
(VISTA
and
VIVID)§
1 year 0/287 0/287
(*): denominator is total number of participants at mean follow-up
(#): no cases mentioned but number of eyes, not patients, given for each group
(§): only one aflibercept regimen was selected, based on similarity to most other trials
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Table 4. Safety comparing 0.3 mg with 0.5 mg monthly ranibizumab in RISE-RIDE
Treatment Frequency Status Outcome
Sham 3 Event Death
Sham 247 Non-event Death
ranibizumab 0.3 mg 7 Event Death
ranibizumab 0.3 mg 243 Non-event Death
ranibizumab 0.5 mg 11 Event Death
ranibizumab 0.5 mg 239 Non-event Death
Sham 83 Event SSAEs
Sham 167 Non-event SSAEs
ranibizumab 0.3 mg 81 Event SSAEs
ranibizumab 0.3 mg 169 Non-event SSAEs
ranibizumab 0.5 mg 91 Event SSAEs
ranibizumab 0.5 mg 159 non-event SSAEs
Sham 13 Event ATC TE
Sham 237 Non-event ATC TE
ranibizumab 0.3 mg 14 Event ATC TE
ranibizumab 0.3 mg 236 Non-event ATC TE
ranibizumab 0.5 mg 18 Event ATC TE
ranibizumab 0.5 mg 232 Non-event ATC TE
Abbreviations
SSAE: serious systemic adverse event
ATC TE: arterial thromboembolic events according to Antiplatelet Trialists’ Collaboration (ATC 1994)
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Table 5. Dataset used in indirect comparisons among antiangiogenic drugs
Study Treatment Gain 3+ lines Total
BOLT 2010 Laser 2 38
BOLT 2010 Bevacizumab 5 42
DRCRnet 2010 Laser 43 293
DRCRnet 2010 Ranibizumab/laser 57 187
Macugen 2005 Sham 3 42
Macugen 2005 Pegaptanib 8 44
Macugen 2011 Sham 13 127
Macugen 2011 Pegaptanib 22 133
READ2 2009 Laser 0 38
READ2 2009 Ranibizumab 8 37
READ2 2009 Ranibizumab/laser 3 40
RESOLVE 2010 Sham 5 49
RESOLVE 2010 Ranibizumab 33 102
RESTORE 2011 Laser 9 110
RESTORE 2011 Ranibizumab 26 115
RESTORE 2011 Ranibizumab/laser 27 118
Soheilian 2007 Laser 6 43
Soheilian 2007 Bevacizumab 16 44
DA VINCI 2011 Laser 5 44
DA VINCI 2011 Aflibercept* 19 45
Nepomuceno 2013 Bevacizumab 12 32
Nepomuceno 2013 Ranibizumab 13 28
RESPOND 2013 Ranibizumab 17 70
RESPOND 2013 Ranibizumab/laser 15 71
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Table 5. Dataset used in indirect comparisons among antiangiogenic drugs (Continued)
RESPOND 2013 Laser 4 62
Azad 2012 Bevacizumab 4 20
Azad 2012 Laser 0 20
Korobelnik 2014 (VISTA) Laser 12 152
Korobelnik 2014 (VISTA) Aflibercept* 47 152
Korobelnik 2014 (VIVID) Laser 12 133
Korobelnik 2014 (VIVID) Aflibercept* 45 135
(*): only one aflibercept regimen was selected, based on similarity to current clinical practice
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Macular Edema] explode all trees
#2 macula* near/3 oedema
#3 macula* near/3 edema
#4 maculopath*
#5 CME or CSME or CMO or CSMO
#6 DMO or DME
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Diabetes Mellitus] explode all trees
#9 MeSH descriptor: [Diabetic Retinopathy] this term only
#10 MeSH descriptor: [Diabetes Complications] this term only
#11 diabet*
#12 retinopath*
#13 #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Angiogenesis Inhibitors] explode all trees
#15 MeSH descriptor: [Angiogenesis Inducing Agents] explode all trees
#16 MeSH descriptor: [Endothelial Growth Factors] explode all trees
#17 macugen* or pegaptanib* or lucentis* or rhufab* or ranibizumab* or bevacizumab* or avastin* or or aflibercept*
#18 anti adj2 VEGF*
#19 #14 or #15 or #16 or #17 or #18
#20 #7 and #13 and #19
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Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular edema/
14. (macula$ adj3 oedema).tw.
15. (macula$ adj3 edema).tw.
16. maculopath$.tw.
17. (CME or CSME or CMO or CSMO).tw.
18. (DMO or DME).tw.
19. or/13-18
20. exp diabetes mellitus/
21. diabetic retinopathy/
22. diabetes complications/
23. diabet$.tw.
24. retinopath$.tw.
25. or/20-24
26. exp angiogenesis inhibitors/
27. angiogenesis inducing agents/
28. endothelial growth factors/
29. exp vascular endothelial growth factors/
30. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin$ or aflibercept$).tw.
31. (anti adj2 VEGF$).tw.
32. or/26-31
33. 19 and 25 and 32
34. 12 and 33
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
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14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula edema/
34. (macula$ adj3 oedema).tw.
35. (macula$ adj3 edema).tw.
36. maculopath$.tw.
37. (CME or CSME or CMO or CSMO).tw.
38. (DMO or DME).tw.
39. or/33-38
40. exp diabetes mellitus/
41. diabetic retinopathy/
42. diabet$.tw.
43. retinopath$.tw.
44. or/40-43
45. angiogenesis/
46. exp angiogenesis inhibitors/
47. angiogenic factor/
48. endothelial cell growth factor/
49. exp vasculotropin/
50. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept$).tw.
51. (anti adj2 VEGF$).tw.
52. (endothelial adj2 growth adj2 factor$).tw.
53. or/45-52
54. 39 and 44 and 53
55. 32 and 54
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Appendix 4. LILACS search strategy
macula$ edema or macula$ oedema or DMO or DME or CMO or CME or CSMO and angiogenesis or endothelial growth factor or
macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept$
Appendix 5. metaRegister of Controlled Trials search strategy
(diabetic macular edema) AND (macugen OR pegaptanib OR lucentis OR rhufab OR ranibizumab OR bevacizumab OR avastin OR
aflibercept)
Appendix 6. ClinicalTrials.gov search strategy
Diabetic Macular Edema AND (Macugen OR Pegaptanib OR Lucentis OR Rhufab OR Ranibizumab OR Bevacizumab OR Avastin
OR aflibercept)
Appendix 7. ICTRP search strategy
diabetic macular edema = Condition AND macugen OR pegaptanib OR lucentis OR rhufab OR ranibizumab OR bevacizumab OR
avastin OR aflibercept = Intervention
F E E D B A C K
Feedback, 25 June 2013
Summary
Comments:1. In the electronic searches,did you not find the article: Lim JW, LeeHK, ShinMC.Comparison of intravitreal bevacizumab
alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: A randomized clinical trial. Ophthalmologica.
2012;227(2):100-6. The article was published online: October 12, 2011, so it should have been found in the last electronic search, June
2012. I understand this article would have been excluded because of the triamcinolone comparison (it compares bevacizumab 1.25 mg
versus bevacizumab 1.25 mg plus triamcinolone 2 mg versus triamcinolone 2 mg) but maybe It should appear in the ’Characteristics
of excluded studies’ section?
2. About the outcome results for ’Quality of life’: Quality of life results should be included from the RESTORE 2011 trial. In the
RESTORE 2011 trial (RESTORE 2011) data on quality of life have been reported using EQ-5D and NEI VFQ-25. It reported 12
months results, so it could also have been included. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R,
et al. The RESTORE 2011 Study ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular
edema. Ophthalmology. 2011;118(4):615-25.
3. In the section Effects of interventions/Anti-VEGF versus sham treatment/ Quality of the evidence: “READ2 2009 provided visual
gain, but not visual loss data”. This section evaluates anti-VEGF versus sham treatment and the READ trial is about ranibizumab versus
laser.
4. For the included study: DRCRnet 2010 {published data only} Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello
LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone
plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77. It seems that you have also considered results
from this trial, from the 2011 publication for 2 years results (Analysis 3.7-3.11): Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL
3rd, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt laser or deferred laser or triamcinolone plus prompt
laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614. The values of “N”, total population evaluated belong to 2011
publication; the numbers are higher than those belonging to the 2010 publication. So this reference should also be cited.
140Anti-vascular endothelial growth factor for diabetic macular oedema (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5. For the included study: READ2 2009 {published data only} Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et
al.Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146-
51. The results that are considered in the review belong to the article by Nguyen 2009 (results and follow up at 6 months). Nguyen
QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the
mAcula in diabetes. Ophthalmology. 2009;116 (11):2175-81. All the analyses have been done with the 6 months follow up. Because
after six months all patients could be treated with ranibizumab, data were not collected beyond six months. So this reference should
also be cited.
6. In the ’Characteristics of included studies’ table for RISE-RIDE, the ’outcomes’ section should be completed.
7. In Tables 2, 5, 6, 7, 8 and 9 ’bevacacizumab’ should be corrected to ’bevacizumab’.
Reply
We thank Ruth Ubago Pérez for her comments submitted through the Feedback system in The Cochrane Library.
1. In the ’Characteristics of excluded studies’ table, we have added that not only Paccola 2008, but also Lim 2012 were excluded because
another Cochrane review focuses on the use of intravitreal steroids in people with diabetic macular oedema.
2. We will include quality of life data in the next review update.
3. We have removed this sentence.
4 and 5. We have added these references.
6. We have completed the ’Outcomes’ section.
7. We have corrected these typos.
Contributors
Comment from Ruth Ubago Pérez, Pharmacist Technician, Andalusian Agency for Health Technology Assessment, Spain
Reply from Gianni Virgili (lead author of review)
WH A T ’ S N E W
Last assessed as up-to-date: 28 April 2014.
Date Event Description
4 November 2014 Amended Plain language summary title has been amended
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 4, 2009
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Date Event Description
17 October 2014 New search has been performed Issue 10, 2014: Electronic searches updated.
17 October 2014 New citation required but conclusions have not
changed
Issue 10, 2014: Five new studies (Azad 2012;
Ekinci 2014; Nepomuceno 2013; NCT01131585
(RELATION); RESPOND2013) have been included
in the update.
4 November 2013 Feedback has been incorporated The authors have made some edits to the review in
response to feedback received. See ’Feedback 1’ for
further details.
14 March 2013 Amended The abstract has been amended to focus on the com-
parison with laser and presenting absolute effects
11 November 2012 New search has been performed Updated searches yielded seven new trials for inclu-
sion. One trial that had previously been included was
excluded. An economic section has been added. One
new author Massimo Brunetti has been added to the
review team
11 November 2012 New citation required and conclusions have changed Inclusion of seven new studies has changed the con-
clusions to this review from the previous version
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between protocol and review in the first published version of this review
We have added LILACS to the list of databases which have been searched for this review. We have used a sensitivity analysis for the
robustness of results in comparisons including only one trial according to a statistical technique derived from a recent publication
(Borm 2009).
Changes in update, 2012 compared to the protocol of the previous version
1. We have specified that studies comparing different anti-VEGF drugs will also be included in this review, but intravitreal steroids
will be excluded as they are the subject of another Cochrane Review. Moreover, we decided not to consider the comparison of
bevacizumab with bevacizumab plus trimacinolone, which included two studies; in fact this comparison investigates the additional
effect of triamcinolone rather than the benefit of anti-VEGF drugs.
2. We have computed indirect comparison odds ratios (OR) of a gain of 3+ and 2+ lines for bevacizumab and pegaptanib versus
ranibizumab as the reference drug using random-effects model logistic regression.
Changes in update, 2014 compared to the protocol of the previous version
1. We have included 5 more studies but the conclusions did not change.
2. We no longer consider economic evidence since antiangiogenic therapy is widely approved and reimbursed.
3. We eliminated the table on retinal detachment as an ocular adverse event since it proved to be extremely rare in all studies.
4. Units of analysis issue: in the update of this review we no longer performed a sensitivity analysis regarding the primary outcome
to determine the impact of excluding studies with eyes, rather than participants, as the unit of analysis. In fact, a significant amount of
evidence from studies with individuals as unit of analysis was achieved for the main comparisons.
5. Single trial issue: In the 2012 and 2014 updates of the review we did not use the sensitivity analysis on the robustness of single
trial results recommended by Borm 2009, as was originally planned. Instead, we calculated the ’Optimal Information Size’ to rate the
quality of evidence regarding imprecision as recommended by the GRADE study group in Guyatt 2011.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Angiogenesis Inhibitors [∗therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [thera-
peutic use]; Aptamers, Nucleotide [therapeutic use]; Bevacizumab; Diabetic Retinopathy [∗complications]; Laser Coagulation [meth-
ods]; Macular Edema [∗drug therapy; surgery]; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial
Growth Factor [therapeutic use]; Recombinant Fusion Proteins [therapeutic use]; Triamcinolone [therapeutic use]; Vascular Endothelial
Growth Factor A [∗antagonists & inhibitors]
MeSH check words
Humans
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